Expanding the phenotype and genetic spectrum of myoclonic astatic epilepsy by Tang, Shan
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 













































Myoclonic	 astatic	 epilepsy	 (MAE)	 is	 a	 rare	 generalised	 childhood	 epilepsy	 with	 variable	 but	
poorly	 described	 neurodevelopmental	 outcome.	 Family	 studies	 suggest	 a	 major	 genetic	
influence	 as	 up	 to	 two	 thirds	 of	 relatives	 have	 seizures,	 or	 electroencephalographic	 (EEG)	








I	 assembled	 the	 largest	MAE	 cohort	 (n=123)	 to	 date.	 The	 epilepsy	 phenotype	 is	 remarkably	
similar	to	previously	published	cohorts.	 I	 identified	a	severe	neurodevelopmental	phenotype:	
intellectual	disability	was	reported	in	64.9%,	autism	spectrum	disorder	in	21.3%	and	attention	
deficit	 hyperactivity	 symptoms	 in	 41.0%.	 Additionally,	 extremely	 low	 adaptive	 behavioural	
scores	were	identified	in	69.4%	of	cases.	I	performed	EEG	studies	on	38	first-degree	relatives	
of	 13	MAE	 families,	 and	 found	 an	 excess	 of	 epileptiform	EEG	 features	 in	 adults	 (>16	 years),	
compared	to	controls	(P=0.05,	RR	6.82).	
	
I	 identified	 likely	pathogenic	or	candidate	variants	 in	11	of	109	cases.	This	comprised	known	
genes	 associated	with	MAE:	CHD2	 n=1,	 SYNGAP1	 n=2,	 SLC6A1	n=1,	KIAA2022	 n=1;	 epilepsy	
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characterised	 by	 onset	 of	 primary	 generalised	 seizures	 in	 the	 form	of	myoclonic	 and	 astatic	
seizures,	 often	 combined	 with	 absences,	 tonic	 clonic	 and	 tonic	 seizures1.	 However,	 the	
phenotypic	manifestations	and	nosological	boundaries	of	MAE	are	frequently	debated2-4.	The	
clinical	 continuum	 of	 MAE	 overlaps	 with	 other	 epilepsy	 syndromes	 like	 benign	 myoclonic	
epilepsy	 of	 infancy	 or	 Lennox	 Gastaut	 syndrome	 (LGS),	 and	 the	 precise	 determination	 of	




evidence	 offered	 from	 family	 history	 and	 family	 electroencephalogram	 (EEG)	 studies5.	 Early	
twins	studies6,7	and	rare	mendelian	pedigrees8-10	offered	a	glimpse	to	the	genetic	premise	of	
MAE	 but	 the	 genetic	 aetiology	 remained	 largely	 elusive	 till	 the	 advent	 of	 next	 generation	
sequencing	(NGS).	The	quest	for	gene	discovery	had	lead	to	10	genes;	SCN1A10,11,	GABRG29,12,	
SLC2A113,	 CHD212,14,15,	 SYNGAP112,16,	 SLC6A117,18,	 KCNA219,	 STX1B20,21,	 TBC1D2422	 and	















wave	 EEG	 pattern	 and	 correlated	 it	 with	 clinical	 manifestations	 of	myoclonic	 jerks,	 atypical	
	 18	
absences,	 astatic	 seizures	 and	 mental	 retardation.	 Subsequently	 in	 1966,	 Henri	 Gastaut	
described	 the	 “Lennox	 syndrome	 or	 childhood	 epileptic	 encephalopathy	 with	 diffuse	 slow	
spike	and	waves”	in	100	patients	with	diffuse	slow	spike	wave	on	EEG,	frequent	tonic	seizures,	
absences,	sometimes	myoclonic	seizures	and	mental	retardation25.	The	contributions	of	both	
groups	were	 recognised	 and	 the	 term	 LGS	 coined	 at	 the	 American	 Electroencephalographic	
Society	proceedings	in	1969.	
	
The	 concept	 of	 separating	 epilepsy	with	myoclonic	 seizures	 emerged	 around	 the	 same	 time	
when	 Harper	 described	 14	 children	 with	 myoclonic	 epilepsy	 distinct	 from	 LGS26.	 Kruse	
described	a	kind	of	epilepsy	characterised	by	myoclonic	and	astatic	seizures	under	the	heading	
of	 ‘myoclonic	astatic	petit	mal’	 among	other	petit	mal	epilepsies27.	Doose	differentiated	 this	
further	 and	 in	 1970	 published	 51	 cases	 of	 “centrencephalic	 myoclonic	 astatic	 petit	 mal”	
characterised	 by	 onset	 of	 primary	 generalised	 seizures	 in	 the	 form	of	myoclonic	 and	 astatic	
seizures,	often	combined	with	absences,	tonic-clonic	and	tonic	seizures	in	children	between	1	
and	5	years	old.	The	prominent	seizure	symptom	was	an	abrupt	 loss	of	postural	tone.	Doose	
photographically	 captured	 this	 abortive	 astatic	 seizure	 shown	 in	 Figure	 1.1,	 the	 child’s	 head	
drops	forwards	and	the	knees	sag,	there	is	myoclonic	flexion	of	the	arms	and	loss	of	postural	
tone.	 The	 EEG	 usually	 showed	 bilateral	 synchronous	 spike	 and	wave	 activity	with	 abnormal	
background	 theta	 rhythm.	 He	 recognized	 that	 the	 course	 of	 the	 disease	 is	 generally	












Within	 this	 original	 group	of	 patients	 reported	 by	Doose	et	 al.,	 discrete	 epilepsy	 syndromes	
can	now	be	recognized5.	Five	of	his	51	cases	had	isolated	myoclonic	seizures	that	might	now	fit	
the	definition	of	benign	myoclonic	epilepsy	of	 infancy.	Ten	cases	had	a	 seizure	onset	before	
the	 age	 of	 1	 year,	 and	 11	 cases	 had	 febrile	 convulsions.	 Although	 specific	 details	 were	 not	
differentiated	 in	 each	 patient,	 these	 cases	 could	 fit	 a	 severe	 myoclonic	 epilepsy	 of	 infancy	
(SMEI)	 phenotype.	 Another	 subgroup	 of	 six	 cases	 had	 evidence	 of	 cerebral	 damage	 with	
neurologic	 symptoms	or	mental	 retardation,	and	one	case	exhibited	 frequent	 tonic	 seizures;	
these	might	better	 fit	 the	 label	of	LGS.	Twenty-two	years	 later,	Doose	refined	his	criteria	 for	
MAE,	adding	that	tonic	seizures	were	an	uncommon	feature,	and	acknowledging	the	overlap	
with	 other	 epilepsy	 syndromes28.	 In	 1989,	 the	 International	 League	Against	 Epilepsy	 (ILAE)29	
recognized	MAE	to	have	the	following	features:	(1)	usually	normal	development	before	onset	
of	 epilepsy;	 (2)	 onset	 of	myoclonic,	myoclonic-astatic,	 or	 astatic	 seizures	 between	7	months	
and	6	years	of	age;	and	 (3)	presence	of	generalized	spike	or	polyspike	wave	EEG	discharges.	
The	ILAE	also	recognized	a	“hereditary	predisposition”	with	a	variable	outcome.	These	criteria	
are	 largely	 based	 on	 Doose’s	 original	 description	 on	 a	 cohort	 that	 is	 now	 recognized	 to	 be	
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The	 concept	 of	 an	 epilepsy	 syndrome	 has	 evolved	with	 the	 recent	 ILAE	 classification35.	 The	
1989	 ILAE	 report	 adopted	 a	 broad	 understanding	 of	 the	 term	 “syndrome”	 as	 an	 epileptic	
disorder	characterized	by	a	cluster	of	signs	and	symptoms	customarily	occurring	together	and	
placed	MAE	within	 the	 category	of	 generalized	 cryptogenic	or	 symptomatic	epilepsies29.	 The	
2010	 ILAE	 classification	 specified	 that	 an	 electroclinical	 syndrome	 is	 a	 complex	 of	 clinical	
features,	signs,	and	symptoms	that	together	define	a	distinctive,	recognizable	clinical	disorder.	
The	2010	 report	 avoids	 the	 cryptogenic	or	 symptomatic	 etiologic	distinction	by	placing	MAE	
(now	 termed	 epilepsy	 with	 “myoclonic-atonic”	 seizures,	 instead	 of	 the	 previously	 called	
“myoclonic-astatic”	 seizures)	 as	 a	 distinct	 electroclinical	 syndrome35.	 Although	 the	













The	 incidence	 of	 MAE	 is	 generally	 low.	 Amongst	 newly	 diagnosed	 adult	 and	 childhood	
epilepsies	 over	 14	months	 in	 a	 French	 centre,	MAE	 account	 for	 0.3%	 of	 1016	 patients36.	 In	
paediatric	centres,	MAE	accounted	for	1-2%	of	childhood	epilepsies	up	to	the	age	of	9	years	in	
the	German	city	of	Kiel37,	were	diagnosed	in	18	(5.5%)	out	of	327	children	with	a	diagnosis	of	
















Generalised	 subcortical	 atrophy	 on	 cranial	 computerized	 tomography	 has	 been	 reported	 in	
groups	of	patients	with	symptoms	similar	to	MAE	prior	to	the	1989	classification25.	However,	
the	pathological	 significance	of	 generalised	 subcortical	 atrophy	 is	 difficult	 to	determine	as	 it	
may	 result	 form	 repeated	 seizures,	 episodes	 of	 status	 epilepticus,	 or	 from	 hormonal	
treatment.	 Subsequent	MAE	 series	 have	 indicated	no	 evidence	of	 brain	 lesions	on	magnetic	
resonance	imaging2,4,32.	There	are	no	published	post-mortem	brain	studies	in	MAE	patients.	
	
A	 EEG-fMRI	 study	offered	 interesting	 insights	 into	 the	pathogenesis	 of	 seizure	 generation	 in	















MAE	 is	 a	 generalised	 epilepsy	 syndrome	 and	 hence	 patients	 predominantly	 present	 with	
generalised	seizures.	Generalised	seizures	are	seizures	that	originate	at	some	point	within	and	
rapidly	engage	to	bilaterally	distributed	networks35,40.	A	typical	MAE	seizure	history	would	be	
of	a	3	 to	4	year	old	boy	presenting	with	 recurrent	 febrile	or	afebrile	generalised	tonic	clonic	
seizure	 (GTCS)	 followed	 by	myoclonic-atonic	 seizures	 and	 variably	 other	 generalised	 seizure	







musculature40.	Whereas	 a	myoclonic	 atonic	 seizure	 is	 defined	 as	 a	 generalised	 seizure	 type	
with	a	myoclonic	jerk	leading	to	an	atonic	drop,	this	was	previously	called	a	myoclonic	astatic	
seizure40.	 Myoclonic	 atonic	 seizures	 are	 the	 hallmark	 seizure	 in	 MAE	 and	 an	 essential	
component	 in	 its	 phenotypic	 manifestation5,28,30,32.	 	 However,	 it	 is	 difficult	 to	 determine	
whether	 all	 reported	MAE	patients	 have	myoclonic	 atonic	 or	 atonic	 seizures	 because	 of	 the	
following:	 	 (1)	 some	series	group	together	myoclonic	seizures,	myoclonic	atonic	seizures	and	
atonic	seizures;	(2)	researchers	use	different	criteria	for	myoclonic	atonic	seizures	and	(3)	it	is	
difficult	 to	 qualify	 the	 exact	 physiologic	 mechanism	 of	 drop	 attacks	 without	 combined	
electroencephalogram/electromyogram	 recordings.	 For	 example	Oguni	 et	 al.	 reported	 in	 his	
earlier	series	a	cohort	with	100%	occurrence	of	either	myoclonic	or	myoclonic	atonic	seizures4,	
subsequently	he	specified	that	the	intensity	of	myoclonia	and	atonia	should	be	equal	in	order	
for	 the	 term	myoclonic	atonic	 seizures	 to	be	used;	and	his	 later	 series	 reported	only	10%	of	
cases	with	myoclonic	atonic	seizures30.	Kaminska	et	al.	 reported	drop	attacks	 in	89%	of	 their	
cohort	but	did	not	distinguish	this	further2.	Interestingly,	precise	seizure	delineation	with	EEG	






A	 myoclonic	 seizure	 is	 defined	 as	 a	 sudden,	 brief	 (<100ms)	 involuntary	 single	 or	 multiple	
contraction(s)	 of	 muscle(s)	 or	 muscle	 groups	 of	 variable	 topography	 (axial,	 proximal	 limb,	
distal)40.	The	frequency	of	myoclonic	seizures	varies	from	approximately	43-100%	in	MAE2,30,34.	
Myoclonic	 jerks	 tend	 to	 involve	 the	 trunk	 and	 proximal	 muscles,	 can	 be	 both	 flexor	 and	
extensor	and	may	cause	drop	attacks.	This	corresponds	to	a	GSW	with	a	median	frequency	of	
1.3	Hz	on	EEG41.	Aicardi	described	some	patients	with	the	so	called	myoclonic	variant	of	LGS	to	
have	 an	 unusually	 marked	 myoclonic	 component42.	 However	 a	 neurophysiologic	 study	
demonstrated	that	myoclonus	originates	differently	in	a	small	cohort	of	LGS	and	MAE	cases43.	
In	three	LGS	cases,	topographic	voltage	mapping	of	the	pre-myoclonic	EEG	spike	peak	showed	
a	 lateralised	 frontal	cortex	distribution,	whereas	 in	 three	MAE	cases,	 this	mapping	showed	a	
diffuse	 distribution	 of	 the	 electrical	 field,	 predominantly	 over	 the	 anterior	 regions	 but	 not	
lateralised,	 suggesting	 that	 myoclonic	 jerks	 in	 MAE	 is	 a	 primary	 generalised	 epileptic	
phenomenon.	 The	 occurrence	 of	 myoclonic	 seizures	 without	 an	 atonic	 component	 should	
prompt	the	consideration	of	alternate	myoclonic	epilepsies	such	as	benign	myoclonic	epilepsy	














stare	and	possible	brief	upward	deviation	of	 the	eyes,	which	 last	a	 few	seconds	 to	a	minute	
with	 rapid	 recovery.	EEG	shows	GSW	during	 the	event40.	An	atypical	absences	 is	an	absence	
seizure	 with	 more	 pronounced	 changes	 in	 tone	 that	 a	 typical	 absence,	 the	 onset	 and/or	
cessation	 of	 the	 seizure	 is	 not	 abrupt.	 EEG	 often	 shows	 slow,	 irregular	 GSW	 activity.	 Both	
	 24	









EEG	 recording	 exhibit	 tonic	 seizures44.	 Tonic	 seizures	may	 appear	 later	 in	 the	 course	 of	 LGS	




Status	epilepticus	was	 re-defined	by	 the	 ILAE	 in	201545.	The	proposed	new	definition	was	as	
follows:	 status	 epilepticus	 is	 a	 condition	 resulting	 either	 from	 failure	 of	 the	 mechanisms	
responsible	 for	 seizure	 termination	 or	 from	 the	 initiation	 of	 mechanisms,	 which	 lead	 to	
abnormally,	prolonged	seizures	(~	after	5	minutes).	It	is	a	condition,	which	can	have	long-term	
consequences	 (~	after	30	minutes),	 including	neuronal	death,	neural	 injury	and	alteration	of	
neuronal	 networks.	 In	MAE,	 a	 ‘petit	mal	 status’	 or	 ‘status	 of	minor	 seizures’	 consisting	 of	 a	
series	 of	myoclonic	 atonic	 seizures	 or	myoclonus	 and	 atypical	 absences	 is	 typical	 and	much	
more	common	than	convulsive	status5	(ILAE	axis	B.2.a.b.	or	B.2.a.c.45).	This	contrasts	with	LGS	
in	 which	 status	 characteristically	 involves	 clouding	 of	 consciousness	 with	 frequent	 tonic	




Focal	 seizures	 are	 defined	 as	 seizures	 that	 originate	 within	 networks	 limited	 to	 one	
hemisphere.	They	may	be	discretely	localised	or	more	widely	distributed.	Focal	seizures	can	be	
classified	into	seizure	with	or	without	awareness	and	then	along	with	further	manifestation	in	










onset	 in	16/18	cases	 in	Trivisano	et	al.’s	 cohort33.	With	progression	of	 the	disease,	bursts	of	
predominantly	 2	 to	 5Hz	 generalised	 irregular	 spike	 and	 wave	 and/or	 polyspike	 and	 wave	
become	 prominent4.	 A	 useful	 additional	 marker	 is	 the	 electromyography	 recording	 during	
atonic	seizures	which	demonstrate	a	slow	wave	component	of	 the	discharge46.	Although	 it	 is	
recognised	that	MAE	can	present	as	an	EE47,	generally	posterior	background	rhythms	and	sleep	
architecture	 are	 normal,	 which	 is	 in	 contrast	 to	 LGS	 where	 there	 is	 little	 or	 no	 normal	
background	activity.	Additionally	although	slow	spike	waves	can	be	seen	in	both	MAE	and	LGS,	
in	LGS	this	is	often	combined	with	focal	abnormalities;	whereas	in	MAE	focal	activity	is	unusual	
and	 acted	 as	 indicators	 of	 poor	 prognosis	 in	 a	 cohort	 of	 nine	 cases48.	During	 remission,	 it	 is	
typical	 for	 a	marked	diffuse	 abnormal	 theta	 rhythm	 to	 develop49.	 Therefore,	 although	 there	





Neurological	 examinations	 of	 MAE	 cases	 have	 been	 recorded	 in	 three	 series	 with	 little	
agreement.	 Doose	 et	 al.	 reported	 6/51	 of	 his	 cohort	 with	 variable	 abnormal	 neurology	 of	










Behavioural	 comorbidities	 including	 autism	 spectrum	 disorder	 (ASD)	 and	 attention	 deficit	
hyperactivity	disorder	(ADHD)	are	common	in	children	with	epilepsy50.	Escayg	et	al.	 reported	
hyperactivity	and	behavioural	disturbances	in	10/22	MAE	patients,	although	specific	measures	





on	 the	 child	 behavioural	 checklist53.	 The	 child	 behavioural	 checklist	 was	 also	 employed	 by	
Trivisano	 et	 al.	 who	 reported	 normal	 scores	 in	 17/18	 cases.	 However,	 when	 scores	 were	
compared	 with	 controls,	 there	 was	 evidence	 of	 significant	 subclinical	 difficulties	 in	 subtest	
involving	 symptoms	 of	 withdrawn/depression	 (P<0.05),	 attention	 behaviour	 (P<0.01)	 and	






programme	 adaptive	 behaviour.	 It	 involves	 the	 ability	 to	 solve	 problems,	 to	 memorise	
information	and	to	focus	attention54.	As	a	group,	355	individuals	with	generalised	epilepsy	had	
impaired	 cognitive	 performance	 in	 comparison	 to	 75	 healthy	 subjects	matched	 for	 age	 and	
education	 (P<0.0003)55.	 	 Children	 with	 symptomatic	 generalised	 epilepsies	 (like	 MAE)29,	
frequent	seizures,	high	antiepileptic	drug	use	and	early	onset	seizures	appear	most	at	risk55,56.	






































Important	 methodological	 issues	 should	 be	 mentioned	 with	 these	 cognitive	 results;	 (1)	
cognitive	 testing	 at	 any	 time	 point	 can	 be	 influenced	 by	 current	 seizure	 burden	 and	
antiepileptic	drug	use,	 (2)	 it	 is	difficult	to	measure	the	cumulative	effect	of	epilepsy	duration	
prior	 to	 cognitive	 testing,	 (3)	 there	 is	 no	 consistent	 data	 on	 pre-seizure	 cognitive	 levels	 and	
problems	 may	 have	 already	 been	 present,	 (4)	 different	 investigators	 use	 different	
psychometric	tools,	(5)	there	is	no	account	on	the	influence	of	psychosocial	factors	which	may	
play	 an	 important	 role	 and	 (6)	 studies	 are	 mostly	 limited	 to	 measures	 of	 intelligence	 (IQ).	
Nevertheless,	 a	 spectrum	 of	 cognitive	 abilities	 is	 seen	 with	 40	 –	 66%	 of	 cases	 classified	 as	
normal	 or	 IQ	 >80.	 Trivisano	et	 al.	 correlated	 cognitive	 delay	with	 family	 history	 of	 epilepsy,	
tonic	 seizures,	 epileptic	 encephalopathy,	 epilepsy	 duration,	 age	 of	 onset	 (P=0.06)	 and	 non	





Prognosis	 is	 variable	 in	MAE.	Doose	 identified	 the	 following	 risk	 factors	 for	 an	unfavourable	











and	 30	 unfavourable	 cases	 based	 on	 electroclinical	 features	 and	 evolution.	 The	 key	




Putting	 together	 the	 evidence,	 cases	with	 unfavourable	 outcome	might	 be	 characterised	 by	
absence	or	minor	epileptic	status,	and	tonic	seizures	–	all	features	that	shift	the	overall	picture	
toward	LGS.	However	when	features	in	groups	of	patients	with	MAE	and	LGS	were	compared,	
there	 was	 no	 transition	 in	 syndrome	 diagnosis	 between	 the	 two	 groups,	 even	 though	 EEG	
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patterns	 were	 changeable	 and	 some	 electroclinical	 features	 overlapped58.	 These	 studies	














monozygotic	 pairs	 are	 assumed	 to	 be	 genetically	 identical	 in	 DNA	 sequences,	 whereas	
dizygotic	 twins	 share	 approximately	 50%	 of	 their	 gene	 sequence.	 Genetically	 influenced	
characteristics	may	show	a	higher	concordance	in	monozygotic	than	dizygotic	twins,	assuming	
that	both	 types	of	 twins	equally	 share	environmental	 influences.	Family	studies	examine	 the	








Twin	 studies	 of	 symptomatic	 or	 cryptogenic	 generalised	 epilepsies29	 have	 shown	 a	 higher	










A	positive	 family	history	of	seizures	 in	 first,	 second	or	 third	degree	relatives	 is	seen	 in	about	
one	 third	 of	 cases5,32,34.	 In	 Doose’s	 series,	 the	 incidence	 of	 afebrile	 or	 febrile	 seizures	 was	
higher	in	siblings	(brothers	18%,	sisters	12%)	than	in	parents	(father	7%,	mother	4%),	although	
these	 differences	 were	 not	 statistically	 significant	 (parents’	 P=0.36;	 siblings’	 P=0.38)1	 (see	
Table	 1.3).	 This	 unusual	 distribution	 is	 seen	 in	 some	 idiopathic	 generalised	 epilepsies	 with	
genetic	 anticipation59,	 but	 is	more	 likely	 to	be	due	 to	 recall	 bias	 for	 seizures	 in	 the	parental	
generation60.	The	seizure	types	present	in	the	relatives	were	predominantly	febrile	or	afebrile	
GTCS	and	myoclonic	or	myoclonic	atonic	seizures	occurred	in	only	three	of	160	siblings5.	The	
low	 familial	 aggregation	 of	 myoclonic	 or	 myoclonic	 atonic	 seizures	 is	 an	 interesting	
observation;	 one	 hypothesis	 is	 an	 interaction	 between	 an	 inherited	 susceptibility	 to	
generalised	 seizures	 with,	 a	 separate	 and	 low	 frequency	 (genetic,	 epigenetic,	 or	
environmental)	 factor	 modifying	 the	 phenotype61.	 This	 situation	 is	 seen	 in	 the	 differential	
















defined	 specific	 EEG	 abnormalities	 evaluated	 as	 (1)	 photoparoxysmal	 responses	 (PPR),	 with	
bilateral	 synchronous	 or	 only	 parietal	 occipital	 irregular	 spike	 and	 waves	 during	 photic	
stimulation,	 (2)	 GSW	 at	 rest	 or	 during	 hyperventilation	 and	 (3)	 dysrhythmia	 defined	 as	 an	
irregular	 background	 activity	 with	 widely	 varying	 amplitudes	 and	 frequencies	 such	 that	 no	
dominant	activity	 is	recognisable.	He	went	on	to	detail	that	 in	dysrhythmia,	the	amplitude	of	
the	 EEG	 may	 vary	 considerably;	 sharp	 transients	 may	 be	 interspersed	 but	 not	 spikes	 and	
distinct	 sharp	 waves.	 Dysrhythmia	 may	 be	 continuous	 or	 may	 occur	 in	 paroxysmal	 groups.	
Table	 1.4	 summaries	 the	 findings	 from	 these	 EEG	 family	 studies.	 The	 most	 common	 EEG	
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abnormality	was	PPR	and	there	seemed	to	be	a	clear	female	excess;	present	in	16	of	39	sisters	





EEG	findings	 Siblings	(n=72)	 Fathers	(n=32)	 Mothers	(n=37)	 Total	
PPR	 20	(27.8%)	 -	 6	(16.2%)	 26	(18.5%)	
GSW	 6	(8.3%)	 1	(3.1%)	 -	 7	(4.9%)	
Dysrhythmia	 14	(19.4%)	 -	 3	(8.1%)	 17	(12.0%)	
Total	 33	(45.8%)	 1	(3.1%)	 9	(24.3%)	 50	(35.4%)	
PPR	photoparoxysmal	responses,	GSW	generalised	spike	wave	
	


















the	 younger	 age	 groups	 (<10	 years)	 had	 more	 frequent	 abnormalities	 particularly	 in	
dysrhythmia	and	PPR,	possibly	capturing	age	related	EEG	features	(see	Table	1.6).	Moreover,	
GSW,	 the	 prototype	 epileptiform	 discharge	 were	 the	 least	 reported	 group	 overall	 (4.9%).	
However,	 It	 is	also	worth	noting	 that	34	 (68%)	 families	were	 recorded	as	having	a	history	of	













PPR	 3	(14.2%)	 11	(44.0%)	 3	(18.7%)	 3	(30.0%)	
GSW	 3	(14.2%)	 1	(4.0%)	 2	(12.5%)	 -	
Dysrhythmia	 9	(42.9%)	 4	(16.0%)	 -	 1	(10.0%)	




(68%)	 of	 families	 had	 members	 (excluding	 the	 proband)	 with	 evidence	 of	 seizure	
susceptibility5.	 These	 34	 families	 included	 11	 families	 with	 both	 pathologic	 EEG	 and	 seizure	





following:	 (1)	 the	 endophenotype	 is	 associated	 with	 illness	 in	 the	 population,	 (2)	 the	
endophenotype	 is	 heritable,	 (3)	 the	 endophenotype	 is	 state	 independent	 (manifest	 in	 an	




























epilepsy	 families	 have	 revealed	 several	 different	mutations	 in	MAE	 patients.	 SCN1A10,70	 and	
SCN1B8	mutations	segregated	in	three	separate	generalised	epilepsy	with	febrile	seizures	plus	
(GEFS+)	 pedigrees	 that	 included	 one	 family	 member	 with	 a	 MAE	 phenotype.	 Additionally,	
linkage	 analysis	 identified	 GABRG2	 in	 a	 large	 epilepsy	 pedigree	 with	 childhood	 absence	
epilepsy	 and	 febrile	 seizures9;	 the	 pedigree	 has	 a	 single	 member	 with	 MAE	 although	 his	
genotype	was	 not	 investigated.	 In	 each	 of	 these	 pedigrees,	 only	 one	member	was	 affected	




This	 hypothesis	 of	 a	private	mutation	was	 tested	 in	 22	 sporadic	 French	MAE	 cases	 and	 four	





a	 recurrent	 SCN1A	 variant	 p.T1174S	 was	 identified	 in	 a	 boy	 with	 sporadic	 MAE,	 but	 the	
pathogenicity	 is	 uncertain	 as	 the	 same	 variant	was	 identified	 in	 his	 asymptomatic	mother72,	








type	 1	 protein	 that	 is	 responsible	 for	 transporting	 glucose	 across	 the	 blood	 brain	 barrier.	
SLC2A1	 is	 associated	 with	 glucose	 transporter	 type	 1	 deficiency	 syndrome73.	 The	 classic	
phenotype	 is	 characterised	 by	 infantile	 onset	 seizures,	 delayed	 neurologic	 development,	
acquired	microcephaly	and	complex	movement	disorders.	Treatment	with	the	ketogenic	diet	is	
highly	effective	in	 improving	seizures,	movement	disorder	and	alertness.	Four	our	of	84	MAE	
cases	 were	 identified	 with	 SLC2A1	 variants	 using	 multiplex	 ligation	 dependent	 probe	









NGS	 or	 high	 throughput/massive	 parallel	 sequencing	 has	 been	 a	 transformative	 technology	
and	 involves	 the	 generation	 of	 sequence	 data	 from	 hundreds	 of	 millions	 of	 short	 DNA	
fragments	in	parallel.	The	first	commercial	machine	for	this	purpose	was	available	in	2008.	This	
reduced	 cost	 and	 increased	 speed	 in	 generating	 sequence	 data	 lead	 to	 a	 rapid	 increase	 of	
genes	 connected	 to	 MAE.	 Several	 different	 methodologies	 and	 commercial	 machines	 to	


















































































































264	 cases	 (infantile	 spasms	 n=149,	 LGS	 n=115)	 by	 the	 Epi4K	 consortium76.	 Subsequently	
targeted	resequencing	of	500	cases	with	EE	identified	six	cases	with	de	novo	CHD2	variants,	of	
these	2/81	cases	had	MAE12.	CHD2	encodes	for	chromodomain	helicase	DNA	binding	protein	2,	
it	 plays	 an	 important	 role	 in	 modulating	 chromatin	 structure,	 cell	 cycle	 regulation,	
development	 and	 cell	 differentiation.	 Pathogenic	 variants	 appear	 to	 be	 loss	 of	 function	 as	
associated	 cases	 mostly	 have	 copy	 number	 deletions	 or	 frameshift	 leading	 to	 nonsense	
mutations77.	The	role	of	CHD2	haploinsufficiency	was	tested	 in	knocked	down	chd2	zebrafish	
larvae	 which	 exhibited	 altered	 locomotor	 activity	 and	 epileptiform	 discharges,	 which	 were	
absent	in	control	larvae77.	
	
Most	 patients	 with	 CHD2	 pathogenic	 variants	 do	 not	 have	 a	 MAE	 phenotype.	 Indeed	 the	
phenotypic	 spectrum	 extends	 to	 LGS,	 SMEI,	 GGE,	 epilepsy	 with	 myoclonic	 absences,	 other	
unclassified	EE	and	ID	without	epilepsy15,77-79.	Moreover,	CHD2	variants	were	evaluated	as	an	
independent	 risk	 factor	 for	 photosensitivity	 in	 epilepsy	 occurring	 in	 11/580	 individuals	 with	









SYNGAP1	was	 identified	 in	a	 similar	 fashion	 to	CHD2,	 first	 through	de	novo	 screening	 in	264	
cases	 with	 EE76,	 and	 then	 subsequently	 through	 targeted	 resequencing	 in	 500	 cases	 with	 a	
spectrum	of	epilepsy	syndromes	that	can	cause	EE12.	The	latter	cohort	 identified	5/500	cases	
with	de	novo	SYNGAP1	 variants	but	 this	did	not	 include	any	of	 the	81	MAE	cases	within	 the	
cohort.	 Subsequently	 Mignot	 et	 al.	 identified	 loss	 of	 function	 SYNGAP1	 variants	 in	 17/251	
patients	 with	 neurodevelopmental	 disorders,	 of	 these	 three	 cases	 had	 a	MAE	 phenotype16.	
SYNGAP1	encodes	the	synaptic	RAS-GTPase	activating	protein	1,	a	protein	of	the	post	synaptic	
density	 of	 glutamatergic	 neurons.	 SYNGAP1	 is	 able	 to	 positively	 or	 negatively	 regulate	 the	











KCNA2	 encodes	 the	 potassium	 channel	 Kv1.2,	 these	 channels	 are	 highly	 expressed	 in	 the	
central	 nervous	 system	 and	 have	 an	 important	 role	 in	 neuronal	 excitability	 and	
neurotransmitter	 release.	KCNA2	was	 first	 identified	as	a	candidate	gene	following	detection	
of	a	de	novo	variant	in	33	patients	with	epilepsy	as	part	of	a	pilot	study80.	Subsequently	several	
parallel	 studies	 investigating	 255	 individuals	 identified	 six	 further	 patients	 with	 previously	
unreported	lost	of	function	or	gain	of	function	de	novo	variants	in	KCNA2,	of	these	were	1/39	
MAE	case19.	KCNA2	associated	epilepsy	can	have	a	broad	phenotypic	spectrum	from	a	GGE	to	






STX1B	encodes	syntaxin	1b,	a	component	of	 the	SNARE	complex,	 that	helps	 tethers	synaptic	
vesicles	at	the	presynaptic	membrane	and	mediates	neurotransmitter	release.	STX1B	was	first	
identified	 in	 two	 large	 German	 pedigrees	 with	 familial	 febrile	 seizures.	 Linkage	 analysis	








SLC6A1	 encodes	 GAT-1,	 a	 voltage	 dependent	 gamma	 aminobutyric	 acid	 (GABA)	 transporter	
that	is	responsible	for	the	re-uptake	of	GABA	from	the	synapse.		Some	have	described	SLC6A1	
as	the	“Doose	gene”	as	it	has	only	been	linked	to	MAE	patients	and	at	4%	(6/160	cases),	 it	 is	
the	 most	 enriched	 causative	 MAE	 gene.	 Carvill	 et	 al.	 published	 six	 pathogenic	 de	 novo	
heterozygous	SLC6A1	variants,	 two	truncation	and	four	missense17.	The	authors	postulated	a	
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loss	 of	 function	 role	 in	 the	 nonsense	 variants	 and	 clustering	 of	 the	 four	 missense	 variants	
around	the	GABA	binding	pocket,	which	 in	 three	dimensional	 space	disrupts	GABA	transport	
from	 the	extracellular	 space	 into	 the	pre-synaptic	 terminal.	 Subsequently	 another	MAE	 case	
with	 a	 de	 novo	 p.C164T	 variant	 was	 identified,	 high	 resolution	 structural	 modelling	










TBC1D24	 (TBC1	 domain	 family	 member	 24)	 is	 involved	 in	 regulation	 of	 synaptic	 vesicle	
trafficking	in	brain	and	somatic	development.	TBC1D24	was	first	mapped	in	a	consanguineous	
Arab	 Israeli	 family	with	 focal	 epilepsy	 and	 ID	 using	multipoint	 linkage	 analysis84.	 Since	 then,	
several	other	reports	including	a	recent	review	on	48	cases	has	been	published;	the	associated	
phenotypic	spectrum	 is	vast,	 ranging	 from	 isolated	deafness,	benign	myoclonic	epilepsies,	 to	
EE	and	severe	developmental	delay22.	All	reported	variants	are	bialleleic.	
	
A	 single	 case	 with	 MAE	 was	 reported	 in	 this	 cohort22.	 He	 carried	 a	 16p13.3	 duplication	 of	
407kb	 including	 but	 not	 interrupting	 TBC1D24	 (2481289-2888632)	 x322.	 This	 case	 (subject	
00523/S2388)	was	 also	 recruited	 to	 this	 study	 and	exome	 sequencing	did	not	 identify	 other	
variants	 of	 interest.	 His	 phenotype	 consists	 of	 seizure	 onset	 at	 3	 years	 of	 absences,	 atonic,	





KIAA2022	 is	 an	 X	 linked	 ID	 gene	which	 is	 highly	 expressed	 in	 the	 brain,	 not	much	 is	 known	
about	its	gene	function	and	it	is	thought	to	have	a	role	in	early	brain	development.	It	was	first	








GABRG2	 encodes	 GABAA	 receptor	 γ2-subunit	 and	 is	 part	 of	 the	 family	 of	 GABAA	 receptor	
subunit	genes	(GABRA1,	GABRB3,	GABRG2	and	GABRD),	all	of	which	have	been	associated	with	
various	epilepsy	syndromes.	GABRG2	was	 first	 connected	 to	MAE	 in	 the	pre	NGS	era	 from	a	
large	 epilepsy	 pedigree	 with	 childhood	 absence	 epilepsy	 and	 febrile	 seizures	 using	 linkage	
analysis9.	 The	 pedigree	 has	 a	 single	 member	 with	 MAE	 although	 his	 genotype	 was	 not	
investigated.	Subsequently,	variants	 in	GABRG2	has	been	related	to	patients	with	GEFS+	and	
SMEI87.	A	role	as	a	genetic	risk	factor	has	also	been	explored.	Rare	variant	association	analyses	
demonstrated	statistical	enrichment	of	 rare	GABRG2	 variants	 in	 febrile	 seizures	and	 rolandic	
epilepsy88,89.		
	









The	GABRG2	 associated	 epilepsy	 phenotype	 appears	 diverse	 and	 it	 is	 difficult	 to	 generalise	
with	only	two	published	MAE	cases	with	quite	different	profiles.	The	role	of	GABRG2	in	MAE	is	













The	 role	 of	 rare	 genomic	 copy	 number	 variations	 (CNVs)	 in	 epilepsy	 is	 now	 recognised	 as	 a	
pathogenic	 principle	 with	 specific	 genomic	 hotspots	 (deletions	 at	 15q11.2,	 15q13.3	 and	
16p13.11)	 predisposing	 to	 neuropsychiatric	 phenotypes	 and	 GGE91,92,93.	 In	 a	 study	 of	 279	
patients	with	epilepsy	and	246	healthy	controls,	9.3%	of	patients	with	epilepsy	had	rare	CNVs;	
which	were	significantly	larger	(>1Mb,	P=0.002),	had	more	than	10	genes	(P=0.005),	and	were	
more	 enriched	 when	 associated	 with	 mental	 retardation	 and	 neuropsychiatric	 features	
(P=0.004)94.	 	 This	 increased	 complexity	 in	 genetic	 architecture	 may	 add	 an	 additional	 risk	




hybridization	 in	 analysis.	 Table	 1.9	 summarises	 the	 positive	 findings	 in	 these	 studies.	 CNVs,	
which	have	been	 reported	as	part	of	 specific	 epilepsy	 gene	 studies	 e.g.	 in	CNVs	 in	TBC1D24	
and	STX1B,	have	not	been	 included	 in	 this	 table.	 	CNVs	were	 reported	 rare	 if	 they	were	not	
present	 in	 control	 populations.	 Rare	 CNVs	 occurred	 in	 9.2%	 (9/97)	 and	 were	 considered	
pathogenic	in	5.1%	(5/97)	of	MAE	cases.	The	size	of	CNVs	ranged	from	85.8kb	to	9.45Mb.	CNVs	






Rare	CNV	 Size	 Overlapping	genes	 Causal?	
Mefford	et	al.	201093		
(2/15)	
5p15.33	dup	inh	M^		 713kb	 NKD2,	SLCA18	 L	
7q36.1	del	inh	P	 85.8kb	 GALNT11	 U	
Mefford	et	al.	201190	
(6/77)	
15q11	del	de	novo	 270kb	 UBE3A	 P	
7q21	del	inh	M^	 3.9Mb	 CACNA2D1,	PCLO	 L	
10p13	del	de	novo	 5.25Mb	 -	 P	
5q33-q34	del	de	novo	 6.45Mb	 GABRA1,	GABRG2	 P	
15q13	del	inh	P	 1.7Mb	 -	 U	
4q35	dup	inh	P	 1.05Mb	 -	 U	
Helbig	et	al.	201495	
(1/5)	
16p13.11	del	de	novo	 -	 -	 P	
Ottaviani	et	al.	201596	
(case	report)	





During	 the	 course	 of	 this	 project,	 the	 number	 of	 genes	 associated	 with	 MAE	 has	 rapidly	





Collectively,	 these	 10	 genes	 account	 for	 approximately	 20%	 of	 genetic	 aetiology.	 This	 list	
comprises	 contribution	 of	 pathogenic	 variants	 in	 combined	 published	 MAE	 cases	 in	 SCN1A	
2.1%	 (1/46),	GABRG2	 0.93%	 (1/107),	SLC2A1	 1.9%	 (4/204),	CHD2	2.9%	 (3/101),	KCNA2	 2.5%	





This	genetic	heterogeneity	may	 in	part	be	accounted	 for	by	 the	phenotypic	heterogeneity	 in	
MAE,	 as	 demonstrated	 by	 phenotypic	 clues	 in	MAE	 cases	 for	 specific	 genes,	 e.g.	movement	
disorders	in	SLC2A1	and	febrile	seizures	in	STX1B.	Phenotypic	heterogeneity	is	compounded	by	
the	difficulties	in	a	precise	epilepsy	syndrome	diagnosis	due	to	the	clinical	continuum	of	MAE	
and	 the	 intricacies	 in	 obtaining	 accurate	 seizure	 types.	 	 Hence	 a	 project	 incorporating	 deep	
phenotyping	 using	 well-validated	 instruments	 along	 with	 an	 NGS	 platform	 to	 generate	









the	 presence	 of	 canonical	 facial	 characteristics	 of	 Kabuki	 syndrome.	MLL2	 mutations	 were	
identified	 in	 seven	 cases.	 They	 identified	 two	 further	 mutation	 positive	 cases	 by	 Sanger	
sequencing,	 and	 a	 less	 carefully	 selected	 replication	 cohort	 of	 43	 identified	 26	 mutation	
positive	cases.	This	publication	highlights	 that	 (1)	Sanger	sequencing	 is	 the	gold	standard	 for	
validating	mutation	 identification	 following	exome	 sequencing,	 (2)	deep	phenotyping	 can	be	
useful	 to	 isolate	 a	 homogenous	 cohort	 and	 (3)	 phenotypic	 heterogeneity	 can	 reduce	 the	
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likelihood	 of	 gene	 identification	 as	 demonstrated	 by	 the	 reduced	 identification	 in	 the	 less	
carefully	selected	replicated	cohort.	
	
Disease	 identification	 strategies	 using	 exome	 sequencing	 can	 be	 divided	 into	 four	 main	
groups98,	all	of	which	have	been	employed	successfully	in	epilepsy.	(1)	Studies	that	use	genetic	
linkage99	 (2)	 studies	 that	 employ	 homozygosity	 or	 a	 recessive	 model	 of	 inheritance	 in	
analysis100	 (3)	 studies	 that	 seek	 to	 identify	 overlapping	 shared	 rare	 variants	 or	 de	 novo	
variants101	 and	 lastly	 (4)	 studies	 that	 use	 a	 candidate	 gene	 based	 strategy12.	 These	 exome	





rise	 to	different	permutations	of	seizure	and	EEG	features	within	 individual	 family	members.	
This	may	be	analogous	to	the	proposed	model	of	oligogenic	inheritance	in	GGE	sub	syndromes	
in	which	there	are	clear	shared	and	distinct	genetic	influences	on	seizures	and	EEG62,63,67,102,103.	
To	help	unravel	 this,	 replicating	 family	EEG	studies	 to	 identify	 familial	EEG	traits	may	help	 in	
informing	 inheritance	models.	 In	addition	specific	EEG	features	such	as	GSW	and	PPR	can	be	






perform	 family	 EEG	 studies	 to	 identify	 heritable	 EEG	 traits	 and	 potentially	 gain	 insight	 into	


















a. Behavioural	 comorbidity	 (autism	 spectrum,	 attention	 deficit	 hyperactive	
disorder)	 and	 adaptive	 behaviour	 will	 be	 investigated	 with	 the	 Social	
communication	 questionnaire	 (SCQ),	 Strength	 and	 difficulties	 questionnaire	
(SDQ),	 developmental,	 dimensional	 and	 diagnostic	 interview	 (3di)	 and	 the	
Adaptive	behaviour	assessment	system	(ABAS).		
b. Subjects	aged	between	3	and	7	years	will	be	directly	phenotyped	for	cognition	
using	 the	 Bayley	 scales	 of	 infant	 and	 toddler	 development	 (Bayleys	 III)	 or	
Wechsler	Preschool	and	Primary	Scale	of	Intelligence	(WPPSI-III);	and	language	
using	 the	 Clinical	 Evaluation	 of	 Language	 Fundamentals	 –	 Preschool	 (Pre	
School	CELF)	or	Bayleys	III.		
c. Detailed	 electroclinical	 features	 will	 be	 obtained.	 Participants	 will	 also	






















This	 study	 is	 under	 the	 umbrella	 study	 of	 Professor	 Deb	 Pal’s	 study	 in	 Genetics	 of	 Human	
Epilepsy,	NIHR	 portfolio	 study	 8858,	 CSP	 34723.	 The	 protocol,	 participant	 information	 sheet	
and	consent	form	was	revised	to	 include	the	relevant	arms	of	this	study.	This	was	submitted	
and	approved	in	stages	to	the	Bloomsbury	research	ethics	committee	(ref:09/H0713/76).	The	
versions	 and	 date-controlled	 documents	 used	 for	 the	 study	 were	 as	 follows:	 Genetics	 in	









(3)	 presence	 of	 generalise	 spike	 wave	 and/or	 polyspike	 wave	 discharges	 on	 EEG	 and/or	










Additionally	an	 internet	based	presence	 for	 the	 study	was	 set	up	 to	 raise	awareness	 for	 the	
study	 and	 prompt	 referrals.	 The	 study	 was	 publicised	 in	 the	 laboratory	 group	 website	
www.childhood-epilepsy.org;	 in	 the	 UK	 epilepsy	 action	 website	
www.epilepsy.org.uk/info/syndromes/myoclonic-astatic-epilepsy-doose-syndrome,	 circulated	
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families	 self	 referred	 primarily	 through	 website	 enquiry.	 Medical	 and	 EEG	 reports	 were	
obtained	from	the	referring	physician	and/or	family.	The	clinical	history	for	all	referred	cases	
was	 reviewed	 to	determine	eligibility.	Eligible	cases	were	 then	contacted	either	 in	person	or	
over	the	phone	where	a	clinical	history	and	family	history	was	taken.	The	study	was	discussed	









A	research	pack	containing	participant	 information	sheets,	consent	 forms,	questionnaires	 for	
the	parent/caregiver	to	complete	and	clearly	labelled	DNA	and	RNA	saliva	kits	was	sent	to	the	
families	along	with	a	prepaid	addressed	envelope	to	return	the	research	materials.	Participants	
































(2)	 The	 MRC	 Social	 Genetic	 Developmental	 Psychiatry	 (SGDP)	 building	 at	 the	 Institute	 of	
Psychiatry,	Psychology	and	Neuroscience	and	(3)	The	Clinical	Research	Facility	at	King’s	College	




Instrument	 Typical	Age	 Duration	 Person	
Preschool	CELF	 3	–	7	years	 30	minutes	 Investigator	+	case	
Baileys	III	 6	–	42	months	 30	–	90	minutes	 Investigator	+	case	
WPSSI	III	 3	–	7	years	 60	minutes	 Investigator	+	case	







from	 referring	 clinical	 collaborators.	 Clinical	 history	 was	 also	 taken	 over	 the	 telephone	 or	
directly	 from	all	 families.	 In	addition,	 Form	C,	 a	questionnaire	 relating	 to	 the	 child’s	medical	
history	and	an	ethnicity	form	generated	from	the	ethnicity	groups	in	the	National	census	2011	







instruments	 are	 well-validated	 cognitive	 tests	 and	 are	 used	 frequently	 in	 research	 and	 in	
clinical	practice104.	The	instrument	selected	was	based	on	the	estimated	cognitive	ability	of	the	







vocabulary	and	 Information	subtest	 for	verbal	 IQ,	and	the	Block	design	and	Object	Assembly	
for	performance	IQ.	Subjects	above	4	years	were	administered	seven	core	subtests.	The	core	









the	 WPPSI	 III	 and	 CELF	 Preschool.	 The	 cognitive	 scale	 of	 the	 Bayleys	 III	 measure	 function	
similar	 to	 the	 WPPSI	 III	 and	 the	 receptive	 communication	 and	 expressive	 communication	














a	wide	 range	 of	 impairments	 in	 social	 and	 communicative	 abilities,	 stereotyped	 behaviours,	










IV	 diagnosis	 of	 autism.	 The	 DSM	 serves	 as	 an	 authority	 for	 classification	 and	 diagnosis	 for	
psychiatric	diagnosis108.		
	
The	SCQ	Autoscore	Form:	Lifetime	was	used.	The	 form	references	 the	 individual’s	behaviour	
during	the	individual’s	entire	developmental	history.	There	are	12	questions	that	cover	three	
areas	of	functioning:	reciprocal	social	interaction,	communication	and	restricted	repetitive	and	





The	Developmental,	 Dimensional	 and	Diagnostic	 Interview	 (3di)	 is	 a	 computerized	 interview	
assessment	 that	 identifies	 clinical	 and	 subclinical	 ASD109.	 The	 3di	 scores	 for	 reciprocal	 social	
interaction	 skills,	 use	 of	 language	 and	 other	 social	 communication	 skills	 and	
repetitive/stereotyped	behaviours	 and	 routines.	 The	 full	 3di	 is	 117	questions	 and	 requires	 2	
hours	so	the	ASD	rapid	assessment	comprising	53	questions	was	used.	The	53	questions	in	the	
ASD	rapid	assessment	was	found	to	be	most	discriminating	and	can	be	scaled	up	to	the	same	
diagnostic	 thresholds	 as	 the	 DSM-5	 for	 ASD110.	 The	 reduced	 testing	 burden	 makes	 it	 more	
feasible	to	be	administered	to	participants.		
	
3di	 diagnosis	 are	 made	 in	 general	 on	 the	 following	 criteria	 where	 A	 is	 social	 reciprocity,	 B	





















informant	 rated	 version	 for	 3	 to	 4	 year	 olds.	 There	 are	 25	 items	 to	 ascertain	 positive	 or	
negative	 attribute	 in	 five	 scales:	 emotional	 symptoms,	 conduct	 problems,	
hyperactivity/inattention,	peer	relationship	problems	and	prosocial	behaviour.	The	 items	can	
be	 rated	 “not	 true”,	 “somewhat	 true”	 or	 “certainly	 true”	 with	 scores	 0-1-2.	 An	 impact	
supplement	 is	 also	 included	 which	 enquires	 further	 about	 chronicity,	 distress,	 social	





Attention	 Deficit	 Hyperactivity	 Disorder	 (ADHD)	 is	 a	 childhood-onset	 neurodevelopmental	
disorder	 characterised	 by	 deficits	 in	 attention	 and/or	 hyperactivity	 and	 impulsivity.	 The	
Conner’s	Comprehensive	Behaviour	Rating	Scales	 (CBRS)	was	used	as	 the	assessment	 tool	 to	
identify	relevant	symptoms.	
	
The	 CBRS	 is	 a	 comprehensive	 assessment	 tool,	which	 assesses	 a	wide	 range	 of	 behavioural,	
emotional	 and	 social	 disorders113.	 Parents	 and	 the	 child’s	 teacher	 are	 asked	 to	 complete	

















In	 2002,	 the	 American	 Association	 on	 Intellectual	 and	 Developmental	 Disabilities	 defined	
disability	as	characterised	by	significant	limitation	in	both	intellectual	functioning	and	adaptive	
behaviour	 including	 conceptual,	 social	 and	 practical	 skills.	 In	 the	 UK,	 the	 Equality	 Act	 2010	
defined	 disability	 as	 a	 physical	 or	 mental	 impairment	 that	 has	 a	 substantial	 and	 long-term	
negative	 effect	 on	 the	 ability	 to	 do	 normal	 daily	 activities.	 Moreover,	 the	 recent	 DSM	 V	
diagnostic	 criteria	 for	 intellectual	 disability	 now	 includes	 criterion	 for	 deficits	 in	 adaptive	
functioning.	
	
The	 ABAS	 II	 provides	 overall	 adaptive	 functioning	 (General	 Adaptive	 Composite)	 as	 well	 as	
assessment	of	the	ten	adaptive	skill	areas	specified	 in	the	DSM	IV.	Additionally	 it	groups	skill	



































The	 results	 are	 represented	 as	 standardised	 data	 and	 allow	 a	 comparison	 between	 an	
individual’s	 adaptive	 skills	 and	 typically	 developing	 individuals	 of	 the	 same	 age.	 A	 General	
Adaptive	 Composite	 (GAC)	 score	 was	 derived	 from	 the	 sum	 of	 the	 conceptual,	 social	 and	
practical	 domains.	 These	 scores	 were	 then	 classified	 into	 very	 superior	 (≥130	 score,	 ≥98th	
percentile),	superior	(120-129	score,	91st-97th	percentile),	above	average	(110-119	score,	75th-







password	 protected	 platform	 http://redcap.uni.lu.	 Where	 data	 were	 missing,	 referring	
clinicians	were	contacted	directly	for	further	clarification.	Phenotypic	data	of	the	Italian	cohort	









































4	 0	 0	 4	
Mixed	ethnic	group	 5	 1	 2	 8	
Asian	 4	 1	 0	 5	
Unknown	 0	 1	 0	 1	










16	 (13.6%)	 cases	 and	 second	 or	more	 degree	 family	member	 in	 28	 (23.9%)	 cases.	 A	 family	
history	of	febrile	seizures	was	reported	in	10	(8.5%)	cases.	There	were	missing	data	on	family	
history	 in	 five	 Italian	 cases	 (009Z,	 565D,	 561D,	 224D,	 027A)	 and	 one	 Euroepinomics	 case	
(W_M_1144326).		
	
20	 (17.5%)	out	of	114	 cases	 reported	developmental	delay	prior	 to	epilepsy	onset.	Of	 these	
cases	 with	 developmental	 delay,	 nine	 cases	 reported	 isolated	 speech	 delay	 prior	 to	 seizure	
onset.	 Seven	 Italian	 cases	 (291J,	 731J,	 565D,	 561D,	 224D,	 768H,	 027A)	 and	 two	 cases	
(W_M_1158897,	W_M_1144306)	in	the	Euroepinomics	cohort	had	missing	information	about	
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cases.	 Seizure	 type	 at	 onset	 was	 missing	 for	 one	 Euroepinomics	 case	 (EG0679).	 During	 the	
course	 of	 the	 epilepsy,	 mainly	 generalised	 seizure	 types	 were	 reported.	 115	 (93.4%)	 cases	
reported	a	history	of	myoclonic-atonic	or	atonic	seizures,	85	(69.1%)	cases	reported	GTCS,	84	
(68.2%)	 cases	 reported	 myoclonic	 seizures,	 67	 (54.4%)	 cases	 reported	 absence	 seizures,	 26	
(21.1%)	 cases	 reported	 tonic	 seizures,	 eight	 (6.5%)	 cases	 reported	 focal	 seizures	 with	 or	
without	secondary	generalisation,	four	(3.2%)	cases	reported	epileptic	spasms	and	two	(1.6%)	















GTCS	 Myoclonic	 Absence	 Tonic	 Focal	
UK	(n=67)	 67	(100%)	 55	(82.0%)	 56	(83.5%)	 43	(64.1%)	 15	(22.3%)	 6	(8.9%)	
Euroepinomics	
(n=38)	
35	(92.1%)	 21	(55.2%)	 20	(52.6%)	 16	(42.1%)	 3	(7.8%)	 2	(5.2%)	
Italian	(n=18)	 13	(72.2%)	 9	(50%)	 8	(44.4%)	 8	(44.4%)	 8	(44.4%)	 0	
Total	(n=123)	 115	
(93.4%)	
85	(69.1%)	 84	(68.2%)	 67	(54.4%)	 26	(21.1%)	 8	(6.5%)	
	
Clinical	examination	 findings	were	available	 in	109	cases,	and	were	 reported	abnormal	 in	23	
(21.1%)	cases.	These	were	cerebellar	signs	mainly	involving	tremor	and	ataxia	in	13	cases,	six	
cases	 with	 pyramidal	 or	 motor	 signs,	 three	 cases	 with	 dysmorphism	 and	 one	 case	 with	
microcephaly.	
	
EEG	 reports	were	 available	 in	 112	 cases	 (61	UK	 cohort,	 37	 Euroepinomics	 cohort,	 14	 Italian	




























Intellectual	 disability	 (ID)	 was	 a	 well-recognised	 co-morbidity.	 As	 a	 general	 measure,	 the	
presence	of	ID	was	elicited	through	data	provided	by	the	referring	clinician.	ID	was	reported	in	
43	 (64.1%)	 cases	 in	 the	 UK	 cohort,	 23	 (60.5%)	 cases	 in	 the	 Euroepinomics	 cohort	 and	 10	
(55.5%)	 of	 the	 Italian	 cohort.	 Data	 from	 six	 cases	
(W_M_1147816/1151981/1151131/1158897/1199453/1202321)	of	the	Euroepinomics	cohort	









and	 with	 the	 Bayleys	 III	 (n=7).	 In	 two	 cases,	 subject	 00568	 and	 subject	 00596,	 testing	 was	

















III	 (n=5).	 In	 total,	 there	was	 evidence	 of	 delayed	 language	 in	 nine	 (64.2%)	 cases.	 Percentile	






















3002	301*	 4y	7m	 7y	2m	 WISC	IV	UK	 96	 98	 96	(91-101)	 -	
3004	301	 3y	7m	 6y	2m	 WPPSI	III	 101	 73	 80	(76-96)	 8th	
00505	 2y	 6y	5m	 WPPSI	III	 102	 77	 90	(85-95)	 45th	
00506*	 3y	 6y	5m	 WPPSI	III	 72	 65	 60	(56-66)	 -	
00524	 4y	 5y	8m	 WPPSI	III	 104	 112	 110	(105-115)	 25th	
00526	 2y	11m	 5y	8m	 WPPSI	III	 61	 59	 48	(45-54)	 0.1th	
00539	 2y	6m	 5y	10m	 WPPSI	III	 95	 90	 93	(88-98)	 66th	
00566*	 4y	3m	 12y	 WISC	IV	 69	 77	 70	(65-75)	 -	
00600*	 2y	11m	 4y	2m	 WPPSI	IV	 75	 75	 67	(63-73)	 <0.1th	
00602	 2y	11m	 7y	8m	 WPPSI	III	UK	 101	 119	 99	(94-105)	 6th	
00608	 3y	6m	 8y	4m	 WPPSI	III	UK	 73	 77	 72	(68-78)	 21st	
00615	 4y	8m	 8y	0m	 WPPSI	III	UK	 100	 100	 97	(92-102)	 50th	
W_M_1147805*	 3y	7m	 9y	7m	 WISC	III	 -	 -	 35-	49	 -	
W_M_1158865*	 -	 12y	 WISC	III	 -	 -	 49	(46-55)	 -	
W_M_1152720*	 3y	 -	 WISC	IV	 -	 -	 50	-	69	 -	
W_M_1145972*	 1y	4m	 4y	9m	 WPPSI	III	 -	 -	 70	-	89	 -	
W_M_1195591*	 4y	 13y	 -	 -	 -	 60	 -	
W_M_1199464*	 3y	 17y	 -	 -	 -	 48	 -	























00518	 2y	11m	 6y	0m	 27m	 22m	 17m	
00560	 2y	6m	 5y	10m	 7m	 <1m	 7m	
00572	 9m	 2y	4m	 10m	 6m	 12m	
00574	 2y	4m	 2y	9m	 22m	 9m	 10m	
00590*	 3y	 6y	6m	 23m	 -	 -	






Euroepinomics	 cohort	 and	 through	 the	 Social	 Communication	 Questionnaire	 (SCQ)	 and	 the	
dimensional	and	diagnostic	interview	(3di)	in	the	UK	MAE	cohort.		
	
Sixty-one	 (43	males,	 18	 females)	 of	 67	 SCQ	questionnaires	were	 returned	 in	 the	UK	 cohort,	
achieving	a	response	rate	of	91.0%.	Sixteen	(26.2%)	cases	reached	the	threshold	for	suspecting	













The	 SCQ	 scores	 were	 also	 distributed	 by	 gender	 and	 compared	 with	 the	 Avon	 Longitudinal	
Study	 of	 Parents	 and	 Children	 (ALSPAC)	 cohort	 of	 4167	 boys	 and	 3927	 girls116.	 The	 ALSPAC	
cohort	 is	 a	 prospective	 longitudinal	 intensively	 studied	 population	 cohort	 of	 children.	 Initial	
recruitment	 targeted	all	 pregnant	women	 living	 in	 the	geographical	 region	of	Avon,	 England	
who	 were	 expected	 to	 deliver	 their	 baby	 between	 April	 1,	 1991	 and	 December	 31,	 1992.	
Contact	 has	 been	 maintained	 with	 the	 families	 and	 surviving	 children	
(http://www.bris.ac.uk/alspac/sci-com).	 In	 the	ALSPAC	 cohort,	males	 had	 significantly	 higher	
scores	than	females	but	this	was	not	seen	in	the	UK	MAE	cohort.	However,	the	UK	MAE	cohort	











UK	MAE	cohort	 8.73	(7.37)	 12.11	(7.13)	 0.1045	






Detailed	 ASD	 symptoms	 were	 investigated	 further	 with	 the	 3di	 interview	 in	 the	 UK	 MAE	
cohort.	Twenty-two	3di	 interviews	with	one	or	both	parents	were	conducted	and	the	results	
are	 shown	 in	 Table	 3.8.	 Based	 on	 the	 results	 of	 the	 3di	 interview,	 nine	 cases	 had	 an	 ASD	
diagnosis.	 	 The	 ASD	 diagnosis	 was	 Autism	 in	 three	 cases,	 Atypical	 autism	 in	 four	 cases	 and	




Thai	 chilren117.	At	 the	 time	of	writing	 (February	2017),	 I	 am	awaiting	data	 for	 the	3di	 scores	
from	British	children	and	in	the	interim	have	used	published	data	from	Thai	children.	Scores	in	
social	 reciprocity	 and	 restricted/repetitive	 behaviours	 and	 interest	 were	 significantly	 higher	
than	 typically	 developing	 (P=0.03)	 and	 yet	 significant	 less	 than	 ASD	 children	 (P=0.002).	 This	
suggests	that	the	MAE	children	had	specific	subclinical	ASD	symptoms	with	significant	levels	of	
difficulties.	 As	 for	 scores	 in	 communication,	 the	MAE	 cohort	 had	 significantly	 higher	 scores	
than	 typically	 developing	 children	 (P=0.003)	 but	 not	 as	 significantly	 different	 with	 the	 ASD	








































































































































































































































































































































































































































































































































































































































































































































































































































































89.5%.	 The	 raw	 scores	 in	 individual	 subscales	 were	 divided	 into	 close	 to	 average,	 slightly	
raised,	high	and	very	high	and	are	represented	in	Figure	3.2.	Cases	reported	high	and	very	high	
scores	 across	 all	 domains.	 This	 consisted	 of	 ten	 (16.6%)	 cases	with	 emotional	 problems,	 19	
(31.6%)	 cases	 with	 conduct	 problems,	 22	 (36.6%)	 cases	 with	 hyperactivity	 problems,	 26	






The	 summary	 of	 the	 proportion	 of	 cases	 with	 high	 and	 very	 high	 scores	 for	 the	 various	
domains	are	demonstrated	in	Table	3.9,	along	with	a	normative	sample	of	10298	5	to	15	year	
old	 British	 children118.	 Scores	 in	 conduct	 problems	 (P<0.0001),	 hyperactivity/inattention	
(P<0.0001),	 peer	 relationship	 problems	 (P<0.0001),	 prosocial	 behaviour	 (P<0.0001),	 total	





















































































































































































































































































































response	 rate	 of	 77.6%	 compared	 to	 other	 questionnaires	 is	 possibly	 due	 to	 the	 increased	
number	 of	 questions	 in	 this	 questionnaire.	 Forty-three	 Teacher	 CBRS	 questionnaires	 were	
collected	achieving	a	response	rate	of	64.1%.	The	Parent	and	Teacher	CBRS	questionnaire	have	








were	 cognitive	 problems/inattention	 (subscale	 B),	 with	 50.0%	 of	 parents	 and	 34.8%	 of	
teachers	scoring	a	T	score	>70.	
	
Joint	 scoring	 of	 Parent	 and	 Teacher	 CBRS	 questionnaires	 and	 statistical	 comparison	 with	 a	
normative	 sample	 was	 also	 performed.	 For	 each	 subscale,	 the	 number	 of	 cases	 were	
assembled	 where	 T	 scores	 was	 70	 and	 above	 for	 both	 Parent	 and	 Teacher	 CBRS	 for	 that	
individual.	 Comparison	 was	 performed	 with	 the	 normative	 sample	 (n=3400)	 used	 in	 the	














A:	Oppositional	 28	(53.8%)	 4	(7.6%)	 5	(9.6%)	 15	(28.8%)	 6	 0.0005	
28	(65.1%)	 3	(6.9%)	 1	(2.3%)	 11	(25.5%)	
B:	Cognitive	problems/	
inattention																																																																																																																																																																											
19	(36.5%)	 5	(9.6%)	 2	(3.8%)	 26	(50.0%)	 12	 0.0001	
15	(34.8%) 6 (13.9%)	 7	(16.2%) 15 (34.8%)
C:	Hyperactivity	 23	(44.2%)	 10	(19.2%)	 3	(5.7%)	 16	(30.7%)	 3	 0.0791	
30	(69.7%)	 3	(6.9%)	 5	(11.6%)	 5	(11.6%)	
D:	Anxious-Shy	
	
39	(75.0%)	 4	(7.6%)	 4	(7.6%)	 5	(9.6%)	 0	 1.0000	
23	(53.4%)	 7	(16.2%)	 6	(13.9%)	 7	(16.2%)	
E:	Perfectionism	 39	(75.0%)	 5	(9.6%)	 2	(3.8%)	 6	(11.5%)	 0	 1.0000	
37	(86.0%)	 1	(2.3%)	 3	(6.9%)	 2	(4.6%)	
F:	Social	Problems	 28	(53.8%)	 3	(5.7%)	 1	(1.9%)	 20	(38.4%)	 3	 0.0791	
30	(69.7%)	 1	(2.3%)	 7	(16.2%)	 5	(11.6%)	
G:	Psychosomatic	 27	(51.9%)	 5	(9.6%)	 7	(13.4%)	 14	(26.9%)	 -	 0.0001	
H:	Conner’s	ADHD	
Index	
19	(36.5%)	 5	(9.6%)	 4	(7.6%)	 24	(46.1%)	 9	 0.0001	
23	(53.4%)	 7	(16.2%)	 4	(9.3%)	 9	(20.9%)	
I:	CGI	Restless-
Impulsive	
27	(51.9%)	 5	(9.6%)	 2	(3.8%)	 18	(34.6%)	 5	 0.0034	
24	(55.8%)	 7	(16.2%)	 4	(9.3%)	 8	(18.6%)	
J:	CGI	Emotional	
Liability	
27	(51.9%)	 6	(11.5%)	 6	(11.5%)	 13	(25.0%)	 3	 0.0791	
29	(67.4%)	 2	(4.6%)	 3	(6.9%)	 9	(20.9%)	
K:	CGI	Total	 21	(40.3%)	 7	(13.4%)	 5	(9.6%)	 19	(36.5%)	 6	 0.0005	
25	(58.1%)	 4	(9.3%)	 2	(4.6%)	 12	(27.9%)	
L:	DSM	IV	Inattentive	 22	(42.3%)	 2	(3.8%)	 6	(11.5%)	 22	(42.3%)	 9	 0.0001	
18	(41.8%)	 8	(18.6%)	 4	(7.3%)	 13	(30.2%)	
M:	DSM	IV	
Hyperactive-Impulsive	
23	(44.2%)	 5	(9.6%)	 5	(9.6%)	 19	(36.5%)	 4	 0.0182	
28	(65.1%)	 7	(13.4%)	 3	(5.7%)	 5	(9.6%)	
N:	DSM	IV	ADHD	 19	(36.5%)	 3	(5.7%)	 9	(17.3%)	 21	(40.3%)	 7	 0.0001	
23	(53.4%)	 3	(6.9%)	 8	(18.6%)	 9	(20.9%)	
Shaded	 cells	 are	 parents’	 questionnaires,	 ADHD	 attention	 deficit	 hyperactivity	 disorder,	 CGI	 Conner’s	













Adaptive	 skills	 were	 low	 in	 all	 three	 domains	 of	 conceptual,	 social	 and	 practical	 and	 in	 the	
general	adaptive	composite	score.	Extremely	low	adaptive	scores	which	indicated	a	percentile	
rank	 of	 ≤2	 were	 the	 most	 commonly	 reported	 group	 and	 seen	 in	 36	 (61.0%)	 cases	 for	
conceptual,	 25	 (42.3%)	 cases	 for	 social	 and	 42	 (71.1%)	 cases	 for	 practical	 domains.	
	 65	
Correspondingly,	 41	 (69.4%)	 cases	had	extremely	 low	 scores	 for	 general	 adaptive	 composite	
score.	 Practical	 adaptive	 scores	 were	 the	 worst	 performing	 with	 less	 than	 average	 scores	


























The	 electroencephlogram	 (EEG)	 endures	 as	 the	 first	 line	 investigative	 tool	 for	 supporting	 a	
diagnosis	of	epilepsy	since	Hans	Berger’s	first	publication	of	the	alpha	rhythm	in	1929.	The	EEG	




The	 basis	 of	 the	 EEG	 is	 the	 recording	 of	 summated	 and	 synchronised	 postsynaptic	 field	
potentials	 of	 many	 cortical	 neurons	 recorded	 by	 multiple	 electrodes	 usually	 placed	 on	 the	
scalp	surface.	These	electrical	discharges	are	generated	by	excitatory	postsynaptic	potentials	
from	 apical	 dendrites	 of	 pyramidal	 cells	 on	 layer	 five	 of	 the	 cortex.	 Electrical	 activity	 is	
measured	as	the	voltage	difference	between	two	electrodes.	The	electrodes	are	connected	to	
a	differential	amplifier.	The	differential	amplifier	amplifies	 the	difference	 in	voltage	between	
two	 electrode	 sites	 and	 also	 rejects	 the	 interference	 that	 simultaneously	 affects	 both	
electrodes.	 The	 combination	 of	 two	 electrodes	 in	 one	 amplifier	 is	 known	 as	 a	 derivation	 or	
channel	 and	 a	montage	 consist	 of	 a	 combination	 of	 derivations.	 In	 a	 bipolar	montage,	 each	
channel	 represents	 the	 potential	 difference	 between	 2	 adjacent	 electrodes	 in	 a	 chain.	 In	 a	
referential	 montage,	 each	 channel	 represents	 the	 potential	 difference	 between	 individual	


















the	 spatial	 resolution	 of	 the	 EEG,	 on	 the	 one	 hand	 electrodes	 too	 far	may	 not	 detect	 small	









It	 is	possible	 to	 identify	a	wide	 range	of	 individual	 variability	 in	 the	normal	EEG.	The	human	
EEG	usually	shows	activity	in	the	range	of	1	to	30Hz,	with	amplitudes	in	the	range	20	to	300μV.	












































In	 sleep	 the	 EEG	 is	 markedly	 changed.	 Specific	 sleep	 features	 are	 seen	 as	 the	 individual	
fluctuates	between	 the	 three	stages	of	non	 rapid	eye	movement	 sleep	N1,	N2	and	N3	sleep	
and	 then	 rapid	 eye	 movement	 tonic	 and	 phasic	 sleep.	 Table	 4.3	 summarises	 these	 sleep	
features	and	stages	based	on	the	American	Academy	of	Sleep	Medicine	2007	manual119.	The	
close	relationship	between	sleep	and	epilepsy	is	undisputed.		Non	rapid	eye	movement	sleep	
leads	 to	 a	 state	 of	 EEG	 synchronisation	 and	promotes	 seizure	propagation	 and	 activation	of	
interictal	 epileptic	 discharges.	 Gibbs	 et	 al.	 first	 observed	 an	 increase	 of	 interictal	 epileptic	
discharges	from	36%	in	awake	EEGs	to	82%	with	sleep	in	500	epilepsy	patients	in	1947120.	Since	
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then,	 several	 studies	 have	 observed	 an	 increase	 in	 interictal	 epileptic	 discharges	 in	 sleep	 in	













Discrete	burst	 of	 diffuse	high	 voltage	 rhythmic	 theta	during	 arousal.	 Seen	 in	
early	childhood.	

























Paroxysmal	 EEG	 discharges	 can	 be	 separated	 into	 potentially	 epileptiform	 discharges	 and	
benign	 EEG	 variants.	 Table	 4.4	 list	 the	 features	 of	 potential	 epileptiform	 discharges.	
Generalised	spike	and	wave	(GSW)	can	be	considered	the	prototype	epilepsy	associated	EEG	
phenomenon.	 Different	 types	 of	 GSW	 are	 commonly	 described.	 In	 MAE,	 an	 irregular	 GSW	
often	preceded	by	polyspike	 is	 seen;	 this	 has	quite	 a	different	 appearance	 to	3Hz	 spike	 and	
wave	 complexes	 seen	 in	 childhood	 absence	 epilepsy.	 However	 as	 the	main	 purpose	 of	 this	
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the	 baseline	 and	 the	 peak	 of	 the	 spike)	 easily	 differentiated	 from	 the	
background.	Amplitude	can	be	variable.	
Sharp	wave	 A	 pointed	 peak	 between	 80	 and	 200ms	 in	 duration	 (measured	 at	mid-point	
between	the	baseline	and	the	peak	of	the	spike)	easily	differentiated	from	the	







Benign	 variants	 are	 considered	 benign	 as	 they	 can	 occur	 in	 healthy	 individuals	 without	
epilepsy.	 However,	 these	 patterns	 merit	 careful	 consideration	 not	 only	 to	 avoid	













6/14	Hz	positive	spikes	 Rhythmic	 arched	waves	with	 a	 smooth	negative	 component	 and	a	 spike	 like	















The	 photoparoxysmal	 response	 (PPR)	 is	 defined	 as	 the	 occurrence	 of	 spikes	 or	 spikes	 and	
waves	discharges	in	response	to	intermittent	photic	stimulation.	Continuous	flashes	presented	
at	 18Hz	with	 eye	 closure	 are	most	 likely	 to	 elicit	 a	 discharge	 in	 those	who	 are	 susceptible.	
Sleep	deprivation	and/or	awakening	 form	a	sleep	stage	can	also	 increase	 the	 likelihood.	PPR	
needs	 to	 be	 distinguished	 from	photic	 driving	which	 are	 rhythmic	 potentials	 in	 the	 occipital	











Participants	 were	 invited	 to	 have	 EEG	 at	 one	 of	 three	 sites	 depending	 on	 participant	
preference,	 age	 of	 participant	 and	 availability	 of	 research	 appointments.	 The	 digital	 EEG	
systems	used	were:	NicoletOne	(Natus)	at	King’s	College	Hospital,	Neurofax	EEG-1200	(Nihon	
Koden)	 at	 Evelina	 Children’s	 Hospital	 and	 Xltek	 EEG32U	 amplifier	 (Natus)	 at	 St	 Thomas’	





scalp	 impedence.	 Silver-Silver	 chloride	EEG	electrodes	are	positioned	onto	 the	prepped	with	
10-20	EEG	paste.	The	electrodes	were	placed	based	on	the	International	10-20	system.	Ground	
and	reference	electrodes	were	placed	between	Pz	and	Cz	and	Cz	and	Fz	respectively	except	in	
the	 Nihon	 Koden	 recordings	 where	 a	 linked	 C3-C4	 reference	 was	 utilised.	 A	 lead	 I	
electrocardiogram	 (ECG)	was	 placed	 on	 the	 bilateral	 shoulders	 and	 is	 used	 to	 identify	 pulse	
artefact	and	ECG	breakthrough.	EMG	electrodes	were	placed	on	bilateral	deltoids	to	capture	













be	 sampled	without	aliasing	of	 the	 signal.	 This	 is	 twice	 the	highest	 frequency	present	 in	 the	
signal	 we	 wanted	 to	 record	 and	 therefore	 was	 set	 above	 200Hz	 (see	 individual	 sampling	























rhythmic	potential	 in	the	occipital	 leads	time	locked	to	the	frequency	of	the	 light	stimulus.	A	


























first	 adult	 study	was	 published	 in	 1953123.	 The	 authors	 investigated	 682	 air	 force	 applicants	
aged	 17	 to	 24	 years	 with	 an	 eight	 channel	 EEG,	 at	 rest,	 with	 hyperventilation	 and	 photic	




personality	 disturbances,	 neurological	 disturbance	 on	 examination	 or	 history,	 medical	 or	
miscellaneous	 reasons.	 EEG	 paroxysmal	 discharges	 were	 present	 in	 2.6%	 at	 rest,	 2.9%	with	
hyperventilation	 and	 5.1%	 with	 hyperventilation	 and	 photic	 stimulation	 prior	 to	 metrazol	
administration.	 The	 incorporation	 of	 these	 unfiltered	 subjects	 may	 explain	 why	 subsequent	







































The	 prevalence	 of	 epileptiform	 discharges	 in	 children	 range	 from	 0.76%	 to	 13.2%	 across	
different	 studies.	 This	 broad	 range	 may	 be	 due	 to	 a	 number	 of	 reasons:	 differences	 in	
recording	 conditions,	 selection	 of	 control	 individuals,	 age	 dependent	 EEG	 features,	
inconsistent	 classification	 of	 EEG	 features	 recorded	 and	 challenges	 in	 interpretation	 of	 the	
paediatric	EEG.	Table	4.8	summarises	the	key	features	of	these	EEG	studies	in	healthy	children.	
It	 is	 worth	 noting	 that	 Eeg	 Olofsson	 et	 al.	 recorded	 paroxysmal	 discharges	 resulting	 in	 an	
overall	 prevalence	 of	 13.2%126.	 This	 could	 have	 included	 non-epileptic	 discharges;	 such	 as	
photic	 driving	 within	 the	 PPR	 group	 and	 bilateral	 synchronous	 paroxysmal	 activity	 during	























































































Evidence	 for	 the	 genetic	 basis	 of	 the	 EEG	 exists	 across	 a	 range	 of	 EEG	 features	 and	 can	 be	
gleaned	 through	 family	 studies,	 linkage	 analysis	 studies	 and	 quantitative	 EEG	 studies.	 The	
familial	occurrence	of	non-epileptiform	discharges	was	recognised	in	families	when	Koshino	et	
al.	 reported	 the	 incidence	 of	 the	 mμ	 rhythm	 in	 13/35	 relatives	 of	 14	 families131.	 Specific	
epileptiform	 features	 have	 also	 been	 investigated.	 Centrotemporal	 sharp	 waves	 in	 rolandic	
epilepsy	 families	were	found	to	segregate	 in	an	autosomal	dominant	mode	of	 inheritance132.	
GSW	 discharges	 were	 seen	 in	 32/83	 (38.5%)	 of	 siblings	 of	 54	 probands	 with	 symptomatic	
GTCS,	and	only	seen	in	sleep	in	15	siblings133.	Doose	investigated	specific	EEG	features	of	PPR,	
GSW	or	dysrhythmias	with	his	initial	description	of	MAE	and	identified	abnormalities	in	35.4%	
of	72	siblings	and	79	parents5	 (see	section	1.7	 for	 further	details).	PPR	were	 identified	 to	be	
heritable	 by	 Waltz	 et	 al.	 when	 he	 demonstrated	 that	 type	 IV	 PPR	 occurred	 more	 often	 in	







PPR	 (type	 II	 to	 IV)	 myoclonic	 epilepsy	 families66.	 Tauer	 et	 al.	 investigated	 two	 different	





twin	 pairs,	 spectral	 power	 for	 the	 four	major	 frequency	 bands;	 alpha,	 beta,	 theta	 and	 delta	
demonstrated	 average	 heritabilities	 of	 89%,	 86%,	 89%	 and	 76%	 respectively134.	 The	 next	
section	will	 focus	 on	quantitative	 EEG	and	power	 spectral	 analysis.	 Although	not	 one	of	 the	





Quantitative	EEG	 is	 the	mathematical	processing	of	 transforming	digitally	 recorded	EEG	data	
into	 numerical	 data	 to	 derive	 quantitative	 patterns	 that	 may	 correspond	 to	 diagnostic	
information	or	cognitive	effects.	One	of	the	parameters	of	quantitative	EEG	analysis	 includes	







of	 pure	 sinusoidal	 components,	 each	 of	 a	 different	 frequency,	 which	 when	 added	 together	
yield	the	original	signal.	The	magnitude	corresponds	to	the	amount	of	energy	that	the	original	






alpha	 activity	 maximal	 in	 the	 posterior	 leads,	 (2)	 the	 absence	 of	 artefacts	 (eye	 blinks,	 eye	
movements,	 muscle	 contractions,	 movement	 of	 recording	 electrodes)	 and	 epileptiform	
activity,	 (3)	 the	 absence	 of	 patterns	 indicating	 drowsiness	 or	 sleep	 and	 (4)	 not	 during	




All	 power	 spectral	 analysis	 was	 carried	 out	 using	 FieldTrip135,	 a	 MATLAB-toolbox	 for	 the	
analysis	 of	 EEG	 and	 other	 electrophysiology	 data,	 which	 is	 freely	 available	 from	
http://www/ru.nl/neuroimaging/fieldtrip.	Custom	scripts	were	implemented	in	Matlab	R2016a	
(Mathworks,	Natick,	Massachusetts,	USA).	Custom	MATLAB	scripts	utilising	Fieldtrip	functions	
for	 EEG	data	 preprocessing	 and	 analyses	were	written	originally	 by	Dr	Adam	Pawley	 and	Dr	
Chayanin	 Tangwiriyasakil,	 and	 adapted	 by	 Dr	 Chayanin	 Tangwiriyasakil	 for	 this	 analysis.	 The	
EEG	 signals	were	 first	 re-sampled	 individually	 to	 a	 uniform	 256Hz	 sampling	 frequency.	 They	
were	then	de-trended	to	remove	signal	drifts,	and	bandpass	filtered	between	0.5	to	70Hz	using	




Hz,	 and	 gamma	 30	 to	 70Hz)	 was	 estimated	 by	 numerically	 integrating	 the	 power	 spectral	
density	 over	 the	 band	 and	 divided	 by	 a	 total	 power	 of	 all	 five	 bands.	 To	 avoid	 possible	
amplitude	 differences	 in	 recorded	 EEG	 signals	 across	 subjects,	 due	 to	 variation	 caused	 by	
different	anatomic	features	such	as	size	and	shape	of	the	cranium;	a	normalized	power	of	each	
band	was	estimated	by	dividing	the	power	of	each	 frequency	band	with	 its	 total	power.	The	
total	 power	 was	 estimated	 by	 numerically	 integrating	 the	 power	 spectral	 density	 over	 1	 to	
70Hz.		
	
The	 Kruskal-Wallis	 test	 by	 ranks	was	 used	 to	 test	 if	 the	 average	 normalized	 powers	 at	 each	
frequency	 band	 were	 significantly	 different	 between	 the	 three	 groups	 (fathers,	 mothers,	
siblings).	 The	 Kruskal	 Wallis	 test	 also	 called	 the	 one-way	 analysis	 of	 variance	 (ANOVA)	 on	
ranks,	 is	 a	 rank	 based	 non	 parametric	 test	 used	 to	 determine	 statistical	 differences	 of	 an	
independent	variable	between	two	or	more	groups	of	equal	or	different	sizes.	Wilcoxon	rank’s	
test	 was	 then	 applied	 to	 compare	mean	 normalized	 power	 between	 the	 three	 groups.	 This	
comprised	a	total	of	15	comparisons:	fathers	and	mothers,	mothers	and	siblings,	 fathers	and	
siblings	multiplied	 by	 the	 five	 different	 frequency	 bands.	 The	 test	was	 re-applied	with	 a	 5%	
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Thirteen	 families	with	38	 first-degree	 family	members	were	 recruited	 to	 the	EEG	arm	of	 the	
study	(see	Table	5.1).	This	comprised	of	12	fathers	(mean	age	47.2	years,	SD	7.13),	13	mothers	
(mean	age	43.7	years,	SD	6.12),	8	brothers	(mean	age	12.7	years,	SD	4.84)	and	5	sisters	(mean	
age	 11.6	 years,	 SD	 7.56).	 Family	 size	 ranged	 from	 three	 to	 six	 individuals.	 Four	 families	 had	
incomplete	 studies.	 Family	 506,	 518	 and	 526	were	 incompletely	 recruited	with	 one	missing	
family	member	 in	family	506	and	526	and	two	missing	family	members	 in	family	518.	Family	
602	 had	 a	 child	 with	 Down’s	 syndrome	 who	 was	 unable	 to	 carry	 out	 the	 EEG.	 Some	
participants	 (±)	 did	 not	 receive	 activation	 procedures	 of	 hyperventilation	 and	 photic	
stimulation	as	 the	wrong	EEG	recording	protocol	was	completed	for	 the	study	 in	error.	EEGs	


































3002	 3002201	 Father	 54y	 STH	 1:09:04	 256	
	 3002202±	 Mother	 50y	 KCH	 48:50	 256	
	 3002302±	 Sister	 19y	 KCH	 57:38	 256	
	 3002303	 Brother	 17y	 STH	 55:19	 256	
	 3002304	 Brother	 17y	 STH	 49:14	 256	
505	 10505	 Father	 45y	 ECH	 45:24	 500	
	 20505	 Mother	 40y	 ECH	 54:19	 500	
	 30505	 Brother	 8y	 ECH	 1:27:53	 500	
	 40505	 Sister	 2y	 ECH	 54:25	 500	
506*	 10506	 Father	 44y	 STH	 45:02	 256	
	 20506	 Mother	 44y	 STH	 1:10:46	 256	
518*	 10518	 Father	 50y	 ECH	 44:53	 500	
	 20518	 Mother	 40y	 ECH	 36:43	 500	
524	 10524	 Father	 46y	 ECH	 43:41	 500	
	 20524	 Mother	 50y	 ECH	 37:31	 500	
	 30524	 Brother	 9y	 ECH	 43:41	 500	
526*	 20526±	 Mother	 -	 KCH	 1:05:15	 256	
	 30526±	 Brother	 12y	 KCH	 55:02	 256	
528	 10528	 Father	 59y	 STH	 56:54	 256	
	 20528	 Mother	 47y	 STH	 58:10	 512	
	 30528	 Sister	 16y	 STH	 45:14	 256	
539	 10539	 Father	 41y	 STH	 47:52	 256	
	 20539	 Mother	 44y	 STH	 49:42	 256	
554	 10554	 Father	 56y	 STH	 54:59	 512	
	 20554	 Mother	 52y	 STH	 49:51	 256	
	 30554	 Brother	 20y	 STH	 35:51	 256	
560	 10560±	 Father	 34y	 KCH	 56:39	 256	
	 20560±	 Mother	 35y	 KCH	 58:36	 256	
571	 10571	 Father	 40y	 STH	 1:06:20	 512	
	 20571	 Mother	 33y	 STH	 53:58	 512	
	 30571	 Brother	 5y	 ECH	 1:00:23	 500	
574	 10574±	 Father	 48y	 KCH	 58:48	 256	
	 20574+	 Mother	 41y	 KCH	 59:53	 256	
	 30574±	 Sister	 5y	 KCH	 58:11	 256	
602*	 10602	 Father	 50y	 STH	 55:28	 256	
	 20602	 Mother	 49y	 STH	 53:41	 256	
	 30602±	 Sister	 16y	 KCH	 1:02:34	 256	





















Two	 subjects	 had	 epileptiform	 features,	 both	 were	 asymptomatic	 and	 had	 no	 history	 of	
seizures	 at	 the	 time	 of	 EEG	 recording.	 The	 two	 subjects	 were	 subject	 20526	 (mother)	 with	
epileptiform	left	frontal	temporal	sharp	waves	(see	Figure	5.1)	and	subject	30574,	a	5-year-old	


























PPR,	 the	most	 frequently	 seen	 abnormal	 finding	 in	 Doose’s	MAE	 family	 EEG	 study,	was	 not	
recorded.	 Table	 5.2	 shows	 the	 comparison	 of	 epileptiform	 EEG	 features	 with	 Doose	 et	 al.5	
using	Fisher’s	exact	 test	and	 the	 relative	 risk	 (RR)	of	 recording	each	EEG	 feature	 in	Doose	et	
al.’s	cohort	compared	to	this	cohort.	This	shows	that	there	was	no	statistical	difference	in	the	
identification	 of	 specific	 traits	 in	 both	 cohorts.	 However,	 the	 RR	 of	 observing	 PPR	 (siblings=	













Siblings	 PPR	 20/72	(27.8%)	 0/9	(0%)	 5.61	 0.21	
GSW	or	Sharp	wave	 6/72	(8.33%)	 1/13	(7.6%)	 1.08	 0.93	
Parents	 PPR	 6/69	(8.69%)	 0/19	(0%)	 3.71	 0.36	






20	 systems.	 The	 lack	of	 activation	procedures,	 specifically	photic	 stimulation	 in	 some	of	 this	
study’s	 subjects	would	have	 compromised	 results.	 The	 small	 sample	 size	 in	 this	MAE	 cohort	
and	 incomplete	 families	 recruited	 limits	 the	 power	 of	 discovery.	 The	 definitions	 of	 PPR	 and	
EEG	abnormalities	may	have	differed.	 In	addition,	Doose	recorded	dysrhythmias,	which	were	
not	 accounted	 for	 in	 this	 study	group.	An	attempt	 is	made	 to	address	 this	with	quantitative	
EEG	analysis	(see	section	5.3).		
	
Comparison	with	 population	 prevalence	 of	 epileptiform	 EEG	 features	 is	 shown	 in	 Table	 5.3.	
The	 MAE	 parents	 and	 siblings	 were	 divided	 into	 age	 groups	 above	 and	 below	 16	 years	 to	
reflect	 differences	 in	 adult	 and	 paediatric	 EEG	 studies.	Gregory	et	 al.	was	 used	 as	 the	 adult	
control	study124	and	Borusiak	et	al.	was	used	as	the	paediatric	control	study127;	these	controls	
were	 selected	 due	 to	 similar	 recording	 conditions.	 This	 shows	 that	 the	 presence	 of	






















These	 patterns	were	 observed	 in	mothers	 or	 fathers	 but	 not	 in	 siblings.	 Some	 patterns	 had	
features	 of	 well-described	 benign	 variants,	 e.g.	 rhythmic	 mid-temporal	 discharges	 and	 were	
classified	as	such.	Other	patterns	are	simply	described	based	on	their	visual	appearance.		The	

















in	 the	 drowsy	 state.	 RMTD	 is	 reported	 to	 have	 an	 incidence	 of	 0.1	 to	 0.3%	 with	 little	 sex	
preference136,137.	 Few	 conflicting	 studies	 exist	 for	 the	 clinical	 significance	 of	 RMTD.	 RMTD	
appeared	 to	 have	 a	 subclinical	 role	 in	 the	 occurrence	 of	 epileptic	 seizures137	 but	 was	 also	
reported	in	patients	without	epileptic	seizures138,139.	RMTD	has	also	been	associated	in	patients	
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frequently	 in	young	siblings	of	epilepsy	probands	and	also	acted	as	a	 risk	 factor	with	63%	of	
‘theta	 positive’	 children	 subsequently	 developing	 febrile	 convulsion68.	 Subsequently	
quantitative	EEG	studies	in	adolescent	twin	pairs	demonstrated	a	heritability	of	89%	for	theta	
power134,	a	finding	which	was	supported	by	Tye	et	al.	who	calculated	a	cross	twin	within	trait	
correlation	 for	 theta	 power	 in	monozygotic	 twins	 of	 r=0.79	 compared	 to	 dizygotic	 twins	 of	
r=0.13141.	
	
Theta	 rhythms	were	 recorded	 in	 two	 adult	 patients.	 Subject	 10529	 is	 a	 41-year-old	 healthy	

























runs	 of	 slow	 activity	 in	 subject	 10528	 (see	 Figure	 5.9)	 were	 also	 recorded.	 As	 an	 isolated	
finding	 in	 a	 healthy	 individual,	 it	 is	 difficult	 to	 speculate	 what	 these	 may	 represent.	
Intermittent	 focal	 slowing	 often	 reflects	 disordered	 intra-cortical	 connectivity.	 This	 can	 be	
transient	 (e.g	 migraine,	 post	 ictal,	 metabolic),	 structural	 (e.g.	 ischaemic	 stroke,	 tumour)	 or	
even	represent	an	epileptogenic	focus.	The	 locations	of	these	patterns,	the	temporal	regions	
are	 the	 sites	 for	 many	 well-recognised	 benign	 variants	 (wicket	 spikes,	 RMTD,	 subclinical	
































number	 representation	were	as	 follows:	 ch2=C3,	 ch3=C4,	 ch4=O1,	 ch5=O2,	 ch6=A1,	 ch7=A2,	



































































Significant	 differences	were	 seen	 in	 the	 theta	 frequency	 band	 in	 ch3	 (P=0.0125),	 and	 in	 the	





Significant	 differences	 were	 seen	 in	 the	 theta	 frequency	 band	 in	 ch3	 (P=0.0011)	 and	 ch8	
(P=0.0027);	and	in	the	beta	frequency	band	in	ch11	(P=0.0047).	
	
The	 increased	power	 spectrum	 in	 the	 theta	 frequency	band	 in	 siblings	 compared	 to	parents	
could	be	possibly	explained	by	slower	dominant	background	rhythms	in	children,	although	it	is	






Differences	 in	 the	 power	 spectrum	 within	 the	 theta	 and	 beta	 frequency	 bands	 can	 be	









case,	 father,	 mother	 and	 other	 relevant	 family	 members	 affected	 with	 seizures	 and/or	
neurological	 disorders.	 Saliva	 DNA	 and	 RNA	 was	 the	 main	 mode	 of	 collection,	 blood	 was	
collected	when	subjects	were	directly	recruited	or	where	saliva	collection	was	difficult.		
	
Samples	 were	 processed	 and	 stored	 in	 two	 facilities.	 This	 was	 either	 by	 the	 Social	 Genetic	









Saliva	 collection	 was	 particularly	 suited	 for	 postal	 recruitment	 of	 subjects.	 Each	 saliva	
collection	kit	was	clearly	labelled	with	the	subject’s	name	and	unique	ID.	Two	makes	of	saliva	




















Nucleic	 acids	 absorb	 ultraviolet	 light	 due	 to	 the	 heterocycylic	 rings	 of	 nucleotides.	 The	





















The	 main	 steps	 of	 the	 sequencing	 process	 can	 be	 divided	 into	 (1)	 library	 preparation	 and	








The	DNA	 is	 fragmented	by	ultrasonic	 shearing	 to	150bp	 fragments.	 The	 sheared	blunt	 ends	
are	repaired	and	adenylated.	Adaptor	oligos	are	ligated	to	both	ends	of	the	fragment	and	the	




(2)	Cluster	 generation	and	amplification.	 Sequencing	occurs	 in	 arrays	 called	 flow	cells.	 Each	






(3)	 Sequencing	 and	 basecalling.	 Hundreds	 and	 millions	 of	 clusters	 of	 DNA	 fragments	 are	
sequenced	simultaneously	and	in	parallel	with	reversible	terminator-based	method.	The	DNA	
fragment	 is	 sequenced	 base-by-base	 using	 four	 fluorescent-labelled	 reversible	 binding	
nucleotides	 (dNTPs).	 The	 four	 nucleotides	 compete	 with	 each	 other	 to	 bind	 to	 the	 DNA	
template.	 Since	 all	 four	 reversible	 terminator-bound	 dNTPs	 are	 present	 during	 each	
sequencing	 cycle,	 natural	 competition	 minimizes	 incorporation	 bias.	 After	 each	 round	 of	
synthesis,	a	laser	is	used	to	image	and	emit	the	colour	of	the	newly	added	base.	The	dNTP	is	







Data	 analysis	 in	 exome	 sequencing	 involves	 several	 bioinformatics	 analysis	 steps.	 Different	
commercially	 available	 and	 open	 access	 tools	 are	 available	 for	 each	 stage.	 Herein	 the	 tools	










In	general,	quality	 control	 (QC)	 steps	are	carried	out	 to	assess	quantity	of	data,	base	quality	









excluded;	 (ii)	homopolymer	filter	to	check	 if	 the	same	base	 is	called	all	 the	way	through;	 (iii)	





Using	CASAVA,	 an	 Illumina	platform	 software,	 the	 raw	 sequencing	 files	 are	 converted	 into	a	





















Sequencing	error	and	PCR	can	 result	 in	propagation	of	duplicates.	Picard	 tools,	a	 Java-based	
command-line	was	used	to	manipulate	SAM	files	and	marks	and	removes	duplicates.	
	
The	 next	 step	 is	 variant	 calling,	 which	 is	 carried	 out	 by	 comparing	 the	 aligned	 sample	
sequences	with	 known	 reference	 sequences	 to	 determine	which	 positions	 deviate	 from	 the	
reference.	Variant	calling	can	be	complicated	by	alignment	and	sequencing	errors	such	as	the	
presence	 of	 indels,	 PCR	 artefacts,	 variable	 GC	 content	 in	 short	 reads	 and	 variable	 quality	
scores.	SAMtools	was	the	program	used	for	variant	calling.	It	has	a	Bayesian	variant	and	short	
indel	 caller	 and	 can	 sort,	 remove	 cluster	 single	 nucleotide	 polymorphisms	 (group	 of	 SNPs	
mapped	to	an	identical	location),	merge,	index	and	generate	alignment	and	create	consensus	











Annotation	 is	 the	 process	 where	 variants	 in	 a	 VCF	 file	 are	 tagged	 or	 annotated	 with	
information	 from	 various	 databases	 in	 order	 to	 inform	 specific	 characteristics	 of	 the	 variant	
such	as	minor	allele	frequency	(MAF)	or	functional	consequence	to	the	associated	protein.	This	
helps	with	informed	variant	filtering	during	analysis.	Annovar	was	used	to	perform	gene	based	
and	 functional	 annotation	 of	 genetic	 variants	 for	 human	 genome	 build	 GRCh37	 (hg19)	
http://annovar.openbioinformatics.org/en/latest/user-guide/startup/144.	 Annovar	 uses	 an	
input	 format	with	 details	 of	 chromosome,	 start	 position,	 end	 position,	 reference	 nucleotide	
and	observed	nucleotide.	The	relevant	functions	and	outputs	obtained	were:	
• Gene	based	annotation:	 identify	whether	 the	SNP	cause	protein	coding	changes	and	
amino	acids	that	are	affected.	
• Filter	based	annotation:	 identify	variants	 that	are	documented	 in	 the	1000	Genomes	




columns.	 Table	 6.1	 details	 the	 description	 of	 the	 individual	 outputs	 derived	 from	 the	 Guy’s	
































































in	 this	 read	 depth.	 A	 R	 package	 software	 called	 ExomeDepth	was	 used145.	 ExomeDepth	was	
programmed	to	feed	100	controls	both	ways	from	the	sample	ID	and	searches	for	the	control	
samples	with	 the	best	 coverage	distribution	match	of	 read	 count	data	with	 the	 sample.	 The	






in	potentially	 functional	non-coding	elements.	 This	 technique	presumes	 that	disease	 causing	
mutations	 only	 occur	 in	 protein	 coding	 regions	 by	 excluding	 interrogation	 of	 intronic	




Next,	 exome	 sequencing	 relies	 on	 defined	 protein	 coding	 regions	 in	 the	 genome	 but	 the	
definitions	 of	 these	 regions	 are	 constantly	 evolving.	 The	 first	 exome	 capture	 kits	 were	
designed	based	on	 the	consensus	coding	 sequence	consortium	database	 (CCDS).	The	Agilent	
CCDS	SureSelect	Human	All	 Exon	Kit	 covers	37.6Mb	and	30030	genes	as	 compared	with	 the	
GENCODE	exome	released	in	2011	with	a	coverage	of	47.9Mb	and	35989	genes147;	moreover	
an	 updated	GENCODE	 exome	 is	 currently	 being	 prepared.	 Therefore,	 certain	 protein	 coding	
regions	 might	 be	 incompletely	 annotated	 and	 coverage	 of	 coding	 regions	 is	 platform	
dependent.	
	
The	 efficacy	 of	 exome	 sequencing	 is	 dependent	 on	 the	 sequence	 capture	 probes	 and	
sequencing	 platform	 used.	 Uneven	 uniformity	 of	 coverage	 and	 uneven	 read	 depth	 from	
differential	capture	efficiencies	where	reads	are	either	on,	off	or	near	target	annotated	regions	
can	lead	to	false	positive	and	false	negative	calls	in	genotyping.	False	calls	are	also	commonly	a	
result	of	misalignments,	particularly	as	 segmental	duplications;	 intervals	 that	are	 larger	 than	
1kb	with	 homology	 of	 >90%	with	 other	 parts	 of	 the	 genome,	 encompass	 5%	 of	 the	 human	
genome,	can	lead	to	misalignment	of	reads	to	the	reference	genome	due	to	these	similar	DNA	
sequences.	 Batch	 effects	 in	 different	 sequencing	 runs	 further	 complicate	 this	 by	 creating	







copy	 number	 variants,	 translocation	 and	 inversions.	 Several	 software	 packages	 have	 been	












for	 4275	 (85.5%)	 variants149.	 Thus	 using	multiple	 prediction	 tools	 can	 be	 counterproductive	
and	three	tools,	SIFT,	Polyphen-2	and	CADD	were	selected.	SIFT	and	Polyphen	were	selected,	
as	 they	 are	 historical,	 frequently	 used	 tools,	 which	 are	 assessable	 to	 readers.	 CADD	 is	 a	






SIFT	 is	 a	 sequence	 homology	 based	 tool	 that	 sorts	 intolerant	 from	 tolerant	 amino	 acid	
substitutions.	 It	predicts	whether	an	amino	acid	substitution	affects	protein	function	and	can	
be	 applied	 to	 naturally	 occurring	 nonsynonymous	 polymorphisms	 or	 laboratory-induced	
missense	mutations151.	SIFT	 is	based	on	the	degree	of	conservation	of	amino	acid	residues	 in	
sequence	 alignments	 derived	 from	 closely	 related	 sequences	 collected	 through	 PSI_BLAST	
(Position-Specific	 Iterated	Basic	Local	Alignment	Search	Tool).	This	 relies	on	the	presumption	
that	 amino	 acid	 residues	 that	 are	 essential	 for	 protein	 function	 should	 be	 evolutionally	






PolyPhen-2	 (Polymorphism	 Phenotyping	 v2)	 predicts	 the	 possible	 impact	 of	 an	 amino	 acid	
substitution	 on	 the	 structure	 and	 function	 of	 a	 human	 protein152.	 The	 tool	 uses	 features	
comprising	 the	 sequence,	 phylogenetic	 and	 structural	 information	 characterising	 the	
substitution.	 An	 amino	 acid	 replacement	 might	 occur	 at	 a	 site	 where	 binding	 to	 other	
molecules	or	formation	of	a	secondary	or	tertiary	structure	is	disrupted	e.g.	disulphide	bond,	
transmembrane	 domain	 etc.	 The	HumVar-trained	 PolyPhen-2	 (PP2hvar)	model	was	 used	 for	
this	 study.	 The	 HumVar	 datasets	 consist	 of	 all	 human	 disease	 causing	 mutations	 from	
UniProtKB,	 together	 with	 common	 human	 non-synonymous	 SNPs	 (MAF>1%)	 without	
annotated	 disease	 involvement,	 which	 was	 treated	 as	 non-damaging	
(http://genetics.bwh.harvard.edu/pp2/dokuwiki/docs).	 For	 a	mutation,	 PolyPhen-2	 calculates	
a	 naïve	 Bayes	 posterior	 probability	 that	 the	 mutation	 is	 damaging.	 An	 appraisal	 of	 benign	





Combined	Annotations	Dependent	Depletion	 (CADD)	 scores	 for	 deleteriousness	of	 SNPs	 and	
small	 insertions	 and	 deletions	 (indel)	 variants	 in	 the	 human	 genome153.	 CADD	 integrates	 63	
annotations	into	one	metric	and	calculates	deleteriousness	by	contrasting	14.7	million	variants	
that	 survived	 natural	 selection	 with	 14.7	 million	 simulated	 mutations.	 Annotations	 span	 a	
range	 of	 data	 types,	 including	 conservation	 metrics,	 regulatory	 information,	 transcript	
information,	 cell	 lines	 expression	 levels	 and	protein	 level	 scores	 such	as	 those	 generated	by	
SIFT	and	PolyPhen.	A	C	 score	 is	obtained	and	correlates	with	allelic	diversity,	 annotations	of	
functionality,	pathogenicity,	disease	severity,	experimentally	measured	regulatory	effects	and	
complex	trait	associations.	Pre-computed	CADD	based	scores	(raw	C-scores)	are	available	for	
all	 8.6	 billion	possible	 SNPs	 in	 the	 reference	 genome,	 1000	Genome	and	Exome	Sequencing	
Project	 (ESP)	 variant	 releases.	 Raw	 C	 scores	 can	 be	 phred-scaled	 by	 expressing	 the	 rank	 in	
order	of	magnitude	to	scaled	C	scores.	For	example,	a	scaled	CADD	score	of	10	 indicates	the	









genetic	 variation	 by	 comparing	 observed	 and	 predicted	 levels	 of	 standing	 variation	 in	 the	
regulatory	region	of	human	genes	(http://genic-intolerance.org).	Genes	are	given	a	percentile	
RVIS	 score,	 genes	 that	 are	 more	 intolerant	 and	 hence	 less	 likely	 to	 demonstrate	 genetic	
variation	will	 have	 a	 lower	 RVIS	 percentile	 and	 are	more	 suggestive	 to	 be	 pathogenic.	 RVIS	
appears	 to	 be	 a	 sensitive	 measure	 for	 use	 in	 EE	 and	 when	 applied	 to	 the	 trio	 sequencing	
dataset	of	Epi4K	cohort,	de	novo	mutations	were	observed	 to	 lie	 in	 the	most	 intolerant	25th	
percentile	 RVIS	 scores	 when	 compared	 with	 controls	 or	 immunological	 disorders154.	 In	
addition,	a	RVIS	≤25th	percentile	was	used	to	assess	the	likelihood	of	pathogenicity	of	variants	





The	 Annovar	 system	 provides	 splice	 site	 effect	 predictions	 by	 AdaBoost	 (Ada)	 and	 random	
forests	 (RF)	 (section	6.5).	Ada	and	RF	are	ensemble	 learning	methods	 that	were	constructed	
following	 the	 evaluation	 of	 eight	 in	 silico	 splice	 site	 tools156.	 The	 eight	 tools	 examined	were	
Position	 Weight	 Matrix	 model,	 MaxEntScan,	 Splice	 Site	 Prediction	 by	 Neural	 Network,	
GeneSplicer,	 Human	 Splicing	 Finder,	 NetGene2,	 GENSCAN	 and	 SplicePredictor.	 The	 authors	








Gene	 expression	 was	 determined	 using	 genevestigator	 (https://genevestigator.com).	









disease.	These	 resources	 included	Pubmed	search,	 the	Online	Mendelian	 Inheritance	 in	Man	
(OMIM),	 Genecard,	 Clinvar,	 Uniprot	 and	 HGMD.	 In	 some	 instances	 locus	 specific	 databases	






resolutions	 from	 whole	 chromosome	 to	 base	 level157.	 A	 password	 protected	 BAM	 file	 was	
loaded	from	http://athena.kcl.ac.uk/igv-data/exome/SAMPLEid/SAMPLEid_novoalign.bam	and	
the	 region	 of	 interest	 visually	 interrogated.	 Visual	 interrogation	was	 used	 to	 view	 coverage	
data,	 read	 depth,	 individual	 aligned	 reads	 and	 individual	 base	 mismatches	 which	 are	
highlighted	 by	 colour	 and	 intensity	 according	 to	 base	 call	 and	 quality.	 IGV	 interrogation	 of	












with	 frequencies	 of	 at	 least	 1%	 in	 the	 populations	 studied158.	 The	 resource	 consists	 of	 2504	
individuals	from	26	populations.	All	participants	declared	themselves	to	be	healthy	at	the	time	









lung	 and	 blood	 disorders.	 Specifically	 neurological	 and	 psychiatric	 disorders	 were	 not	
considered.	 The	 ESP	 exome	 variant	 data	 were	 aligned	 to	 GRCh37	 using	 Genome	 Analysis	
Toolkit	 (a	 tool	 for	processing	and	variant	calling	high	 throughput	sequencing	data).	SNP	calls	
were	 generated	 using	 the	 Michigan	 SNP	 calling	 pipeline	
(http://genome.sph.umich.edu/wiki/UMAKE).	Small	indel	variants	were	analysed	at	the	Broad	
Institute	using	the	GATK	variation	discovery	pipeline	following	the	guideline	in	the	GATK	best	




The	 Exome	 Aggregation	 Consortium	 (ExAC)	 seeks	 to	 aggregate	 and	 harmonise	 exome	
sequencing	data	 from	a	variety	of	 large-scale	sequencing	projects,	 including	some	data	 from	
the	 1000	 Genomes	 and	 ESP,	 in	 order	 to	 make	 the	 data	 available	 to	 the	 wider	 scientific	
community160.	The	resource	consists	of	60706	unrelated	individuals	as	part	of	various	disease	









The	 Genome	 Aggregation	 Database	 (gnomAD)	 is	 the	 latest	 release	 from	 the	 ExAC	 group	
(http://gnomad.broadinstitute.org).	 Rather	 than	 containing	 only	 exome	 data	 with	 ExAC,	
gnomAD	dataset	spans	126,216	exomes	and	15,137	genomes.	Individuals	that	were	known	to	
be	 affected	 by	 severe	 paediatric	 disease	 as	 well	 as	 their	 first-degree	 relatives	 have	 been	




gnomAD	 is	 currently	 in	early	beta	mode	 (November	2016)	and	was	not	part	of	 the	standard	






technicalities	 from	 sequencing	 production	 to	 variant	 annotation,	 the	 challenge	 in	 gene	








a	monogenic	 aetiology	 spanning	 10	 genes9-23.	 In	 the	majority	 of	 cases,	 reported	 pathogenic	
variants	are	de	novo,	although	private	mutations	 in	multiplex	families	have	been	reported	as	
well	 as	 parent	 to	 child	 affectedness17.	 In	 addition,	 the	 emerging	 paradigm	 of	 the	 role	 of	de	
novo	 mutations’	 impact	 in	 developmental	 disorders	 and	 neuropsychiatric	 phenotypes	 was	




this	 project,	 was	 to	 exome	 sequence	 cases,	 and	 then	 prioritise	 genetic	 variants	 based	 on	
different	 filtering	 criteria	 and	 associated	 hypothesis.	 Candidate	 variants	 assembled	 were	














provide	 guidance	 of	 the	 thresholds	 and	 limits	 to	 set	 for	 MAF	 and	 with	 in	 silico	 predictors	
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A	 search	 term	 of	 ‘epilepsy’,	 ‘epileptic	 encephalopathy’,	 ‘myoclonic	 epilepsy’	 and	 ‘myoclonic	
astatic	 epilepsy’	 was	 used	 to	 assemble	 relevant	 variants.	 Variants	 annotated	 as	 benign	 and	
translocations	were	 removed.	Two	datasets	were	 then	 created,	 first	 the	 ‘All_epilepsy’	 group	
that	 consisted	 of	 heterogeneous	 groups	 of	 disorders	 with	 epilepsy	 symptoms	 included	 in	 a	
diagnosis	 such	 as	 ID	 syndromes,	 metabolic	 disorders	 and	 congenital	 syndromes	 etc.	 The	
second	 ‘Pure_epilepsy’	 group	 where	 each	 Clinvar	 entry	 was	 reviewed	 and	 only	 classified	
epilepsy	syndrome29	variants	were	kept.	Additionally	in	the	Pure_epilepsy	group,	the	epilepsy	
syndromes	and	genes	were	stratified	into	autosomal	dominant	or	autosomal	recessive	groups	









	This	 is	 an	 open	 access	 online	 database	 containing	 499	genes	and	 3931	 variants	 associated	
with	 331	 clinical	 epilepsy	 phenotypes	 collected	 from	 818	 publications	 curated	 by	
researchers163.	 All	 variants	 in	 the	database	were	 included	 into	 the	All_epilepsy	 group	 as	 the	
investigators	 selected	epilepsy	variants	 from	heterogenous	epilepsy	 related	studies	 including	
metabolic	and	mitochondrial	disease.	
	
All	 entries	 were	 collated	 together	 within	 the	 two	 groupings,	 duplicates	 were	 removed	 and	
entries	were	converted	 into	Browser	Extensible	Data	(BED)	file	format	(column	headings:	chr	
start-end	 ref	 alt).	 Annotation	was	 performed	 using	 Annovar	 (see	 appendix	 E	 for	 annotation	
script).	The	main	annotated	output	fields	of	interest	were:	MAF	based	on	1000	Genomes,	ESP,	
ExAC	and	 in	silico	predictions	with	SIFT,	PolyPhen-2hvar	and	CADD.	 In	analysing	the	range	of	












1000	Genomes	(n=2403)	 3.59	 27.8	 3.96	 	
ESP	(n=6503)	 9.33	 72.2	 	 9.68	




One	of	 the	 initial	methods	used	 to	 identify	 causative	variants	was	a	 gene	based	 rare	variant	
case	 control	 association	 analysis.	 This	 was	 performed	 using	 EPACTS	 v3.2.3	 (Efficient	 and	
Parallelizable	Association	Container	Toolbox)	(http://genome.sph.umich.edu/wiki/EPACTS)	and	
plotting	was	 performed	with	 R	 3.0.0.	 EPACTS	 is	 a	 framework	 that	 allows	 for	 gene	 based	 or	




of	cases	with	epilepsy	were	previously	 removed.	 	First,	a	principal	component	analysis	 (PCA)	
plot	was	generated	to	determine	whether	cases	and	controls	were	ancestrally	matched.	PCA	
reduces	 SNPs	of	 common	variants	not	 in	 linkage	disequilibrium	with	 each	other	 and	 sample	
data	 to	 linear	 uncorrelated	 representation	 called	 principal	 component	 (PC).	 Each	 PC	 is	
orthogonal	 to	 other	 PCs	 and	 is	 ranked	 by	 variance.	 The	 first	 PC	 has	 the	 largest	 possible	
variance	and	each	succeeding	component	in	turn	has	the	highest	variance	possible	under	the	
constraint	that	it	is	orthogonal	to	the	preceding	components.	55	cases	and	524	controls	were	


















and	 annotated	 function;	 dominant	 altering	 (dom.alter),	 dominant	 truncating	 (dom.trunc),	
recessive	 altering	 (rec.alter)	 and	 recessive	 truncating	 (rec.trunc).	 Altering	 variants	
encompassed	 nonsynonymous	 missense	 variants	 whereas	 truncating	 variants	 were	
nonsynonymous	frameshift,	stop	gain	and	splice	site	variants.	A	gene	collapsing	fisher	test	was	
used,	where	the	number	of	rare	variants	 (set	at	MAF	<0.01	for	dominant	and	MAF	<0.05	for	
recessive)	 in	 any	 one	 gene	 was	 counted	 in	 cases	 and	 compared	 with	 controls.	 A	 quartile-
quartile	plot	demonstrating	the	distributions	of	the	expected	versus	observed	P	values	for	any	







The	 Euroepinomics	 consortium	assembled	 38	MAE	 trios	 for	 exome	 sequencing.	 	 Sequencing	
was	 performed	 at	 the	 Wellcome	 Trust	 Sanger	 Institute	 (Hinxton,	 Cambridgeshire)	 and	 has	
	 110	
been	described	before77.	 In	brief,	 paired	end	DNA	 librarys	were	prepared	using	TruSeq	DNA	
Sample	Preparation	Kit	from	Illumina,	target	enrichment	performed	with	SureSelect	Human	All	
Exon	 50Mb	 Kit	 from	 Agilent	 Technologies.	 DNA	was	 sequenced	 on	 a	 HiSeq2000	 Illumina	 as	
paired	 end	 75bp	 reads.	 Sequencing	 reads	 were	 aligned	 using	 Burrows	 Wheeler	 Aligner	
(http://bio-bwa.sourceforge.net/).	GATK	was	used	to	perform	QC	on	Fastq	files.	Variant	calling	
was	 performed	 with	 SAMtools	 mpileup,	 GATK,	 UnifiedGenotyper	





de	 novo	 SNVs	 and	 Indels	 from	 trio	 exome	 BAM	 files.	 This	 was	 double	 checked	 by	
GenomeComb	analysis.	
	
Sequencing	 files	were	 transferred	and	 included	 into	 the	MAE	exome	sequencing	cohort.	VCF	





During	 the	 course	of	 the	project,	 the	number	of	 genes	 associated	with	MAE	 increased	 from	







consistent	 with	 the	 King’s	 Health	 Partners	 epilepsy	 gene	 panel,	 and	 most	 commercially	
available	 epilepsy	 gene	 panels	 (Amplexa,	 Ambry).	 The	 list	 contains	 genes	 that	 are	 most	
commonly	 associated	 with	 epilepsy	 and	 includes	 examples	 of	 metabolic	 disorders	 (PNPO),	
neonatal	 encephalopathy	 (KCNQ2),	 specific	 epilepsy	 syndromes	 (GRIN2A),	 ID	 syndromes	
(IQSEC2),	 congenital	 syndromes	 (MECP2),	 cortical	 malformations	 (MTOR)	 as	 well	 as	 specific	






ADSL	 DNM1	 HNRNPU	 PIGA	 SLC1A2	
ALDH7A1	 EEF1A2	 HUWE1	 PIGO	 SLC25AA	
ALG13	 FASN	 IQSEC2	 PIGT	 SLC2A1	
ARHGEF9	 FOXG1	 KCNA2	 PIK3AP1	 SLC35A2	
ARX	 GABBR1	 KCNB1	 PIK3R2	 SLC35A3	
ATP1A2	 GABBR2	 KCND2	 PLCB1	 SLC6A1	
ATP1A3	 GABRA1	 KCNH5	 PNKP	 SLC6A8	
ATRX	 GABRA5	 KCNQ2	 PNPO	 SLC9A6	
CACNA1A	 GABRB3	 KCNQ3	 POLG	 SMARCA2	
CACNA1D	 GABRD	 KCNT1	 PRRT2	 SPTAN1	
CACNA1H	 GABRG2	 KIAA2022	 PURA	 ST3GAL3	
CACNB4	 GAMT	 LAMC3	 RELN	 STX1B	
CDKL5	 GATM	 LGI1	 SCN1A	 STXBP1	
CHD2	 GNAO1	 MECP2	 SCN1B	 SYNGAP1	
CHRNA2	 GRIN1	 MEF2C	 SCN2A	 SZT2	
CHRNA4	 GRIN2A	 MTOR	 SCN8A	 TBC1D24	
CHRNB2	 GRIN2B	 NBEA	 SETBP1	 TCF4	
CNKSR2	 GRIN2D	 NPRL2	 SIK1	 UBE3A	
CPA6	 HCN1	 NPRL3	 SLC12A5	 WWOX	
DEPDC5	 HDAC4	 PCDH19	 SLC13A5	 ZDHHC9	
	
Only	 novel	 variants	 i.e.	 variants	 not	 found	 in	 1000G,	 ESP	 and	 ExAC	 were	 considered.	
Deleterious	variants	have	lower	MAF	than	neutral	ones	due	to	negative	selection,	as	MAE	is	a	
rare	 severe	 childhood	 epilepsy,	MAF	 was	 expected	 to	 be	 rare	 or	 ultra	 rare	 (MAF	 <0.0001).	
Indeed,	 annotation	 analysis	 from	 the	 Pure_epilepsy	 variant	 group	 (see	 section	 6.14)	 were	
mostly	 novel.	 Novelty	 was	 also	 a	 feature	 in	 the	 solved	 cases	 in	 the	 Euroepinomics	 cohort.	
Following	 filtering	 for	novelty,	variants	 from	MAE	cases	that	were	annotated	as	synonymous	
and	non-frameshift	were	removed.	Each	variant	was	then	reviewed	on	IGV	and	classified	into	
whether	 the	variant	was	 failed,	was	 inconclusive	or	passed	based	on	visual	 interpretation	of	


























and	the	case	 in	question	had	no	evidence	of	 ID,	the	variant	was	down-weighted.	 Inheritance	
and	 penetrance	 studies	were	 reviewed	where	 available,	 and	 variants	 down-weighted	where	
inheritance	 was	 demonstrated	 without	 evidence	 of	 phenotypic	 segregation.	 Variants	 where	
zygosity	did	not	match	mode	of	inheritance	for	the	gene	in	question	were	also	down	weighted.	
The	literature	surrounding	the	genes	in	question	were	reviewed	in	order	to	determine	if	there	
was	 a	 pattern	 in	 the	 reported	 pathogenic	 variants	 e.g.	 location,	 mutation	 types,	 recurrent	
mutations	etc.	Where	available	locus	specific	databases	were	reviewed.	Annotation	with	SIFT,	
PP2hvar,	CADD	and	splice	site	(Ada	and	RF)	 in	silico	predictors	were	applied	for	each	variant.	
Each	 variant	was	 then	 classified	 into	 likely	 benign,	 variant	 of	 uncertain	 significance	 (VUS)	 or	
likely	 pathogenic.	 	 Likely	 pathogenic	 candidate	 variants	 were	 Sanger	 sequenced	 to	 validate	
















To	 unpick	 the	 genetic	 heterogeneity	 of	 MAE,	 gene	 exploration	 with	 aetiologically	 relevant	
gene	 sets	were	 performed.	 Three	 gene	 sets,	 neuropsychiatric	 genes,	 ion	 channel	 genes	 and	















There	 lies	 an	 increased	 awareness	 of	 shared	 genes,	 pathways	 and	 co-expression	 networks	
between	the	various	neurodevelopmental	phenotypes	of	autism,	ID,	and	epilepsy163,165-168.		The	
prevalence	of	epilepsy	in	patients	with	autism	and	ID	is	up	to	40%,	and	conversely	autism	and	




for	 gene	 disrupting	 mutations	 (nonsense,	 splice	 site	 and	 frameshift)172-174	 and	 are	 more	
intolerant	 to	 functional	 variation	 with	 a	 lower	 RVIS	 percentile	 compared	 with	 controls154.	
Neuropsychiatric	gene	sets	were	collated	from	eight	published	de	novo	sequencing	studies	of	
four	 primary	 phenotypes,	 (1)	 developmental	 disorders,	 (2)	 epileptic	 encephalopathy,	 (3)	
intellectual	disability,	and	(4)	autism	spectrum	disorder	(see	Table	6.4).	Duplicate	genes	were	





















































O’Roak	et	al.176	 ASD	 189	trios/quads	 225	 SNV	 and	 17	
Indels	
181	





ASD	 200	quads	 172	SNV	 143	
UK	United	Kingdom,	SNV	single	nucleotide	variation,	LGS	Lennox	gastaut	sundrome,	IS	infantile	spasms,	




Ion	 channel	 genes	 were	 a	 strongly	 enriched	 paralogue	 amongst	 de	 novo	 variants	 in	 10,000	
neurodevelopmental	 trios,	 with	 sodium	 channel	 genes	 conferring	 specific	 risk	 for	 severe	
seizures	 (OR	 4.23)	 (Lal	 et	 al.	 ASHG	 abstract	 2016).	 Other	 ion	 channel	 genes	 such	 as	KCNQ2	
(potassium	 channels),	GABRA1	 (GABA	 receptor	 channels),	 CACNA1A	 (calcium	 channels)	 and	
CHRNA2	 (cholinergic	 receptor	 channels)	 have	 all	 been	 implicated	 as	 monogenic	 causes	 of	












were	 matched	 with	 genes	 form	 the	 three	 gene	 sets.	 In	 the	 neuropsychiatric	 gene	 set,	
recurrent	variants	where	there	was	more	than	one	novel	nonsynonymous	variant	with	a	CADD	
score	>20	in	a	matched	gene	were	reviewed.	Following	each	gene	match,	the	following	steps	
were	carried	out	to	prioritise	candidate	genes:	(1) Variant	interrogated	on	IGV	and	classified	as	pass	or	inconclusive.	(2) GOI	has	a	RVIS	score	<	25th	centile	or	positive	ExAC	Z	score	if	missense	mutation.	(3) Gene	 expression	 from	 Genevestigator	 above	 a	 threshold	 of	 ‘medium’	 in	 central	
nervous	system	tissue	expression.		(4) Segregation	data	not	conflicting	(5) Gene	function	not	conflicting	with	MAE.		(6) Associated	phenotypes	not	conflicting	with	MAE.	
	












Enrichment	 analysis	 per	 gene	 in	 each	 gene	 set	was	 carried	 out	 using	 the	 ExAC_Non	 Finnish	




The	 ExAC	 vcf	was	 downloaded	 and	 converted	 into	 annovar	 input	 format.	 Standard	 annovar	
protocol	was	 carried	out	 to	annotate	 the	entire	dataset.	 First,	 only	novel	 genetic	 variants	 in	
genes	 from	 the	 three	 gene	 sets	were	 selected	 in	 this	MAE	 cohort.	 Then	 in	 the	 ExAC	 group,	
variants	that	occurred	only	in	one	individual	and	were	not	seen	in	1000	Genomes	project	and	
ESP	 was	 considered	 novel.	 Next,	 the	 novel	 variants	 in	 both	 cohorts	 were	 filtered	 for	 CADD	
scores	>20	variants.	The	number	of	filtered	variants	per	gene	was	counted	in	each	cohort	and	
compared	using	chi	squared	test	with	yates	correction.	Level	of	significance	was	corrected	for	





















Exome	 sequencing	data	was	performed	 for	 some	 sibling	pairs.	 Filtering	 involved	 shared	 rare	
variant	 analysis	 and	 where	 sequencing	 data	 from	 other	 family	 members	 were	 available,	
segregation	 of	 variants	was	 performed.	 For	 heterozygous	 variants,	 only	 novel	 variants	were	
considered	 and	 for	 homozygous	 variants,	 a	 MAF	 <0.001	 was	 considered	 to	 account	 for	 a	
presumed	 carrier	 frequency	 in	 the	 population.	 Synonymous,	 non	 frameshift	 and	 variants	
annotated	with	unknown	function	were	removed.	Gene	variants	assembled	were	reviewed	as	








region	 of	 the	 genome.	 The	 procedure	 uses	 oligonucleotide	 primers,	 deoxynucleoside	
triphosphates	 (dNTPs)	 and	 Taq	polymerase	 to	 synthesise	DNA	 strands	 in	 a	 chosen	 region	of	
interest.	
	
The	 procedure	 involves	 three	 successive	 steps,	 which	 are	 repeated	 30	 to	 40	 times.	 Step	 1:	
Denaturing,	DNA	 is	 heated	 to	 a	 high	 temperature	 to	 break	 the	 hydrogen	 bonds	 holding	 the	
two	complimentary	DNA	strands	into	a	single	stranded	DNA.	Step	2:	Annealing,	the	reaction	is	
cooled	allowing	the	primers	to	bind	by	base	pairing	to	a	complementary	sequence	on	a	single	
stranded	 DNA.	 Step	 3:	 Amplification,	 four	 dNTPs,	 dATP,	 dCTP,	 dGTP	 and	 dTTP	 and	 Taq	
polymerase	 from	 Thermus	 aquaticus	 initiates	 the	 synthesis	 of	 new	 DNA	 strands	 that	 are	













In	 order	 to	 allow	 maximum	 complementarity,	 annealing	 and	 avoidance	 of	 internal	 base	
pairing,	primer	design	was	carried	out	using	the	following	criteria:	(1)	melting	temperature	58-
63oC,	within	1-2oC;	(2)	GC	content	35-70%,	optimum	50%;	(3)	primer	length	18-30bp,	optimum	
22bp;	 (4)	 maximum	 self	 complimentary	 4bp;	 (5)	 maximum	 3’	 self	 complementary	 3bp;	 (6)	
maximum	pair	 complimentary	5bp;	 (7)	maximum	polyX	 run	of	 same	base	3bp;	 (8)	maximum	
GC	in	3’	end	3bp.		
	
The	 selected	 primer	 was	 checked	 with	 University	 of	 California	 Santa	 Cruz	 (UCSC)	 Genome	
Browser	In-Silico	PCR	tool	https://genome.ucsc.edu/cgi-bin/hgPcr	to	ensure	that	the	genomic	
region	was	tightly	matched	and	it	did	not	bind	to	any	other	location.	Primers	were	purchased	






























































2g	 agarose	 in	 100ml	 Tris	 Borage	 EDTA	 (TBE)	 (Sigma-Aldrich	 UK),	 and	 heating	 for	 about	 90	
seconds	 in	a	microwave	on	 full	power	 to	dissolve	 the	agarose.	12μl	SYBR	Safe	DNA	gel	 stain	



















electrode)	 to	 positive	 charge	 (red	 electrode)	 for	 about	 45	 minutes.	 This	 is	 because	 DNA	































synthesized	 DNA	 strands.	 The	 ends	 of	 the	 strands	 are	 marked	 with	 fluorescent	 chain	




template	DNA	 segment.	 The	 template	DNA	 to	 be	 sequenced	 is	 combined	with	 primer,	 DNA	
	 123	
polymerase,	 four	 deoxynucleosidetriphosphates	 (dNTPs),	 dATP,	 dCTP,	 dGTP,	 dTTP	 and	 di-
deoxynucleotidetriphosphates	(ddNTPs)	that	serves	as	a	base	chain	terminator	by	competing	
with	 its	 dNTP	 counterpart	 for	 insertion.	 These	 ddNTPs	 lack	 a	 3’OH	 group	 required	 for	 the	
formation	 of	 a	 phosphodiester	 bond	 between	 two	 nucleotides,	 causing	 DNA	 polymerase	 to	
cease	extension.	
	
The	mixture	 is	 first	heated	to	denature	and	separate	the	double	stranded	DNA	strands,	 then	
cooled	so	the	primer	can	bind	to	the	single	stranded	DNA.	Next	the	temperature	is	raised	again	
to	 allow	amplification	of	new	DNA	using	DNA	polymerase.	DNA	polymerase	will	 continue	 to	
add	dNTPs	 to	 the	 chain	until	 it	 happens	 to	add	a	ddNTPs.	Because	 there	are	many	 identical	
copies	 of	 the	 PCR	 template,	 a	 range	 of	 different	 fragments	 is	 produced	 depending	 on	 the	








the	 DNA	 fragments	 migrate	 past	 this	 position,	 the	 laser	 causes	 the	 dyes	 to	 fluoresce.	







































Step	 Description	 Temp	(oC)	 Time	
1	 Initial	denaturation	 96	 1	minute	
2	 Denaturation	 96	 30	seconds	
3	 Annealing	 50	 15	seconds	
4	 Extension	 60	 4	minutes	
5	 Go	to	step	2	and	repeat	for	28	cycles	 	 	


















































Quantification	 in	 RTPCR	 depends	 on	 detecting	 a	 fluorescence	 signal	 that	 is	 generated	 after	
binding	of	SYBR	Green	to	amplified	product	at	the	early	stages	of	the	PCR	reaction.	SYBR	Green	
dye	 shows	 relatively	 little	 fluorescence	 when	 free	 in	 solution	 but	 when	 it	 binds	 to	 double-
stranded	 DNA,	 its	 fluorescence	 increases	 more	 than	 1000	 fold.	 	 This	 produces	 sigmoidal-
shaped	amplification	plots	in	which	fluorescence	is	plotted	against	the	number	of	cycles.	The	
threshold	cycle	(CT)	value	is	obtained	from	the	plot.	This	 is	the	point	at	which	there	 is	a	first	











The	 comparative	 or	 ΔΔCT	 threshold	 point	 relies	 on	 direct	 comparison	 of	 CT	 values	 of	 the	
target	sample	GOI	and	a	control	sample/s	with	a	reference	assay.	The	Type-it	CNV	reference	




not	 changed	 among	 different	 samples;	 therefore	 any	 CT	 difference	 of	 the	 reference	 assay	
reflects	the	difference	of	the	template	DNA	amount	in	the	target	sample.		
	
Primers	 for	 the	 gene	 of	 interest	 (GOI)	 were	 designed	 as	 described	 previously.	 Two	 sets	 of	
primers	for	each	CNV	region	were	designed	as	described	previously	(see	section		6.19.1.1);	one	











The	 Type-it	 SYBR	 Green	 PCR	master	mix	 contains	 HotStarTaq	 plus	 DNA	 Polymerase,	 Type-it	
SYBR	Green	PCR	Buffer	and	dNTPs.	Each	reaction	is	done	in	triplicate	and	the	mean	calculated.	






























When	 the	 reaction	 is	 complete,	 the	 following	 calculations	 are	 performed:	 The	 copy	 number	























The	 exome	 sequencing	 cohort	 (n=109)	 comprises	 cases	 within	 the	 same	 three	 phenotyping	
groups;	the	UK	cohort	(n=49),	the	Euroepinomics	cohort	(n=42)	and	the	Italian	cohort	(n=18).	I	
recruited	 the	 UK	 cohort	 (see	 section	 2.2),	 the	 Euroepinomics	 cohort	 was	 assembled	 by	
European	collaborators	 (see	 section	2.3.2),	 and	 the	 Italian	cohort	was	provided	by	Professor	
Renzo	Guerrini	 and	 Professor	 Carla	Marini	 (Anna	Meyer	 Children’s	Hospital,	 Florence,	 Italy).	
The	 UK	 and	 Italian	 cohorts	 were	 sequenced	 at	 the	 Guy’s	 Genomics	 Facility	 while	 the	
Euroepinomics	 cohort	 consisted	 of	 40	 European	 trios	 sequenced	 at	Wellcome	 Trust	 Sanger	
Institute	 and	 two	 cases	 from	 a	multiplex	 family	 sequenced	 at	 the	Danish	 Epilepsy	 Centre	 in	
Denmark.	Out	of	 the	109	 cases	with	MAE	 in	 the	 exome	 sequencing	 cohort,	 three	 cases	had	












The	mean	 percentage	 of	 reads	mapped	 to	 target	 regions	 was	 70.07%	 (SD	 4.51),	 and	 when	
















depth	 of	 20x	was	 90.5%	 (SD	 7.49),	 although	 there	was	 a	 clear	 difference	 between	 samples	
sequenced	 at	 the	 Guy’s	 Genomics	 Facility	 and	 elsewhere	 (see	 Figure	 7.2).	 When	 analysed	
separately,	 samples	 sequenced	 at	 the	 Guy’s	 Genomics	 Facility	 achieved	 95.5%	 (SD	 2.60)	
coverage	of	 20x	 compared	with	 the	 Euroepinomics	 cohort,	which	 achieved	83.0%	 (SD	2.84).	











reduced	 capture	 efficiency	 or	 read	 depth	would	mainly	 result	 in	 false	 negatives.	 In	 addition	





Annotated	 variant	 characteristics	 and	 variant	 numbers	 in	 each	 sample	 were	 reviewed.	 Per	
sample,	the	mean	total	number	of	coding	variants	was	25333	(SD	1537),	there	was	a	mean	of	
15656	 (SD	 1185)	 heterozygous	 variants	 and	 9677	 (SD	 549)	 homozygous	 variants	 (see	 Figure	
7.3).	 Three	 samples	 were	 removed	 from	 further	 analysis	 as	 they	 had	 insufficient	 variants	
called.	They	were	S2539	with	957,	S2544	with	3930,	and	S2537	with	12747,	total	numbers	of	





hom_variant	 homozygous	 variants,	 het_variants	 heterozygous	 variants,	 troughs	 in	 graph	 from	 left	 to	
right	represent	variant	counts	from	S2537,	S2539	and	S2544.	
	
In	 the	 samples	 remaining	 after	 the	 three	 samples	 with	 insufficient	 variants	 were	 removed,	
there	was	a	mean	of	104	(SD	52.1)	novel	coding	variants	consisting	of	a	mean	of	99.9	(SD	51.1)	
novel	heterozygous	variants	and	4.5	(SD	2.8)	homozygous	novel	variants	(see	Figure	7.4).	The	
three	 samples	with	 the	most	novel	 variants	were	 ethnically	diverse;	 S2536	of	Asian	Gujarati	
descent	with	440	novel	variants,	S2286	with	300	and	S2540	with	274	novel	variants,	both	of	










The	 transition	 –	 transversion	 ratio	 is	 a	 useful	 diagnostic	metric.	 Transitions	 involve	 bases	 of	
similar	shape	and	are	interchanges	of	purine	(A	<->	G)	or	of	pyrimidine	(C	<->	T).	Transversions	
involve	 exchange	 of	 purine	 for	 pyrimdine	 bases	 (A	 <->	 C,	 A	 <->	 T,	 G	 <->	 C	 or	 G	 <->	 T).	
Transitions	occur	more	frequently	than	transversions	due	to	shifts	during	replication.	In	exome	













Annotations	 of	 variants	 with	 MAF	 from	 1000	 Genomes,	 ESP	 and	 ExAC	 revealed	 that	 even	




















Gene	 Chr:position	ref>alt	 dbSNP	ID	 Weighted	
MAF	
Clinical	significance	
SCN1A	 2:166909544	C>T	 rs3812718	 0.4934	 Risk	factor	for	familial	
febrile	seizures	
NHLRC1	 6:18122506	G>A	 rs10949483	 0.6196	 Benign	
CHRNA7	 15:32460616	C>T	 rs2229956	 0.2857	 No	information	
CACNA1A	 19:	13397560	C>T	 rs16027	 0.1578	 Benign/Likely	benign	
GJD2	 15:35045057	G>A	 rs3743123	 0.5223	 In	HGMD	






out	 of	 1704)	 and	 a	CADD	 score	of	 20	 captured	86.0%	 (2025	out	 of	 2353)	 of	 variants.	When	


















As	an	 internal	validation,	 the	 inverse	relationship	between	SIFT	and	PP2hvar	scores	was	also	
explored.	 The	 pathogenic	 cut	 off	 scores	 for	 SIFT	 and	 PP2hvar	 are	 opposite;	 SIFT	 considers	
scores	 <0.05	 as	 pathogenic	whereas	 PP2hvar	 considers	 scores	 >0.909	 pathogenic.	 Therefore	
for	any	given	presumed	pathogenic	variant,	it	should	have	a	low	SIFT	score	and	high	PP2hvar	















622	 unique	 variants	 from	 45	 genes	made	 up	 the	 Pure_epilepsy	 autosomal	 dominant	 group	
following	 stratification	 of	 the	 ClinVar	 search	 results.	 97.6%	 of	 variants	 were	 novel	 with	 the	
remaining	15	variants	with	a	median	weighted	MAF	of	9.03	x	10-5	(range	8.2	x	10-6	to	3.17	x	10-
3).	 	 As	 expected,	 in	 silico	 predictors	 predicted	more	 variants	 to	 be	 pathogenic	 in	 this	 group	
compared	 to	 the	 All_epilepsy	 group	 since	 these	 variants	 represented	 specific	 epilepsy	
syndrome	phenotypes.	SIFT	predicted	pathogenicity	in	82.4%	(320	out	of	388),	PP2hvar	80.4%	
(305	 out	 of	 379)	 and	 a	 CADD	 score	 of	 20	 and	 above	 captured	 93.0%	 (400	 out	 of	 430)	 of	




From	 the	Pure_epilepsy	 group,	 41	 variants	were	 stratified	 as	 having	 an	 autosomal	 recessive	
inheritance	 following	 individual	 variant	 review	of	 the	ClinVar	 search	 results.	Of	 these	only	 3	
variants	were	annotated	(Table	7.3).	
Table	7.3.	Pure_epilepsy	autosomal	recessive	variant	annotation.	
Annotations	 11:	792735	C>G	 11:	749509	A>G	 19:	2438464	T>C	
1000	Genomes	MAF	 0.00019	 	 	
ESP	MAF	 0.0006	 	 	
ExAC	MAF	 0.0004	 	 	
CADD	score	 -	 27.6	 25.4	
SIFT	score	 	 0.07	 0.04	





The	 Euroepinomics	 consortium	 sequenced	 and	 analysed	 40	MAE	 trios	 for	 de	 novo	 variants.	
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of	membrane	protein	 trafficking	and	 is	 required	 for	 the	 formation	and	 functioning	of	central	
synapses180.	NBEA	 is	not	a	previously	recognised	epilepsy	gene	and	this	de	novo	variant	is	yet	
unpublished.	Further	cases	with	pathogenic	variants	have	been	collected	and	functional	work	




SMARCA2	 encodes	 the	 catalytic	 subunit	 components	 of	 the	 SWItch/sucrose	 nonfermentable	
like	chromatin	remodelling	complex	(SWI/SNF	complex).	Variants	in	the	SNF2	ATPase	domain	
of	SMARCA2	are	associated	with	80%	of	patients	with	Nicolaides	Baraitser	 syndrome181.	This	
was	 a	 London	 case	 and	 deep	 phenotyping	 and	 Sanger	 sequencing	 was	 carried	 out	 here.	
Subject	 3003301	 had	 a	 de	 novo	 SMARCA2	 missense	 mutation	 c.3721C>G,p.Q1241E	
(ENST00000349721	 NM_0030703).	 Sanger	 sequencing	 confirmed	 this	 in	 the	 patient	 (Figure	







(50th	 centile)	 and	 a	 head	 circumference	 of	 32cm	 (2nd	 centile).	 Her	mother	 referred	 normal	
early	developmental	milestones	as	she	sat	unsupported	at	8	months,	walked	at	12	months	and	













6	 months	 following	 the	 introduction	 of	 solids.	 She	 was	 hypersensitive	 to	 textures	 and	
demonstrated	food	refusal	and	would	hold	food	in	her	mouth	or	vomit	during	meal	times.	No	
dysmorphic	 features	were	 identified	 at	 the	 time.	 Based	 on	 these	 electoclinical	 features,	 her	
epilepsy	 type	was	 thought	 compatible	 with	 a	 diagnosis	 of	MAE	 syndrome.	 She	was	 treated	
with	 sodium	 valproate	 to	 which	 she	 responded,	 attaining	 complete	 seizure	 remission	 at	 3	
years	with	 normalization	 of	 her	 EEG.	 At	 2	 years	 9	months	 her	weight	was	 13.9kg	 (25	 -	 50th	
centile),	height	94.7cm	(50	–	75th	centile)	and	head	circumference	was	49cm	(9	-	25th	centile).	
Antiepileptic	 medication	 was	 discontinued	 at	 4	 years.	 At	 5	 years,	 she	 had	 developed	 a	
restricted	pattern	of	feeding	with	aversion	to	lumpy	foods.	The	3di	autism	interview	revealed	
abnormalities	 in	 communication	 and	 non-verbal	 communication,	 with	 borderline	 scores	 in	
social	reciprocity	and	restricted/repetitive	behavior	and	interests	and	she	was	diagnosed	with	
autism	 spectrum	 disorder.	 On	 neurodevelopmental	 assessment	 with	 the	 WPPSI	 III,	 she	
















lip	over	 the	premaxilla,	 thin	upper	 vermillion	 and	 thick	 lower	 vermillion	border.	 She	did	not	
have	 brachydactyly	 or	 prominent	 interphalangeal	 joints	 (see	 Figure	 7.10).	 She	 had	 eczema	





















(a)	and	 (b)	Skin	wrinkling,	 frontal	balding,	broad	nasal	base,	upturned	nasal	 tip,	 thick	alae	nasi,	broad	
and	long	philtrum,	thin	upper	vermillion,	thick	lower	vermillion,	anterior	projection	of	the	upper	lip	over	





Variants	 in	SMARCA2	were	 reviewed	 in	 the	 rest	 of	 the	MAE	exome	 sequencing	 cohort.	 Two	
cases	had	novel/rare	SMARCA2	variants.		
	
WTSI_MAE_1158850	had	a	 c.1746+7	G>T	variant	 inherited	 from	an	unaffected	 father.	 Splice	
site	 predictors	 (Ada	 0.0.0002,	 RF	 0.016)	 were	 not	 significant,	 gnomAD	 MAF	 novel.	 Subject	
WTSI_MAE_1158850	 is	 a	 3	 years	 8	months	 old	male	with	 previous	 normal	 development,	 he	
developed	 myoclonic	 atonic	 seizures	 at	 3	 years.	 At	 the	 time	 of	 recruitment,	 he	 had	 no	
associated	 neurodevelopmental	 comorbidity.	 Euroepinomics	 collaborators	 from	 Bucharest	
performed	neurological	 examination	 and	 EEG	with	 photosensitive	 stimulation	 on	 the	 father,	
which	 was	 normal	 (personal	 communication	 Dr.	 Dana	 Craiu).	 The	 variant	 was	 classified	 as	
inconclusive	during	IGV	interrogation	due	to	a	read	depth	of	11	and	17	reads	in	the	child	and	






WTSI_MAE_1153136	has	a	 c.A337G,p.M113V	variation	with	variant	prediction	 scores	of	 SIFT	
0.39	 (tolerated),	 PP2hvar	 0.339	 (tolerated),	 CADD	 25.4.	 The	 variant	 is	 inherited	 from	 his	
unaffected	 mother.	 Subject	 WTSI_MAE_1153136	 is	 a	 17-year-old	 male	 from	 Kiel.	 He	 had	
previous	 normal	 development	 and	 had	 his	 first	 seizure	 at	 3	 years,	 which	 was	 a	 myoclonic-
atonic	seizure,	which	remained	his	only	seizure	type.	He	went	into	seizure	remission	at	5	years.	








for	 enrichment	 of	 rare	 variants	 with	 a	 Fisher	 test	 using	 EPACTS	 v3.2.3.	 Four	 models	 were	
tested;	 dominant	 (MAF<0.01%)	 or	 recessive	 (MAF<0.05%),	 and	 then	 altering	 or	 truncating	
variants.	The	 top	 ten	genes	with	 the	 lowest	P	 values	 in	 the	 four	models	 tested	are	 listed	on	
Table	7.5.	The	distribution	of	observed	and	expected	log10	P	values	is	shown	on	the	quantile-
quantile	plot	 in	Figure	7.11.	Literature	 reviews	were	carried	out	on	 the	genes	but	 it	was	not	
possible	 to	 pick	 out	 an	 obvious	 candidate.	 This	 was	 one	 of	 the	 first	 gene	 identification	
strategies	 that	 was	 attempted	 and	 it	 was	 subsequently	 abolished	 mainly	 due	 to	 the	
understanding	that	most	epilepsy/MAE	variants	discovered	to	date	were	novel	and	this	model	
was	more	suited	for	testing	rare	variants;	eliciting	genes	that	were	enriched	with	rare	variation	


















Dom.Alter	 Dom.	Trunc	 Rec.Alter	 Rec.Trunc	
Gene	 P	value	 Gene	 P	value	 Gene	 P	value	 Gene	 P	value	
RBMS1	 1.37	x	10-8	 STRAP	 7.65	x	10-7	 SH2D2A	 2.79	x	10-14	 IPO5	 0.002649	
UTP23	 2.85	x	10-7	 TFAP2D	 7.65	x	10-7	 PHF21A	 3.69	x	10-13	 PARK2	 0.002649	
MAGOHB	 7.65	x	10-7	 KIAA1432	 6.03	x	10-6	 GOLGA6L2	 7.02	x	10-11	 AF131215.4	 0.002649	
KRT16	 5.07	x	10-6	 GRIK2	 4.66	x	10-5	 GXYLT1	 5.31	x	10-9	 SSX9	 0.002649	
ACADSB	 5.45	x	10-6	 SMC3	 0.000354	 TAS2R46	 4.78	x	10-8	 DSTYK	 0.004625	
PARD6A	 1.00	x	10-5	 C11orf49	 0.000354	 HNRNPC	 6.40	x	10-8	 AC107977.
3	
0.008898	
UBA3	 1.11	x	10-5	 IPO5	 0.000354	 CCNYL2	 5.11	x	10-7	 APIP	 0.009532	
TNIK	 2.47	x	10-5	 KIAA2018	 0.000354	 MED15	 8.91	x	10-7	 NUP214	 0.009532	
MED15	 2.51	x	10-5	 RARS	 0.000354	 CDC27	 9.14	x	10-7	 DDX58	 0.009532	















section	 6.18	 for	 epilepsy	 associated	 gene	 list).	 The	 nine	 cases	 (see	 section	 7.4)	 from	 the	




IGV	 interrogation,	 17	 variants	 failed	 this	 step	 and	were	 removed	 from	 further	 analysis	 (see	
Table	7.6).	IGV	interrogation	was	considered	failed	if	(1)	variant	call	fell	in	a	region	where	total	
read	 depth	 was	 less	 than	 10	 reads,	 (2)	 variant	 call	 was	 in	 less	 than	 20%	 of	 total	 reads	 for	
heterozygous	mutations,	 (3)	 identical	 indel	 in	more	 than	 one	 sample	 and	 in	 other	 in-house	
sample,	(4)	SNV	more	than	10bp	from	intro/exon	boundary	and	(5)	Indel	more	than	2bp	from	
intron/exon	 boundary.	 The	 remaining	 29	 genetic	 variants	 were	 classified	 into	 likely	 benign	
(n=6),	variant	of	uncertain	significance	 (n=16)	or	 likely	pathogenic	 (n=7),	 following	a	detailed	
review	 of	 relevant	 literature,	 variant	 characteristics	 and	 correlation	 with	 phenotype.	 Three	
cases	 had	 more	 than	 one	 novel	 variant	 in	 an	 epilepsy	 associated	 gene.	 Subject	
WTSI_MAE_1195700	had	variants	 in	KIAA2022	and	PLCB1	variant	 inherited	from	her	mother,	
subject	WTSI_MAE_1150147	had	a	GRIN2A	variant	inherited	from	her	father	and	a	POLG	and	




The	 following	 section	 will	 detail	 the	 individual	 genetic	 variants	 described	 above	 and	 the	





























































































































































homozygous.	 Up	 to	 90%	 of	 cases	 present	 in	 the	 first	month	 of	 life	with	 clonic	 seizures	 and	
myoclonic	 jerks,	 often	 with	 irritability	 and	 hypotonia;	 although	 the	 clinical	 spectrum	 can	
extend	 to	 a	 later	 onset	 and	 a	 multisystem	 disorder183,184.	 Pyridoxine	 treatment	 causes	
cessation	of	seizures	in	the	majority.	
	
Subject	 S2294/00554	 has	 seizure	 onset	 at	 3	 years	 2	 months	 with	 multiple	 seizure	 types;	
currently	 at	 the	 age	 of	 13	 years	 she	 has	 been	 seizure	 free	 for	 7	 years	 without	 Pyridoxine	
treatment.	 Her	 c.G1072A,p.E358K	 heterozygous	 variant	 had	 a	 MAF	 of	 1.98	 x	 10-5	 with	










patients	with	 Xp11.22	microduplication186.	 	 A	 dose	 sensitive	 relationship	 is	 inferred	 as	 cases	
demonstrate	 up	 regulation	 of	HUWE1	 on	 expression	 array	 and	 quantitative	 PCR	 analysis186.	
The	 principal	 phenotypes	 are	 affected	males	with	 variable	 degree	of	 ID	 and	delayed	 speech	












KIAA2022	 is	 an	 X-linked	 ID	 gene	which	was	 first	 described	 in	 hemizygous	males85.	 Causative	













PLCB1	 encodes	 the	 phosphoinositide-specific	 enzyme,	 phospholipase	 C	 β1.	 This	 enzymes	
generates	 the	 intracellular	 second	messengers	 diacylglycerol	 and	 inositol-1,4,5-triphsophate	
from	 phosphatidylinositol-4,5-biphosphate.	 	 Biallelic	 loss	 of	 function	 variants	 in	 PLCB1	 has	
been	 described	 in	 four	 cases	with	 early	 infantile	 EE.	 Two	 cases	 had	 a	 homozygous	 deletion	

















POLG	 encodes	 DNA	 polymerase	 gamma	 and	 is	 associated	 with	 five	 MIM	 mitochondrial	
disorders,	 three	 of	which	 are	 associated	with	 refractory	 seizures193.	 The	 seizure	 phenotypes	
are	often	occipital	 lobe	 seizures	and	status	epilepticus.	POLG	 related	diseases	have	different	
degrees	 of	 severity	 and	 timing	 of	 onset,	 often	 with	 overlapping	 range	 of	 symptoms	 with	
multiple	 organ	 system	 involvement193.	 Symptoms	 include	 lactic	 acidosis,	 seizures,	 ataxia,	
peripheral	 neuropathy,	 developmental	 delay,	 myopathy,	 chronic	 progressive	 external	
ophthalmoplegia,	 and	 hepatopathy.	A	 distinctive	 feature	 is	 the	 increasing	 involvement	 of	
neurological	 signs	 and	 symptoms	 during	 illness	 such	 as	 viral	 infections	 and	 physiological	















































































































































































be	principally	 ID	as	well	as	seizures	and	psychiatric	comorbidity	 in	 the	majority,	and	variable	
dysmorphism.	 Only	 three	 female	 cases	 have	 been	 reported,	 two	 with	 evidence	 of	 X	
chromosome	 rearrangements.	 Marco	 et	 al.	 reported	 a	 female	 with	 ID	 and	 sensory	
hyperarousal	with	 a	de	novo	 paracentric	 inversion	of	 one	X	 chromosome	disrupting	 a	 single	
gene	 ARHGEF9	 and	 skewed	 inactivation	 of	 the	 normal	 X	 chromosome198.	 Kalscheuer	 et	 al.	




the	 pathogenic	 role	 of	 ARHGEF9	 haploinsufficiency	 in	 females	 even	 with	 normal	 X	
chromosome	arrangements.	
	
Subject	 00570	 is	 a	 9-year-old	 female	with	 normal	 development	 prior	 to	 seizure	 onset	 at	 12	
months	of	GTCS,	myoclonic	atonic	or	atonic	seizures,	absence	and	 focal	 seizures.	She	had	 ID	
and	a	diagnosis	of	ADHD.	There	was	no	family	history	of	epilepsy	or	psychiatric	disorders.	The	




novel	 as	 no	missense	mutations	 in	 females	 have	 been	 reported,	 and	 the	 variants	 effect	 on	












channel.	 CACNA1A	 variants	 are	 associated	 with	 three	 overlapping	 autosomal	 dominant	
conditions;	 episodic	 ataxia	 type	 2	 (OMIM	 108500),	 spinocerebellar	 ataxia	 type	 6	 (OMIM	
183086)	 and	 familial	 hemiplegic	 migraine	 (OMIM	 141500).	 The	 relationship	 with	 epilepsy	
phenotypes	 is	 more	 complicating.	 Association	 studies	 linking	 an	 exon	 8	 polymorphism	 of	






Subject	 S1389	 is	 a	 nine	 year	 old	 Italian	 male	 with	 seizure	 onset	 at	 9	 months	 of	 atonic,	
myoclonic	atonic	and	myoclonic	seizures.	He	has	been	 in	seizure	 remission	since	6	years	but	
has	 moderate	 ID	 and	 autism.	 His	 mother	 and	 paternal	 uncle	 have	 epilepsy	 and	 ID.	 He	 has	
dysmorphic	 features:	 prominent	 forehead,	 small	 eyes,	 large	 mouth,	 high	 arched	 palate,	
syndactyly	of	first	to	third	toes	of	both	feet.	EEG	demonstrated	GSW.	His	variant	is	supported	
by	 in	 silico	 prediction	but	 is	 now	 reported	 in	 gnomAD.	Given	 the	 family	 history,	 segregation	
studies	will	be	most	instructive	in	determining	the	role	of	this	variant	and	Italian	collaborators	




Carboxypeptidase	 A6	 is	 an	 extracellular	 matrix	 metallocarboxypeptidase	 that	 removes	
hydrophobic	 C-terminal	 amino	 acids	 from	 peptides	 and	 proteins.	 The	 CPA6	 gene	 is	 highly	
expressed	during	brain	development206.	Homozygous	variants	 in	CPA6	were	first	 identified	to	
be	 associated	with	 familial	 febrile	 seizures	 and	 temporal	 lobe	 epilepsy	 in	 four	 siblings	 from	
healthy	 consanguineous	Moroccan	parents207.	 Subsequently,	 heterozygous	missense	 variants	
were	 identified	 in	a	handful	of	 temporal	 lobe	epilepsy	patients,	although	 inheritance	studies	
were	not	performed208.	Allen	et	al.	presented	CPA6	as	a	candidate	gene	in	a	16	year	old	female	
















impaired	neurogenesis210.	FASN	was	a	 statistically	enriched	gene	 for	de	novo	 variants	 in	 two	
individuals	in	a	cohort	of	365	US	and	UK	trios	with	infantile	spasms	and	LGS155.			
	
Subject	 00561	 is	 a	 6-year-old	 female	with	 onset	 of	multiple	 seizure	 types	 at	 2	 years.	 She	 is	
currently	 in	 seizure	 remission	 and	 has	 no	 neurodevelopmental	 comorbidity.	 Her	 father	 has	
epilepsy.	Her	variant	is	present	in	gnomAD	(MAF	5.26	x	10-5)	but	has	supporting	in-silico	scores.	




GRIN2A	 encodes	 the	N	methyl	 D	 aspartate	 (NMDA)	 glutamate	 receptor	 α2	 subunit	which	 is	
involved	 in	 the	 long	 term	 potentiation	 of	 synaptic	 transmission.	 GRIN2A	 variants	 are	
associated	with	 idiopathic	 focal	 epilepsy.	 The	 principal	 phenotypes	 consist	 of	 an	 element	 of	
speech	 and	 language	 impairment;	 namely	 the	 epilepsy	 aphasia	 syndromes	 (Landau-Kleffner	
syndrome,	continuous	spike	and	wave	during	slow	wave	sleep),	rolandic	epilepsy	and	atypical	











and	 is	 in	 the	 identical	 location	but	with	an	alternate	allele	 to	a	 reported	possibly	pathogenic	
variant	 p.A1276G	 	 in	 a	 patient	with	 continuous	 spike	wave	 in	 slow	wave	 sleep.	 The	 authors	




established	 in	 their	 case212.	 Given	 that	 GRIN2A	 is	 usually	 associated	 with	 a	 focal	 epilepsy	
phenotype,	along	with	no	other	strongly	supporting	features	in	genotype	(present	in	gnomAD,	




The	MTOR	gene	 is	part	of	 the	mTOR	(mammalian	 target	of	 rapamycin)	pathway,	which	 is	an	
essential	pathway	 that	 regulates	 cell	 growth	 in	 response	 to	a	wide	 range	of	 stimuli.	 Somatic	
MTOR	mutations	were	first	identified	to	cause	focal	cortical	dysplasia	and	intractable	epilepsy	
from	exome	sequencing	of	paired	blood-brain	DNA	samples217.	Low	frequency	somatic	variants	
reported	 had	 allelic	 read	 frequencies	 typically	 less	 than	 10%	 (range	 1.26%	 to	 12.6%)217.	
Recently,	data	sharing	amongst	European	and	US	 investigators	 led	to	the	 identification	of	12	
patients	with	germline	MTOR	variants.	All	germline	variants	identified	were	either	de	novo	or	
demonstrated	 segregation	 with	 parent	 to	 child	 transmission.	 10/12	 of	 these	 cases	 were	
classified	with	focal	epilepsy	with	MRI	brain	abnormalities	findings	in	nine.	One	case	with	a	de	






myoclonic-atonic	 and	 GTCS.	 EEG	 demonstrated	 generalised	 epileptic	 activity.	 He	 has	 no	
neurodevelopmental	 comorbidity	 and	has	no	 relevant	 family	history.	He	 carries	 an	 inherited	
missense	variant,	which	is	unlikely	to	be	somatic	as	alternate	read	counts	are	44.6%	(54	out	of	






inherited	 from	 his	 mother,	 it	 is	 identified	 in	 gnomAD	 and	 in	 silico	 predictors	 are	 partially	
supportive.	 Alternate	 read	 frequency	 is	 53.2%	 (65	 out	 of	 122),	 not	 suggestive	 of	 a	 somatic	









the	 phosphatidylinositol	 3-kinase-AKT	 pathway219.	 Genes	 within	 the	 phosphatidylinositol	 3-
kinase-AKT	 pathway	 are	 known	 to	 cause	 a	 wide	 range	 of	 developmental	 brain	 and	 body	
disorders.	 PIK3R2	 is	 associated	 principally	 with	 megalaencephaly	 and	 bilateral	 perisylvian	
polymicroqyria,	 both	 conditions	 that	 lead	 to	 epilepsy.	 About	 a	 dozen	 patients	 with	 PIK3R2	
variants	have	been	 reported.	Variants	are	de	novo	 and	can	be	heterozygous	or	mosaic,	with	





Subject	 S2340/00504	 is	 a	 17-year-old	 female	 with	 severe	 MAE	 and	 ID.	 She	 has	 no	
abnormalities	 on	 brain	 neuroimaging.	 She	 has	 a	 novel	 missense	 variant	 in	 the	 Rho	 GAP	
domain,	an	area	not	previously	associated	with	pathogenic	variants.	The	alternate	read	ratio	
for	 the	 variant	 is	 46.8%	 (22	 out	 of	 47).	 This	 variant	 location	 along	with	 lack	 of	 a	 co-existing	






variants	have	been	 identified	and	 this	 cohort	offers	 a	distinct	phenotype	and	genotype.	 The	
clinical	 phenotype	 includes	 EE	 with	 hypsarrhythmia	 (West	 syndrome),	 no	 visual	 attention,	
acquired	 microcephaly,	 spastic	 quadriplegia	 and	 profound	 ID.	 A	 single	 case	 had	 a	 milder	
phenotype	 with	 well-controlled	 generalised	 epilepsy	 but	 still	 profound	 ID224.	 MRI	 brain	
abnormalities	demonstrating	brainstem	and	cerebellar	atrophy	and	cerebral	hypomyelination	
are	present	and	offer	additional	 specific	 clues	 to	 this	 gene	diagnosis.	All	pathogenic	variants	
reported	are	de	novo	 in-frame	in	the	last	two	of	20	spectrin	repeats	in	the	C-terminal	region.	
The	 last	 four	 spectrin	 repeats	 in	 the	 C-terminal	 region	 are	 required	 for	 α/β	 spectrin	










missense	 variant	 located	 in	 spectrin	 repeat	 5.	 Inheritance	 studies	 were	 not	 available.	 	 His	




STX1B	encodes	syntatxin	1b,	a	component	of	 the	SNARE	complex,	 that	helps	 tether	 synaptic	
vesicles	 at	 the	presynaptic	membrane	 and	mediates	 neurotransmitter	 release226.	STX1B	 as	 a	
causative	gene	was	first	identified	in	two	large	German	pedigrees	with	familial	febrile	seizures.	














seizures	 in	 the	maternal	 grandfather	who	 is	 deceased;	 there	 is	 no	 history	 of	 seizures	 in	 the	




Subject	 S2340/00504	 is	 17-year-old	 female	with	 seizure	onset	 at	19	months.	 She	has	 severe	
MAE	 with	 multiple	 seizure	 types	 and	 moderate	 to	 severe	 ID.	 There	 is	 no	 history	 of	 febrile	

















CHD2,	KCNH5,	KCNB1,	KIAA2022,	MECP2,	 SLC6A1	and	 SYNGAP1	 (see	Table	7.9).	Of	 these	 six	
were	de	novo	variants	and	in	the	other	two	(KIAA2022,	SYNGAP1),	inheritance	was	not	known.	





Some	of	 the	work	presented	here	were	done	elsewhere.	 The	MECP2	 variant	 in	 subject	291J	





















































































variants	 have	 been	 identified	 in	 individuals	 with	 MAE,	 LGS	 and	 EE14,15,77.	 The	 phenotype	 is	
consistent	 with	 seizure	 onset	 usually	 between	 2	 to	 3	 years	 of	 myoclonic	 seizures,	 with	







demonstrated	polyspike	and	wave	activity.	 She	has	 ID	and	ADHD.	There	 is	no	 family	history.	














4	 years	 7	months	with	GTCS,	myoclonic	 atonic,	myoclonic	 and	absence	 seizures.	 She	has	no	










KCNB1	 (voltage	 gated	potassium	 channel	 subfamily	 B	member	 1)	 encodes	 the	Kv2.1	 voltage	
gated	 potassium	 channel	 that	 mediates	 transmembrane	 potassium	 transport	 in	 excitable	
membranes,	primarily	in	the	brain,	but	also	in	the	pancreas	and	cardiovascular	system.	Allen	et	
al.	 first	 identified	a	single	de	novo	case	with	a	p.T374I	variant	 in	a	5	year	old	 female	with	EE	
and	cerebral	palsy101.		Since	then	five	further	patients	with	EE	and	infantile	epilepsy	have	been	















were	 no	 similarities	 of	 specific	 seizure	 types	 or	 EEG	 features	 in	 these	 two	 cases	 but	 atonic	
seizures	 and	 multifocal	 spikes	 on	 EEG	 seen	 in	 subject	 S2393/00533	 have	 been	 reported	 in	
other	patients	with	pathogenic	KCNB1	variants.	Additionally	it	can	be	difficult	to	ascertain	prior	






























of	 the	 ether-a-go-go	 family	within	 the	 voltage	 gated	 potassium	 channel	 superfamily.	 Kv10.2	
channels	are	natively	expressed	in	the	nervous	system	but	its	function	is	not	well	understood.	
Only	 one	 case	 with	 a	 de	 novo	 c.G980A,p.R327H	 in	 KCNH5	 has	 been	 reported,	 the	 authors	
considered	this	variant	a	good	candidate230.	The	patient	was	a	13-year-old	male	with	seizure	
onset	at	6	months.	 Seizure	 types	were	GTCS	or	hemiclonic	with	occasional	brief	 facial	 clonic	


















features	 on	 EEG,	which	 in	 Subject	 S2391/00525	 is	 an	 unusual	 finding	 in	MAE.	 There	 are	 no	
available	 further	 supportive	 features	 based	 on	 the	 variant	 type,	 location	 or	 with	 in	 silico	











first	 seizure	 at	 21	months	with	myoclonic	 atonic	 seizures.	 EEG	 demonstrated	 GSW.	 She	 has	
associated	mild	 to	moderate	 ID.	 She	has	a	 frameshift	 variant	 in	exon	3,	 a	 genomic	 ‘hotspot’	
where	most	of	reported	pathogenic	variants	are	 located.	Her	phenotype	consisting	of	 ID	and	
seizures	is	also	supportive.	Italian	collaborators	are	now	carrying	out	inheritance	studies.	This	




The	MECP2	 (methyl-CpG-binding	 protein	 2)	 gene	 is	 an	 X-linked	 gene	 associated	 with	 Rett	
syndrome	(OMIM	3127250).	Classic	Rett	syndrome	is	easily	identifiable	to	clinicians	and	occurs	
mainly	 in	 girls.	 It	 is	 a	 severe	 neurodevelopmental	 disorder	 characterised	 by	 arrested	
development	 in	 the	 first	 18	months	 of	 age	with	 regression	 of	 skills	 and	 speech,	 stereotypic	
movements,	 microcephaly,	 ID	 and	 seizures.	 Seizures	 were	 present	 in	 94%	 in	 a	 series	 of	 54	
cases,	 with	 focal	 seizures	 with	 secondary	 features	 most	 common232.	 Whilst	 no	 unique	 or	
diagnostic	 EEG	 features	 exist,	 certain	 EEG	 findings	 are	 more	 common.	 There	 is	 a	 loss	 of	
occipital	 dominant	 rhythm	 and	 a	 slow	 background	 with	 theta	 and	 delta	 activity,	 and	 both	
generalised	and	focal	electrographic	seizures	are	seen233.	
	
Atypical	 forms	 of	 Rett	 syndrome	with	 an	 either	milder	 or	more	 severe	 phenotype	 exist	 and	
revised	 diagnostic	 criteria	 differentiating	 classic	 and	 atypical	 forms	 have	 been	 proposed232.	
Other	 phenotypes	 associated	 with	 MECP2	 variants	 include	 non-specific	 ID,	 autism	 and	
neonatal	encephaloathy233.	Pathogenic	variants	are	de	novo	 in	99%	of	Rett	syndrome	and	the	




Subject	 S1395/291J	 is	 a	 15-year-old	 Italian	 female	 with	 a	 previous	 history	 of	 febrile	
convulsions.	Her	 seizure	onset	was	at	6	years	with	myoclonic	atonic	and	 tonic	 seizures.	 	 She	




seizure	 remission.	 EEG	 shows	 disorganised	 background	 activity	 with	 bilateral	 paroxysmal	
activity.	Her	novel	de	novo	variant	p.P225T	 is	 in	 the	transcriptional	 repression	domain	 in	 the	
same	 position	 but	 a	 different	 allele	 from	 p.P225L	 in	 a	 male	 patient	 with	 ID	 and	 autism234.	
Although	her	phenotype	would	not	 fall	 into	 the	diagnostic	criteria	 for	classic	or	atypical	Rett	
syndrome,	she	has	cerebellar	signs	and	disorganised	background	on	EEG,	which	are	consistent	
with	a	Rett	syndrome	phenotype	and	are	unusual	for	MAE.	This	variant	was	classified	as	likely	
pathogenic.	 A	 possible	 clinical	 implication	 is	 the	 awareness	 of	 prolonged	 QTc	 (QT	 corrected	
interval)	 syndrome	 in	 patients	 with	 Rett	 syndrome	 regardless	 of	 the	 severity	 of	 their	




SLC6A1	 encodes	 GAT-1,	 a	 voltage	 dependent	 gamma	 aminobutyric	 acid	 (GABA)	 transporter	
that	is	responsible	for	the	re-uptake	of	GABA	from	the	synapse.	SLC6A1	has	been	described	as	
the	Doose	gene	as	it	has	been	linked	only	to	MAE	patients	and	at	4%	(6/160	cases)17,	it	is	the	
most	 enriched	 causative	 MAE	 gene.	 Carvill	 et	 al.	 published	 six	 pathogenic	 de	 novo	
heterozygous	SLC6A1	variants,	 two	truncation	and	four	missense17.	The	authors	postulated	a	
loss	 of	 function	 role	 in	 the	 nonsense	 variants	 and	 clustering	 of	 the	 four	 missense	 variants	
around	 the	GABA	binding	pocket	which	 in	 three	dimensional	 space	disrupts	GABA	 transport	
from	 the	 extracellular	 space	 into	 the	 pre-synaptic	 terminal.	 Subsequently	 another	 de	 novo	
missense	variant	in	p.C164T	was	identified75.	The	authors	performed	high	resolution	structural	
modelling	 to	 demonstrate	 disruption	 of	 a	 disulphide	 bond	 necessary	 for	 stabilization	 of	 the	
transmembrane	helix.	No	functional	or	animal	studies	have	been	performed.	
	





Subject	 00595	 is	 an	 8	 year	 old	with	 prior	 development	 delay	 and	 had	 his	 first	 seizure	 at	 13	
months,	which	was	a	myoclonic	seizure.	Subsequently	he	developed	myoclonic	atonic	seizures	
but	has	been	in	seizure	remission	for	the	past	2	years.	He	has	ID	and	autism.	There	is	no	family	
history	of	 epilepsy.	His	 EEG	demonstrated	 an	unusual	 feature	of	 eye	 closure	 sensitivity	with	
GSW	on	the	posterior	third	of	the	head.	He	was	found	to	have	a	novel	de	novo	p.F385L	SLC6A1	














5	 months.	 He	 has	 mild	 ID	 and	 hyperactive	 behaviour.	 He	 carries	 a	 novel	 splice	 site	 variant	
within	 the	 GABA	 binding	 pocket.	 Given	 the	 unique	 association	 between	 SLC6A1	 and	 MAE,	
these	 results	 were	 communicated	 and	 Italian	 collaborators	 performed	 validation	 and	
inheritance	 studies.	 The	 variant	 was	 validated	 and	 inherited	 from	 an	 unaffected	 father	




De	 novo	 SYNGAP1	 variants	 were	 first	 identified	 in	 1%	 of	 500	 individuals	 with	 EE227.	 The	
phenotype	 is	 characterised	 by	 early	 neurodevelopmental	 delay	 typically	 preceding	 onset	 of	
generalised	 seizures	 consisting	 of	 absences	 and	 myoclonic	 jerks.	 Seizure	 triggers	 appear	
common	 and	 were	 present	 in	 7/16	 in	 a	 recent	 cohort	 (photosensitivity	 in	 five,	 fixation	 off	
sensitivity	in	two	and	chewing	in	one)16.	Hypotonia	and	unstable	gait	are	frequently	associated	











seizures	 at	 17	 months.	 His	 epilepsy	 evolved	 into	 a	 refractory	 epilepsy	 with	 severe	 ID	 and	
speech	 delay.	 He	 has	 clinical	 signs	 of	 hypotonia	 and	 ataxia.	 EEG	 shows	 GSW	 with	 diffuse	
background	 slowing.	 He	 carries	 a	 frameshift	 deletion	 in	 exon	 15.	 Both	 his	 phenotype	 and	








frameshift	 deletion	 in	 exon	 13.	 This	 variant	 was	 validated	 and	 identified	 as	 de	 novo	 by	
collaborators	in	Kiel,	Germany	(personal	communication	Dr	Manuela	Pendziwiat).	Like	subject	









Subject	 WTSI_MAE_1150147	 is	 a	 previously	 normally	 developing	 11-year-old	 female	 with	
seizure	onset	at	3	years	of	myoclonic	atonic	seizures.	She	has	reported	ID.	There	is	no	family	















Twenty	 genes	 from	 the	 neuropsychiatric	 gene	 set	 had	 recurrent	 CADD>20	 non-synonymous	
variants	 in	 the	MAE	cohort.	There	were	no	 identical	 variant	matches	 in	 the	MAE	cohort	and	
the	gene	set	variants.	Additional	filtering	was	carried	out	in	order	to	select	the	best	candidate	
genes	 for	 Sanger	 validation	 and	 inheritance	 studies.	 The	 additional	 filtering	 results	 were	 as	
follows;	ten	genes	were	de-prioritised	due	to	RVIS	>25th	centile	and	negative	Z	score	(CNTN5,	
CUBN,	MARK1,	MKI67,	MYOM3,	SHANK2,	TACC2,	TET1,	USH2A,	WDFY4),	four	genes	were	de-
prioritised	 due	 to	 conflicting	 gene	 function	 and/or	 inadequate	 nervous	 system	 expression	
(BAGALNT4,	 LRP4,	 MDM2,	 NCOR2),	 three	 genes	 were	 de-prioritised	 due	 to	 variant	 or	































































molecule	 required	 for	 synaptic	 formation236.	 More	 noteworthy	 is	 that	 gene	 ontology	




are	 novel	 on	 gnomAD.	 WTSI_MAE_1202321	 had	 a	 maternally	 inherited	 variant;	 there	 is	 a	
family	history	of	epilepsy	but	only	 in	the	paternal	uncle.	Subject	00530/S2392	 is	a	7	year	old	
male	 with	 seizure	 onset	 at	 6	 months.	 He	 has	 multiple	 seizure	 types:	 myoclonic	 atonic,	
myoclonic,	GTCS,	absence,	tonic	and	they	are	refractory.	EEG	shows	GSW	and	polyspike	as	well	
as	focal	activity	maximal	in	the	right	temporal	region.	He	has	moderate	to	severe	ID,	ASD	and	
ADHD.	 There	 is	 no	 family	 history	 of	 epilepsy.	 He	 has	 a	 p.R1342X	 ASH1L	 variant.	 Sanger	
sequencing	 and	 inheritance	 studies	 demonstrated	 that	 it	 was	 de	 novo	 (see	 Figure	 7.19),	









CHD4	 (chromodomain	 helicase	 DNA	 binding	 protein	 4)	 is	 an	 ATP	 dependent	 chromatin	







of	 these	 cases	 did	 not	 have	 seizures	 (personal	 communication	Dr.	 Katherine	 Lachlan).	Most	
recently	five	de	novo	substitutions	were	identified	in	individuals	with	overlapping	phenotypes	
of	 developmental	 delay,	 ID,	 hearing	 loss,	 macrocephaly,	 distinct	 facial	 dysmorphisms	 and	
hypogonadism238.	On	 further	 enquiry	with	 the	 authors,	 it	was	 confirmed	 that	 none	of	 these	
cases	had	seizures	(personal	communication	Dr.	Melita	Irving).		
	






CADD	 24.6).	 She	 has	 severe	MAE	 and	 severe	 ID.	 Unfortunately	we	were	 not	 able	 to	 collect	










79	 cases	 compared	with	 10773	 (mean	 0.32)	 out	 of	 ExAC_NFE	 33370	 controls.	 Per	 gene,	 96	
genes	 in	 the	 neuropsychiatric	 gene	 set	 reached	 statistical	 significance	 set	 at	 P<2	 x	 10-5	 for	
enrichment	 of	 novel	 CADD>20	 variants	 in	 the	 MAE	 cohort.	 Table	 7.12	 lists	 the	 10	 most	
enriched	genes	 in	 the	MAE	cohort	compared	 to	 the	ExAC_NFE	cohort.	Nine	genes	 in	 this	 list	
overlapped	with	the	de-prioritised	genes	identified	from	direct	gene	matching.	The	only	gene	
not	 previously	 reviewed	 was	 CDH23.	 CDH23	 (Cadherin	 Related	 23)	 is	 part	 of	 the	 cadherin	
superfamily	and	encodes	calcium	dependent	cell	adhesion	glycoproteins.	The	encoded	protein	
is	 involved	 in	proper	organisation	of	the	sterocilia	bundle	of	hair	cells	 in	the	cochlea	and	the	









Gene	 MAE_pos	 MAE_neg	 NFE_pos	 NFE_neg	 Chi-square	 1	tailed	P	
value	
OBSCN	 12	 67	 0	 33370	 5070.6798	 <	1	x	10-5	
CDH23	 6	 73	 0	 33370	 2534.8850	 <	1	x	10-5	
AHDC1	 4	 75	 0	 33370	 1689.8223	 <	1	x	10-5	
WDFY4	 4	 75	 0	 33370	 1689.8223	 <	1	x	10-5	
BRSK2	 3	 76	 0	 33370	 1267.3288	 <	1	x	10-5	
MYOM3	 3	 76	 0	 33370	 1267.3288	 <	1	x	10-5	
BAGALNT4	 2	 77	 0	 33370	 844.86064	 <	1	x	10-5	
CNTN5	 2	 77	 0	 33370	 844.86064	 <	1	x	10-5	
MDM2	 2	 77	 0	 33370	 844.86064	 <	1	x	10-5	








Overall,	 31	 (mean	 0.39)	 novel	 CADD>20	 ion	 channel	 gene	 set	 variants	were	 identified	 in	 79	




Additional	 filtering	of	 genes	was	 as	 follows:	 four	 genes	 (CACNA1H,	GRIN2A,	 KCNB1,	 SCN1A),	
were	de-prioritised	as	they	are	known	epilepsy	associated	genes	and	were	reviewed	already.	
Nine	genes	(BSND,	CACNA1F,	CHRNA5,	GRM2,	HCN3,	HTR2A,	HTR4,	KCNA3,	KCNS2)	were	de-
prioritized	due	 to	RVIS	or	 ExAC	 score,	 five	 genes	 (CACNA1S,	GLRA1,	RYR1,	 SCN10A,	 SCN11A)	
were	 de-prioritised	 due	 to	 inadequate	 nervous	 system	 expression,	 one	 gene	 (KCNJ12)	 was	
removed	as	 it	was	a	calling	error	on	 IGV	and	seven	genes	 (GRID1,	GRIK4,	GRM3,	CACNA2D3,	
CACNB2,	CLCN1,	SLC12A5)	were	de-prioritised	due	to	demonstrated	inheritance	of	the	variants	
with	 unaffected	 parents.	 One	 subject,	 WTSI_MAE_1147805	 carried	 a	 maternally	 inherited	












including	a	 role	 in	 triggering	muscle	 contraction.	 Interestingly,	 two	EE	patients	with	de	novo	
RYR3	 variants	 were	 identified	 in	 the	 Epi4K	 study76.	 Here,	 subject	 00505/S2341	 has	 a	
c.C4135A,p.H1379N	 RYR3	 variant	 SIFT	 0.21	 (tolerated),	 PP2hvar	 0.707	 (likely	 pathogenic),	




CLCN3	 (Chloride	 Voltage	 Gated	 Channel	 3)	 (ExAC	 Z	 score	 4.24,	 RVIS	 18.59%)	 encodes	 a	
member	of	the	voltage	gated	chloride	channel	 family	and	mediates	the	exchange	of	chloride	
ions	against	protons.	It	 is	expressed	primarily	in	tissues	derived	from	the	neuroectoderm	and	
may	 play	 an	 important	 role	 in	 neuronal	 cell	 function	 through	 regulation	 of	 membrane	
excitability	 by	 protein	 kinase	 C237.	 	 Subject	 00568/S2297	 carries	 a	 c.C2216T,p.P739L	 CLCN3	
variant	SIFT	0.08	(tolerated),	PP2hvar	0.923	(pathogenic),	CADD	27.9,	gnomad	MAF	7.96	x	10-6.	










CLCN4	 (Chloride	Voltage	Gated	Channel	4)	(ExAC	Z	score	4.7,	RVIS	7.05%)	 is	an	X	 linked	gene	
that	 encodes	 the	 chloride/hydrogen	 ion	 exchanger,	 which	 is	 highly	 expressed	 in	 the	 brain.	
Veeramah	 et	 al.	 identified	 a	 de	 novo	 variant	 in	 a	male	 with	 EE230.	 Recently,	 a	 cohort	 of	 52	
males	and	females	with	de	novo	and	 inherited	mutations	were	described	with	 ID,	behavioral	




carries	 a	 c.C812A,p.P271Q	 CLCN4	 variant	 SIFT	 0	 (pathogenic),	 PP2hvar	 0.996	 (pathogenic),	
CADD	 32,	 gnomad	 MAF	 novel.	 Sanger	 sequencing	 studies	 carried	 out	 did	 not	 validate	 this	
variant	in	the	child	nor	parents.	This	is	the	same	case	(subject	00505/S2341)	where	I	was	also	
not	 able	 to	 validate	 the	 RYR3	 variant	 of	 interest.	 It	 is	 unclear	 whether	 a	 sample	 mix	 up	
occurred	 here	 and	 sample	 QC	 processes	 were	 re-checked	 but	 no	 error	 was	 identified.	 Re	












The	 results	of	 filtering	was	as	 follows:	13	genes	 (CASR,	 FKRP,	GUCA1,	GALNS,	GPHN,	GPR98,	
LAMA2,	MP1,	PEX6,	PQBP1,	SLC17A5)	were	de-prioritised	due	to	a	negative	ExAC	Z	and/or	RVIS	




incongruent	gene	 function	or	allelic	pattern	and	 seven	genes	 (CEP152,	 FUCA1,	NPC1,	PDSS2,	







recessive	 spinocerebellar	 ataxia	with	 epilepsy	 (OMIM	 613832).	 Its	 role	 in	 epilepsy	 has	 been	
debated	 as	 the	 initial	 pathogenic	 association	 with	 progressive	 myoclonic	 epilepsy	 was	
subsequently	 withdrawn241.	 Subject	 00530/S2392	 has	 a	 c.G569A,p.C190Y	 PRICKLE2	 variant,	







































Exome	 sequencing	data	was	 available	 for	 some	 sibling	pairs	with	 epilepsy.	 Filtering	 involved	
shared	 rare	 variant	 analysis	 and	 where	 sequencing	 data	 from	 other	 family	 members	 were	
available,	 segregation	 of	 variants	 was	 performed.	 For	 heterozygous	 variants,	 only	 novel	
variants	were	 considered	 and	 for	 homozygous	 variants,	 a	MAF	 of	 <0.001	was	 considered	 to	
account	for	a	presumed	carrier	frequency	in	the	population.	Synonymous,	non-frameshift	and	












Family	 one	 is	 a	 Bangladeshi	 family	with	 consanguineous	 parents	 residing	 in	 London.	 Exome	
sequencing	was	performed	in	subject	00518	and	40518.	Subject	00518	has	drug	resistant	MAE.	
He	 was	 a	 previously	 normally	 developing	 child	 until	 his	 first	 seizure	 at	 2	 years	 11	 months,	
which	was	a	GTCS.	Subsequent	seizure	types	 include	myoclonic	atonic	or	atonic	seizures	and	
myoclonic	seizures.	He	was	recruited	at	the	age	of	6	years	and	at	the	time	he	was	having	daily	






35	 shared	 novel	 nonsynonymous	 genetic	 variants	 were	 identified	 in	 subject	 00518	 and	 his	
brother	40518.	Of	note	they	shared	a	c.3079G>A:p.A1027T	SPTAN1	variant	(ExAC	Z	score	6.8,	
RVIS	 0.31%)	 SIFT	 0.5	 (tolerated),	 PP2hvar	 0.002	 (tolerated),	 CADD	 21.2.	 As	 described	
previously,	 SPTAN1	 associated	 phenotypes	 have	 a	 hallmark	 feature	 of	 brainstem	 and	
cerebellar	atrophy	and	cerebral	hypomyelination	on	neuroimaging.	At	the	time	of	recruitment,	
neither	child	had	abnormal	neuroimaging	findings	and	the	referring	clinician	was	invited	to	re-
review	their	brain	 imaging.	Additionally	all	pathogenic	variants	 reported	previously	cluster	 in	
the	last	two	spectrin	repeats	(19	and	20)	in	the	EF	hand	domain225,	and	the	variant	described	




This	 identified	 a	 homozygous	 deletion	 of	 180bp	 probe	 within	 exon	 2	 of	 KLHL1	 in	 subjects	
00518	 and	 40518	 (see	 Table	 7.13).	 This	 CNV	 was	 not	 in	 a	 segmental	 duplication	 region.	




Sample	ID	 Position	 Probe	 Expected	reads	 Observed	reads	
00518	 chr13:7053417-70535597	 180bp	 179	 0	













KLHL1	 (Kelch-like	 family	 member	 1)	 is	 a	 neuronal	 actin	 binding	 protein.	 It	 is	 located	 at	
13q21.33	and	spans	11	exons.	 It	 is	primarily	expressed	 in	brain	tissue	and	modulates	voltage	
gated	 CaV2.1	 and	 CaV3.2	 calcium	 channels242.	 KLHL1	 expression	 was	 correlated	 to	 clinical	























7.15.	 Subjects	 10518	 and	 20518,	 both	 had	 a	 CN<1,	 suggesting	 a	 heterozygous	 deletion	






KLHL_1	primer	 ΔCT	 KLHL_2	primer	 ΔCT	
1052	 18.9610	 23.2464	 4.2854	 24.9316	 5.9706	
1039	 19.5461	 23.5676	 4.0215	 25.5602	 6.0141	
00518	 20.3937	 No	product	
10518	 19.9083	 24.9557	 5.0474	 26.7301	 6.8217	





Subject	 ΔΔCT1052	 CNvs1052	 ΔΔCT1039	 CNvs1039	 Interpretation	
00518	 No	product	 Homozygous	deletion	
10518	 0.7619	 0.5896	 1.0258	 0.4911	 Heterozygous	deletion	
1.7984	 0.2874	 1.1698	 0.4444	
20518	 0.7063	 0.6128	 0.9702	 0.5104	 Heterozygous	deletion	









The	 two	 parents	 are	 heterozygous	 for	 the	 deletion	 and	 all	 three	 children,	 including	 the	
unaffected	daughter	 (subject	 30518)	were	homozygous.	 	 The	 variant	 did	 not	 segregate	with	
the	 phenotype	 and	 subject	 30518	 did	 not	 wish	 to	 take	 part	 in	 further	 deep	 phenotyping	
studies.	
	
In	 addition	 to	 this,	 the	 significance	 of	 KLHL1	 copy	 numbers	 was	 explored	 in	 other	 sources.	
Forty-two	 Bangladeshi	 exome	 sequencing	 cases	 recruited	 for	 an	 eczema	 study,	 and	 were	
available	 as	 exome	 in-house	data,	were	 interrogated	using	 Exomedept	 and	no	 copy	number	











atonic	 seizures	 which	 was	 his	 only	 seizure	 type	 at	 2	 years	 6	 months.	 His	 brother	 S1041	
developed	 GTCS	 at	 10	 years	 and	 was	 diagnosed	 with	 GGE.	 He	 has	 a	 history	 of	 mild	
developmental	delay	and	was	diagnosed	with	ASD	at	6	years.	He	also	has	an	intention	tremor	
that	 is	 worst	 in	 the	 morning.	 Whilst	 their	 seizure	 phenotype	 differs,	 EEG	 findings	 for	 the	
brothers	 are	 similar.	 Their	 EEGs	 have	 a	 normal	 posterior	 dominant	 background	 with	
intermittent	 runs	 of	 high	 voltage	 notched	 slow	 waves	 which	 are	 occipitally	 dominant	 and	









Their	maternal	 cousin	 S1039	 is	 a	 six-year-old	 female	with	 a	 history	 of	 blank	 spells	 and	was	














UBE3A	 (Ubiquitin	Protein	Ligase	E3A)	 (ExAC	Z	score	4.2,	RVIS	19.54%)	 is	part	of	the	ubiquitin	
protein	 degradation	 system.	 This	 imprinted	 gene	 is	 maternally	 expressed	 in	 brain	 and	
biallelically	expressed	in	other	tissues.	UBE3A	variants	are	associated	with	Angelman	syndrome	
(MIM	105830),	a	neurodevelopmental	disorder	with	severe	ID,	ataxia,	hypotonia,	epilepsy	and	





region	on	 the	maternal	 chromosome	15q11.2-q13	 (70-75%),	paternal	uniparental	disomy	 (5-
10%),	imprinting	defects	(2-5%)	and	mutations	in	the	maternal	copy	of	UBE3A	(10%)244.	About	
90%	of	patients	with	Angelman	syndrome,	carry	a	de	novo	variant	and	the	rest	are	a	result	of	
UBE3A	 mutations	 occurring	 on	 the	 maternally	 expressed	 chromosome.	 Loss	 of	 functional	
UBE3A	gene	expression	is	the	principal	cause	of	Angelman	syndrome	and	pathogenic	variants	
are	 mainly	 nonsense	 or	 frameshift	 although	 missense	 causative	 variants	 have	 been	
published245.	
	
Subjects	 S1040	 and	 S1041	 do	 not	 have	 an	 Angelman	 syndrome	 diagnosis	 but	 share	 several	
Angelman	 syndrome	 phenotypic	 features.	 Epileptic	 seizures	 are	 common	 in	 Angelman	
syndrome,	and	44%	of	18	patients	in	one	series246	and	46.3%	of	115	patients	in	another	were	




with	 a	 de	 novo	 15q11	 CNV	 deletion	 of	 270kb	 encompassing	UBE3A90.	 Patients	 with	 EE	 and	
features	 suggestive	 of	 Angelman	 syndrome	 have	 also	 been	 reported;	 a	 recurrent	 p.R506C	
variant	in	two	siblings	inherited	from	an	unaffected	mother	was	identified	by	Carvill	et	al.,	as	
well	as	a	de	novo	p.C604Yfs*23	variant	identified	by	Helbig	et	al.12,248.	The	differing	phenotypes	
in	 the	 two	 siblings	 in	 family	 two	has	 also	 been	 similarly	 described	 before	 in	 a	 family	with	 a	
Leu125Stop	UBE3A	variant	where	the	brother	had	seizures	and	ID	and	the	sister	had	Angelman	
syndrome249.	 Possible	 reasons	 for	 this	 may	 be	 due	 to	 unknown	 genetic,	 epigenetic	 or	
environmental	 factors,	 which	 may	 modulate	 the	 expression	 of	 UBE3A	 leading	 to	 variable	
phenotypic	expression	within	the	family.	
	
S1040	 and	 S1041	 carry	 a	 c.A2046G,p.I682M	UBE3A	 variant,	 SIFT	 0.01(P),	 PP2hvar	 0.991(P),	
CADD	 24,	 gnomad	 MAF	 novel.	 There	 was	 no	 match	 of	 this	 variant	 in	 166	 entries	 on	
Manchester	 Leiden	Open	 variation	database	UBE3A	 https://secure.ngrl.org.uk/LOVDv.2.0/	or	
in	 2515	 reported	 cases	 with	 Angelman	 syndrome245.	 Sanger	 sequencing	 validated	 and	




















absent	 in	 their	 unaffected	 sibling,	 the	major	 consideration	 in	 a	pathogenic	hypothesis	 is	 the	



















A	 large	multiplex	epilepsy	 family	was	 recruited	 from	 the	Danish	epilepsy	 centre	and	exome-
sequencing	data	shared	with	this	study.	Two	family	members	had	MAE	(EG1238	and	EG1239),	
and	 these	 cases	 along	 with	 sequencing	 data	 from	 immediate	 first-degree	 family	 members	
(EG0435,	EG0434	and	EG0603)	were	investigated.	
	
Nineteen	genes	with	novel	nonsynonymous	variants,	 in	19	different	genes	were	 identified	 in	
both	MAE	brothers	EG1238	and	EG1239.	Eight	of	these	genetic	variants	were	also	shared	with	
their	 brother	 EG0603	 with	 autism.	 The	 pedigree	 suggests	 that	 the	 extended	 family	 on	 the	
maternal	 side	 had	 a	 history	 of	 neurodevelopmental	 disorders;	 hence	 maternally	 inherited	
variants	were	prioritised.	Eight	shared	variants	were	maternally	 inherited	and	of	 these	 three	












This	 thesis	 describes	 the	 largest	MAE	 cohort	 (n=123)	 assembled	 to	 date	 detailing	 the	main	
seizure	 types,	 EEG	 features,	 associated	 neurological	 symptoms	 and	 neurodevelopmental	
comorbidities.	 The	 spectrum	of	 ID	 is	 presented	 as	well	 as	 novel	data	 on	 prevalence	 of	 ASD,	
ADHD,	diminished	adaptive	functioning	and	other	behavioural	symptoms	in	patients	with	MAE.		
	
EEG	 studies	 were	 performed	 on	 38	 first-degree	 relatives	 of	 13	 MAE	 families.	 I	 identified	
epileptiform	 activity	 in	 two	 individuals	 and	 atypical	 or	 benign	 EEG	 features	 in	 six	 other	






methods	 of	 exome	 sequencing	 data	 following	 annotation	 analysis	 of	 previously	 published	
epilepsy	variants.	I	identified	known	genes	associated	with	MAE:	a	de	novo	CHD2	variant	(n=1),	
a	 de	 novo	 SLC6A1	 variant	 (n=1),	 a	 KIAA2022	 variant	 (n=1)	 and	 SYNGAP1	 variants	 (n=2).	
Additionally,	 I	 identify	 epilepsy	 associated	 genes	 novel	 for	 MAE:	 a	 de	 novo	 KCNB1	 variant	





correlate	 with	 known	 and	 novel	 specific	 gene	 associations.	 I	 propose	 that	 MAE	 is	 the	
phenotypic	 and	 genetic	 nosological	 bridge	 between	 genetic	 generalised	 epilepsy	 (GGE)	 and	












epilepsy	was	reported	 in	44	 (37.6%)	out	of	117	cases.	The	median	age	of	seizure	onset	 is	35	
months	(range	3	-	72).	The	characteristic	seizure	type	in	MAE	is	the	myoclonic	atonic	or	atonic	
seizure	 and	 this	 is	 the	 most	 frequent	 seizure	 type	 (93.4%),	 followed	 by	 GTCS	 (69.1%),	
myoclonic	 seizures	 (68.2%)	 and	 absence	 seizures	 (54.4%).	 Focal	 seizures	 remain	 uncommon	
(6.5%)	 but	 are	 still	 accounted	 for	 and	 some	 unusual	 seizure	 types	 such	 as	 epileptic	 spasms	
(n=4)	and	myoclonic	absence	seizures	(n=1)	are	recorded.	
	
Possible	 explanations	 for	 a	 male	 bias	 have	 been	 explored	 before	 (see	 Table	 1.5),	 and	 one	
plausible	 reason	 is	 the	 contribution	 of	 X-linked	 genes	 associated	 with	 ID	 syndromes250	 (e.g.	
KIAA2022,	 IQSEC2),	 and	 the	 recognition	 of	 shared	 genes	 and	 pathways	 between	 ID	 and	
epilepsy168,170.	 The	 three	 major	 seizures;	 atonic	 or	 myoclonic	 atonic,	 GTCS	 and	 myoclonic	
seizures	are	similarly	reported	in	other	MAE	series2,31,32,34.	Four	cases	(subjects	00591,	00598,	
00576,	00605)	were	reported	to	have	epileptic	spasms.	Epilepsy	spasms	are	characterised	by	a	
sudden	 flexion,	 extension	 or	mixed	 flexion-extension	 of	 predominantly	 proximal	 and	 truncal	
muscles,	which	 is	more	 sustained	 than	 a	myoclonus,	 but	 not	 as	 sustained	 as	 tonic	 seizures.	
Epileptic	 spasms	were	 not	 reported	 in	 earlier	 cohorts,	 but	 were	 recently	 described	 in	 eight	
MAE	cases	by	two	groups251,252.		
	
EEG	 reports	were	 available	 for	 112	 cases.	Generalised	 epileptic	 activity	was	 reported	 in	 104	
(92.8%)	 cases,	 and	 additional/isolated	 focal	 epileptiform	 activity	was	 reported	 in	 13	 (11.6%)	
cases.	Focal	activity	has	been	considered	a	marker	of	poor	prognosis	in	MAE48	but	in	the	MAE	
cohort	 here	 this	 was	 not	 so,	 as	 5/9	 cases	 with	 focal	 EEG	 abnormalities	 achieved	 seizure	
remission	 (defined	 as	 seizure	 freedom	 for	 2	 years),	 compared	 to	 25/70	 cases	 without	 focal	
abnormalities.	 An	 abnormal	 EEG	 background	was	 reported	 as	 a	 feature	 in	 15	 (13.3%)	 cases	
within	 the	 MAE	 cohort.	 These	 unusual	 EEG	 features	 i.e.	 focal	 abnormalities	 and	 abnormal	
background	may	offer	a	hint	of	a	monogenic	association.	For	example,	subject	291J	identified	






11.7%5,31,34.	13	of	 the	cases	reported	here	had	ataxia	or	 tremor.	Ataxia	was	reported	 in	3/21	
MAE	 cases	 by	 Nabbout	 et	 al.	 and	 has	 been	 recognised	 in	 MAE	 patients	 with	 pathogenic	







degree	 of	 difficulty	 in	MAE	 patients.	 ID	was	 reported	 in	 76	 (64.9%)	 of	 117	 cases,	 ASD	 in	 24	
(22.8%)	of	105	cases	and	ADHD	symptoms	in	39	(41.0%)	out	of	95	cases.	Additionally,	high	and	
very	 high	 scores	 in	 SDQ	 domains	 of	 conduct	 problems	 (P<0.0001),	 hyperactivity/inattention	
(P<0.0001),	 peer	 relationship	 problems	 (P<0.0001),	 and	 difficulties	 with	 prosocial	 behaviour	
(P<0.0001)	domains	were	significantly	higher	than	normative	populations.	
	
ID	 based	 on	 parental	 or	 clinician	 history	was	more	 frequently	 reported	 (64.9%)	 than	 results	
from	previous	published	cohorts	(mean	45.8%)	(see	Table	1.2).	Formal	cognitive	testing	in	25	
cases	 demonstrated	 even	 greater	 burden	 of	moderate	 to	 severe	 ID	 (IQ<71)	 in14	 (56%)	 and	
four	(16%)	with	mild	ID	(IQ	71-85).	The	presence	of	cognitive	difficulties	was	also	evident	from	
results	 of	 cognitive	 and	 inattentive	 subscale	 from	 the	 joint	 CBRS	 parent	 and	 teachers	
questionnaires,	where	scores	(T	score	>70)	were	significantly	higher	than	controls	(P=0.0001).	
This	 increased	 prevalence	 of	 ID	 may	 be	 due	 to	 ascertainment	 bias	 from	 referring	 clinical	
collaborators	and	self-referring	parents.	Additionally	I	did	not	control	for	multiple	factors	that	
may	 have	 affected	 results;	 such	 as	 current	 seizure	 burden,	 antiepileptic	 drug	 use	 and	 sleep	
problems.	Filippini	et	al.	described	an	MAE	case	from	a	group	of	seven	who	showed	cognitive	
and	 behavioural	 disturbances	 that	 remitted	 entirely	 with	 early	 successful	 treatment	 of	






of	 children	 with	 epilepsy	 where	 the	 prevalence	 of	 ASD	 range	 from	 5	 to	 37%253.	 This	 broad	
range	 reflects	 the	 heterogeneity	 of	 groups	 studied	 and	 measurement	 methods	 in	 different	
cohorts.	No	prevalence	 rates	of	ASD	 in	MAE	cohorts	are	available.	The	UK	cohort	 (61	of	 the	
105	 cases)	 was	 classified	 as	 having	 autistic	 symptoms	 based	 on	 parental	 completion	 of	 the	
social	 communication	 questionnaire	 (SCQ).	 Comparison	 of	 SCQ	 scores	 of	 these	 61	 cases	 (43	
males,	 18	 females)	 with	 the	 ALSPAC	 cohorts	 showed	 significantly	 higher	 scores	 in	 the	MAE	
cohort	 (P<0.0001)	 with	 no	 male	 bias	 (P=0.0901)	 than	 were	 seen	 in	 the	 ALSPAC	 cohort116,	
suggesting	 that	 the	MAE	 disease	 specific	 effect	 is	 greater	 than	 the	 gender	 effect	 of	 autism.	






The	high	prevalence	of	ASD	may	be	due	 to	a	 combination	of	predisposing	 factors	present	 in	
MAE:	 ID,	early	onset	of	 seizures,	and	EE253.	 In	addition,	ASD,	 ID	and	epilepsy	share	causative	
genes	and	biological	pathways	including	gene	transcription	regulation,	neurotransmission	and	
maintenance	 of	 synaptic	 structure166,168,170.	 A	 notable	 example	 is	MECP2	 related	 disorders.	
MECP2	 is	 a	 transcriptional	activator	during	brain	development	and	mutations	 lead	 to	 loss	of	





50%	 found	 in	 groups	 of	 paediatric	 patients	 with	 other	 epilepsies255,256.	 Both	 parents	 and	
teacher’s	 CBRS	 eliciting	 relevant	 symptoms	 were	 available	 in	 43	 cases.	 The	 collection	 of	




Several	 other	 studies	 have	 reported	 this	 predominant	 inattentive	 presentation	 rather	 than	
hyperactive	 or	 impulsive	 presentation	 of	 ADHD	 in	 children	 with	 epilepsy,	 leading	 to	 more	
difficulties	with	complex	attention	tasks	than	with	simple	attention	tasks50,255.	
	
Children	with	ADHD	are	more	 likely	 to	have	oppositional	defiant	disorder,	 and	children	with	
epilepsy	 and	 ADHD	 are	 more	 like	 to	 have	 oppositional	 defiant	 disorder	 than	 children	 with	
epilepsy	 without	 ADHD256.	 Accordingly,	 cases	 with	 scores	 in	 the	 oppositional	 domain	
(P=0.0005)	 of	 the	 CBRS	 and	 conduct	 problems	 domain	 (P<0.0001)	 in	 the	 SDQ	 questionnaire	
were	 significantly	 higher	 compared	 to	 controls.	 Additionally	 35	 (58.3%)	 of	 63	 cases	 sampled	






This	 is	 the	 first	 reported	 study	 of	 adaptive	 behaviour	 in	MAE.	 I	 have	 shown	 that	 cases	with	
MAE	 have	 significantly	 diminished	 adaptive	 functioning.	 41	 (69.4%)	 of	 59	 cases	 scored	
extremely	low	general	adaptive	scores	on	the	ABAS	questionnaire.	General	adaptive	scores	are	
a	composite	of	the	three	main	domains	explored	in	the	ABAS	questionnaire:	conceptual	(e.g.	








Low	 adaptive	 skills	 have	 been	 validated	 in	 several	 studies	 of	 children	 with	 epilepsy257-259.	
However,	the	greater	difficulties	in	practical	skills	in	MAE	cases	warrants	further	exploration	as	
previous	 studies	 of	 children	 with	 epilepsy	 have	 indicated	 greatest	 difficulties	 in	 the	
communication	 domain	 using	 the	 Vineland	 Adaptive	 Behaviour	 Scale257,258.	 One	 possible	
explanation	 is	 the	 excess	 of	 myoclonic	 atonic	 and	 myoclonic	 seizures	 as	 well	 as	 cerebellar	
symptoms	in	the	MAE	cases	 inhibiting	motor	execution.	The	presence	of	 ID	may	be	a	further	
contributing	 factor.	 Buelow	 et	 al.	 investigated	 IQ	 and	 adaptive	 skills	 in	 50	 children	 with	
epilepsy	 and	 found	 that	 correlations	 ranged	 from	 .32	 to	 .45	 depending	 on	 adaptive	 skill	





Children	 with	 MAE	 have	 increased	 prevalence	 of	 ID,	 ASD	 symptoms,	 ADHD	 symptoms	 and	
other	 behavioural	 problems,	 as	 well	 as	 low	 adaptive	 competencies	 required	 to	 function	 in	
everyday	 life.	This	results	 in	a	significant	 impact	on	the	child	and	family.	Further	 longitudinal	
research	 may	 offer	 greater	 insights.	 My	 study	 highlights	 the	 need	 for	 initial	 screening,	






how	 the	 data	 were	 collected.	 Ascertainment	 bias	 may	 have	 influenced	 these	 results.	 For	
example,	the	prevalence	of	a	family	history	of	seizures	may	have	been	elevated	as	a	result	of	
how	the	study	was	advertised.	It	is	also	probable	that	cases	with	more	severe	phenotypes	led	









EEG	 features	 were	 elicited	 either	 from	 clinician	 or	 neurophysiological	 report.	 For	 example,	
cases	 recruited	 from	 the	 Euroepinomics	 cohort	 completed	 EEG	 details	 through	 an	 online	




no	 standardised	 format	 in	 reports,	 although	 main	 neurophysiological	 features	 are	 usually	
detailed.	
		
Many	 cases	 were	 phenotyped	 for	 behavioural	 and	 neuropsychiatric	 symptoms	 through	
screening	 questionnaires	 e.g.	 the	 SCQ	 and	 SDQ.	 These	 screening	 tools	 do	 not	 substitute	 for	
comprehensive	 observation	 and	 neuropsychological	 testing,	 which	 typically	 takes	 several	
hours	and	are	performed	by	multidisciplinary	teams	with	expertise	across	a	variety	of	cognitive	









EEG	 studies	 were	 performed	 on	 38	 first-degree	 relatives	 of	 13	 MAE	 families.	 I	 identified	
epileptiform	 activity	 in	 two	 individuals;	 subject	 20526	 was	 an	 asymptomatic	mother	 with	 a	
right	 frontal	 temporal	 sharp	wave,	and	 subject	30574	a	5-year-old	 sister	with	3Hz	GSW	who	
was	 subsequently	 diagnosed	 with	 childhood	 absence	 epilepsy.	 It	 was	 not	 possible	 to	 draw	
further	conclusions	regarding	 inheritance	of	 familial	EEG	traits	or	extend	 into	the	use	of	EEG	
traits	as	an	endophenotype	due	to	the	paucity	of	positive	findings.	
	
However,	 there	 was	 an	 excess	 of	 epileptiform	 features	 among	 relatives	 when	 divided	
according	 to	age	and	compared	 to	control	populations	of	>16	years124	 (P=0.05,	RR	6.82)	and	
<16	 years127	 (P=0.58,	 RR	 1.69),	 leaning	 towards	 statistical	 significance	 in	 adults	 but	 not	 in	
children.	There	were	also	no	statistical	differences	in	prevalence	of	PPR	and	GSW/sharp	waves	
in	 the	 MAE	 cohort	 here	 (2/38,	 5.2%),	 when	 compared	 with	 Doose	 et	 al.’s	 cohort	 (33/151,	
21.8%)5,	 although	 these	 P	 values	 may	 not	 be	 accurate	 due	 to	 the	 small	 sample	 sizes.	









The	 identification	of	 epileptiform	 features	 in	 EEG	 studies	 of	 first-degree	 relatives	 have	been	
recognised	in	other	epilepsies63,262.	Pal	et	al.	reported	2.3%	of	first-degree	relatives	with	GSW	
in	139	probands	with	various	sub	syndromes	of	GGE63,	while	Jayalakshmi	et	al	identified	GSW	




Several	 factors	may	account	 for	 the	 lack	of	 identifiable	epileptiform	 features	 in	 siblings	 (<16	
years)	 and	 PPR	 in	 both	 parents	 and	 children.	 First,	 the	 small	 sample	 size	 particularly	 in	 the	
sibling	 group	 in	 this	 MAE	 cohort,	 and	 incomplete	 families	 recruited	 limits	 the	 power	 of	
discovery.	It	is	also	now	acknowledged	that	Doose’s	original	cohort	consist	of	a	heterogenous	
group	 of	 epilepsies	 and	 may	 not	 be	 a	 suitable	 direct	 comparison	 cohort.	 Next,	 recording	
conditions	were	vastly	different.		Doose	carried	out	paper	EEGs	with	8	electrodes	whereas	all	
EEGs	performed	here	were	on	digital	recordings	with	electrodes	laid	out	in	the	10-20	system.	
Additionally,	 it	 is	 unclear	whether	Doose	 carried	 out	 sleep	 recordings,	which	were	 obtained	
here,	 and	 the	 lack	 of	 activation	 procedures	 in	 some	 study	 subjects	 here	 would	 have	
compromised	results,	particularly	PPR	findings.	The	definitions	in	EEG	abnormalities	may	have	




In	 an	 effort	 to	 address	 the	 significance	 of	 dysrhythmias,	 quantitative	 EEG	 power	 spectral	
studies	 of	 the	 five-frequency	 bands,	 delta,	 theta,	 alpha,	 beta	 and	 gamma	 were	 performed.	
Four	 family	members	had	 to	be	eliminated	due	 to	difficulties	 in	obtaining	a	suitable	artefact	
free	 epoch.	 Comparison	 in	 the	 five	 frequency	 bands	 demonstrated	 differences	 in	 theta	 and	
beta	 bands	 in	 parents	 versus	 siblings	 with	 no	 differences	 in	 mothers	 versus	 fathers.	 These	
differences	 could	 be	 accounted	 for	 by	 physiological	 EEG	 differences	 with	 increased	 theta	
frequencies	 in	 siblings	 due	 to	 their	 younger	 age	 and	more	 enhanced	 beta	 rhythm	 in	 adults.	
Comparison	with	control	data	from	other	investigators	was	not	possible	due	to	differences	in	









Another	 unexplored	 strategy	 akin	 to	 the	 genetic	 linkage	 studies	 performed	 in	 PPR/GGE	
families66,67,	would	be	to	stratify	MAE	families	investigated	by	only	performing	EEG	recordings	
in	 MAE	 families	 with	 multiple	 affected	 members	 with	 epilepsy.	 Indeed	 I	 had	 recruited	 16	
families	 with	 a	 first-degree	 relative	 with	 epilepsy	 but	 was	 only	 able	 to	 perform	 family	 EEG	
studies	 in	 three	 of	 these	 families	 (family	 518	 (incomplete),	 574	 and	 602).	 This	was	 because	






I	 assembled	an	exome-sequencing	cohort	of	109	MAE	cases.	 I	 identified	 likely	pathogenic	or	
candidate	variants	in	11	of	109	cases.	This	comprised	known	genes	associated	with	MAE:	a	de	
novo	 CHD2	 variant	 (n=1),	 a	 de	 novo	 SLC6A1	 variant	 (n=1),	 a	 KIAA2022	 variant	 (n=1)	 and	
SYNGAP1	 variants	 (n=2);	 epilepsy	 associated	 genes	 novel	 for	MAE:	 a	de	novo	KCNB1	 variant	
(n=1),	a	de	novo	MECP2	variant	(n=1)	and	a	de	novo	KCNH5	variant	(n=1);	and	three	candidate	






the	 MAF	 and	 prediction	 capabilities	 of	 in	 silico	 predictors.	 Previously	 published	 epilepsy	
variants	were	curated	and	segregated	into	two	groups,	(1)	the	All_epilepsy	group	which	consist	
of	heterogenous	disease	associated	epilepsy	 variants	 and	 (2)	 the	Pure_epilepsy	group	which	
consist	 of	 variants	 associated	 with	 specific	 epilepsy	 syndromes.	 In	 the	 All_epilepsy	 group,	
83.7%	of	 variants	were	novel	 (not	 in	 ExAC,	 1000G	and	 ESP)	 and	95%	were	ultra	 rare	with	 a	
MAF<0.0001.	 In	 the	Pure_epilepsy	group,	97.2%	of	variants	were	novel.	Novelty	was	 further	
validated	 in	 my	 cohort	 when	 all	 pathogenic	 variants	 identified	 by	 the	 Euroepinomics	
consortium	 (see	 table	 7.4)	 and	 by	my	 filtering	 (see	 table	 7.9)	were	 novel	 even	when	 cross-










SIFT	 predicted	 pathogenicity	 in	 82.4%	 and	 PP2hvar	 predicted	 pathogenicity	 in	 80.4%.	 CADD	
scores	 as	 a	measure	of	deleteriousness	has	been	 validated	before	 in	 epilepsy	 studies.	 CADD	
scores	within	EE	genes	were	assessed	in	360	patients	with	epilepsy,	patients	were	more	likely	
to	 have	 novel	 and	 high	 CADD	 score	 variants	 relative	 to	 the	 ExAC	 population150.	 As	 a	





I	 identified	 five	cases	with	variants	 in	 four	different	known	genes	associated	with	MAE.	A	de	
novo	 CHD2	 variant	 (n=1),	 a	 de	 novo	 SLC6A1	 variant	 (n=1),	 a	 SYNGAP1	 variant	 (n=2)	 and	 a	
KIAA2022	 variant	 (n=1);	 the	 latter	 two	 genes	 had	 variants	 of	 unknown	 inheritance	 in	 two	




specific	 genetic	 associations,	 were	 identified	 in	 two	 cases.	 Subject	 00559	 has	 a	 de	 novo	




reported	 in	subject	00559.	 Including	 the	MAE	cohort	here	 (1/67	cases),	 the	adjusted	genetic	
contribution	of	CHD2	variants	 in	MAE	reduces	from	2.9%	to	2.3%	(see	section	1.8	for	genetic	
contributions).	 A	 de	 novo	 c.C1155G,p.F385L	 variant	 was	 also	 identified	 in	 the	 recently	
identified	MAE	gene	SLC6A1	adjusting	its	genetic	contribution	from	3.7%	to	3%,	based	on	the	
cohort	 described	 here.	 Seven	 previous	 MAE	 cases	 have	 been	 reported	 with	 SLC6A1	








neurodevelopmental	 disorders,	 largely	 due	 to	 the	 success	 of	 trio	 based	 sequencing	
studies76,155,165,230.	 	The	human	mutation	rate	per	nucleotide	per	generation	 is	 in	the	order	of	
1.18	 x	 10-8	 (SD	 ±0.15	 x	 10-8)264.	 Therefore,	 each	 individual	 is	 expected	 to	 have	 ~	 1	 de	 novo	





functions	 due	 to	 less	 stringent	 evolutionary	 selection265.	 Pathogenic	 de	 novo	 variants	 are	
thought	to	account	for	at	least	12%	of	EE155	and	42%	of	developmental	disorders165.	The	role	of	




SYNGAP1	 deletion.	 Inheritance	 studies	 were	 not	 possible	 due	 to	 lack	 of	 parental	 DNA.	
However	 these	variants	were	classified	as	 likely	pathogenic	due	 to	 the	consistent	phenotype	
and	 variant	 characteristics	 with	 previously	 reported	 pathogenic	 variants.	 KIAA2022	 is	 an	 X	
linked	 gene	 first	 identified	 in	 males	 with	 ID266.	 	 Epilepsy	 and	 ID	 are	 common	 associated	
features	 with	 KIAA2022	 mutations	 but	 only	 one	 female	 patient	 with	 MAE	 has	 been	
published23.	 Reported	 pathogenic	 variants	 are	 all	 frameshift	 or	 premature	 stop	 codon	 and	
mostly	 located	 in	 exon	 323.	 Subject	 138J	 has	 ID	 and	 her	 KIAA2022	 variant	 carries	 similar	




Subject	00512	and	00514	both	carry	a	SYNGAP1	 variant	with	 features	 that	 fit	with	SYNGAP1	
pathogenic	 variants,	 they	 both	 have	 frameshift	 deletions	 located	 within	 exons	 8	 to	 1516.	
Additionally	they	both	have	a	very	severe	phenotype,	with	pre-existing	global	developmental	




While	SYNGAP1	 variants	 are	more	 recognised	 in	MAE,	 the	 lack	of	SLC2A1	 variants	 identified	
here,	which	was	previously	reported	in	4/84	MAE	patients13	 is	 intriguing.	SLC2A1	variants	are	




early	 onset	 absence	 epilepsy18,267.	 Along	with	 European	 colleagues,	we	 identified	 no	 SLC2A1	
variants	 in	 120	 MAE	 cases18.	 Updated	 with	 further	 subjects	 from	 this	 cohort,	 no	 SLC2A1	
variants	are	identified	in	187	MAE	cases.	Reviewing	the	previously	described	four	MAE	patients	
with	 SLC2A1	 mutations;	 two	 patients	 had	 regular	 paroxysmal	 exertional	 dyskinesia,	 one	
patient	 had	 ataxia,	 dysarthria,	 poor	 motor	 skills	 and	 deceleration	 of	 head	 growth	 and	 one	
patient	 was	 part	 of	 a	 larger	 family	 with	 absence	 seizures	 and	 paroxysmal	 exertional	




Other	 genes	 associated	 with	 MAE,	 and	 which	 were	 described	 in	 the	 introduction,	 were	
identified	 in	 this	 cohort	 by	 the	 Euroepniomics	 consortium	 (KCNA219,	 SCN1A,	 STX1B20)	 and	







variant	 (n=1).	 Individually	 these	 genes	 have	 distinct	 yet	 overlapping	 phenotypic	 features	 to	
account	for	an	MAE	phenotype.			
	
A	 recurrent	de	novo	KCNB1	 p.R306C	variant	was	 identified	 in	 subject	00533.	KCNB1	variants	
are	 generally	 associated	 with	 an	 infantile	 epilepsy/spasms	 phenotype	 with	 severe	 ID,	 and	
seven	 other	 patients	 with	 pathogenic	 KCNB1	 variants	 including	 one	 patient	 with	 a	 p.R306C	
have	been	reported101,228,229,268.	Subject	00533	has	a	severe	MAE	phenotype	with	seizure	onset	





showed	 that	 the	 p.R306C	 mutation	 reduced	 sensitivity	 and	 responsiveness	 of	 the	 voltage	
sensor	 for	 channel	 opening	with	 inhibited	 repetitive	 neuronal	 firing.	 The	 authors	 postulated	
that	 insufficient	 firing	of	pyramidal	neurons	would	disturb	both	development	and	stability	of	







other	 patient	 with	 epilepsy	 with	 a	 de	 novo	 p.R327H	 KCNH5	 variant	 has	 been	 published230.	
KCNH5	is	expressed	predominantly	in	the	brain270	and	the	authors	considered	this	gene	variant	
a	good	candidate	and	subsequently	performed	voltage	clamp	analysis	of	the	mutated	protein.	
This	 showed	 a	 strong	 hyperpolarisation	 shift	 of	 voltage	 dependent	 activation	 and	 they	
hypothesized	 that	 the	 R327H	mutation	weakens	 ionic	 interactions	 and	 favour	 voltage	 gated	
potassium	 channel	 Kv10.2	 opening231.	 That	 patient	 and	 subject	 00525	 share	 phenotypic	





outside	 the	S0-S4	helical	pore.	Blood	RNA	samples	 for	 subject	00525	have	been	collected	 to	





associated	 with	 genes	 previously	 thought	 to	 be	 only	 accountable	 for	 specific	 congenital	
syndromes.	This	 is	so	for	the	next	gene	to	be	discussed	MECP2,	which	were	identified	in	one	
MAE	 case.	 These	 genes	 are	 quietly	moving	 on	 from	 syndrome	 genes	 to	 epilepsy-associated	
genes	as	well	often	with	suggestive	syndrome	features.	
	






291J	 is	an	 Italian	 female	who	carries	a	de	novo	MECP2	p.P225T	variant.	She	has	overlapping	
phenotypic	 features	 found	 in	 classic	 Rett	 syndrome	 of	 cerebellar	 signs	 and	 an	 EEG	 with	 a	
disorganised	 background.	 De	 novo	 MECP2	 variants	 have	 been	 recognised	 as	 causative	 for	
patients	with	epilepsy	by	other	 investigators	through	epilepsy	gene	panels248,268.	Parrini	et	al.	
identified	MECP2	 variants	 in	 4/349	 patients	 with	 epilepsy;	 all	 patients	 identified	 had	 drug	




recognised	 two	patients	with	Rett	 syndrome,	but	 subsequently	 reclassified	 all	 cases	 to	 have	
features	 consistent	 with	 Rett	 syndrome,	 including	 one	 patient	 who	 progressed	 during	
adolescence	 to	 a	 PPM-X	 phenotype	 of	 ID,	 parkinsonism,	 pyramidal	 signs	 and	 parkinsonism	
(PPM-X)268.	 Helbig	 et	 al.	 identified	 MECP2	 variants	 in	 4/293	 patients	 with	 epilepsy,	 two	
patients	were	classified	with	Rett	syndrome	but	the	others	were	reported	as	an	EE	in	one	and	




the	 hypothalamus	 through	 both	 transcriptional	 activation	 and	 repression254.	 This	 p.P225T	
variant	is	located	in	the	transcription	repression	domain	(TRD),	a	well	characterised	canonical	
functional	domain	in	MeCP2	and,	where	many	pathogenic	variants	present.	The	TRD	domain	is	
part	 of	 the	 co-repressor	 interacting	 region	 and	 is	 involved	 in	 transcriptional	 regulation	 by	
interacting	with	the	corepressor	Sin3A	and	histone	deacetylases271.		
	
A	 potential	 clinical	 implication	 for	 subject	 291J	 is	 that	 children	with	 Rett	 syndrome	have	 an	
increased	risk	of	life	threatening	arrhythmias	associated	with	prolong	QTc	interval	and	should	




The	 genes	 described	 in	 this	 section	 were	 identified	 due	 to	 their	 known	 association	 with	






with	a	de	novo	SMARCA2	 variant52,	 subject	00530	with	a	de	novo	ASH1L	 variant	and	 subject	
00526	with	a	CHD4	variant.	
	
Subject	3003	301	with	MAE,	ASD	and	 ID,	was	 identified	with	a	de	novo	 p.Q1241E	SMARCA2	
variant	which	 led	to	clinical	 re-examination	and	a	diagnosis	of	Nicolaides	Baraitser	syndrome	





neither	 seizure	semiology	nor	 specific	epilepsy	syndromes	have	been	well	described,	and	 (3)	
there	is	no	reported	association	between	MAE	and	NCBRS.		
Epilepsy	 occurs	 in	 two-thirds	 of	 patients	 with	 NCBRS,	 and	 in	 a	 series	 of	 61	 individuals	 with	
NCBRS,	 the	 median	 age	 at	 the	 first	 seizure	 was	 18	 months182.	 Generalised	 seizures	 were	
common	in	a	series	of	11	patients	with	NCBRS,	ten	had	GTCS	and	six	had	atonic	seizures	(ECE	
2016	abstract,	Hofmeister	et	al.).	Additionally,	as	in	our	patient,	a	co-occurrence	of	decreasing	




At	 least	80%	of	patients	with	NCBRS	carry	a	variant	 in	SMARCA2	 (OMIM	601358)	but	 to	our	
knowledge	all	point	mutations	have	been	 located	 in	exons	15	-	25,	and	never	before	 in	exon	
26181.	 SMARCA2	 is	 located	 on	 chromosome	 9p24.3	 and	 its	 longest	 transcript	 has	 34	 exons.	
Thus	far,	62	missense	mutations	and	3	in-frame	deletions	clustering	in	the	ATPase	domains	of	
exons	 15	 -	 25	 of	 SMARCA2	 have	 been	 reported	 in	 patients	 with	 NCBRS	 (see	 Figure	 8.1	 for	
schematic	 diagram	 of	 SMARCA2	 protein	 and	 location	 of	 variants)182,272,273.	 These	 pathogenic	
variants	 are	 thought	 to	 have	 a	 dominant	 negative	 effect	 by	 abolishing	 the	 ATP	 hydrolyzing	







QLQ	 glutamine-leucine-glutaimine	 domain,	 Proline	 proline	 rich	 domain,	 HSA	 small	 helicase/SANT	












reported	 here	 carries	 the	 first	 mutation	 located	 in	 exon	 26,	 also	 in	 close	 proximity	 to	 the	
ATPase	 domain.	 We	 hypothesize	 that	 both	 mutations	 similarly	 affect	 ATP	 hydrolysis	 and	
chromatin	 remodelling	 ability.	 Sousa	 and	 colleagues	 reported	 a	 case	with	 a	mutation	 in	 the	
Bromo	domain,	in	exon	30	(p.G420R)182.	Their	case	did	not	have	the	typical	facial	features	seen	
in	NCBRS	but	had	overlap	 features	of	severe	 ID,	absent	speech	and	seizures.	The	absence	of	




Genetic	 aberrations	 involving	 exon	 26	 in	 addition	 to	 ATPase	 disruption	 have	 also	 been	
described.	 NCBRS	 has	 been	 reported	 with	 a	 32	 kb	 de	 novo	 in-frame	 SMARCA2	 deletion	
affecting	exons	20	to	26	and	a	55kb	interstitial	deletion	involving	exons	20	to	27	was	reported	
in	 a	 patient	 with	 the	 phenotypically	 similar	 Coffin-Siris	 syndrome274,275.	 These	 patients	 had	
epilepsy,	 but	 the	 associated	 seizure	 semiology	 and	 epilepsy	 syndromes	 merit	 further	
description.		
	
SMARCA2	 is	 one	 of	 the	 six	 genes	 that	 encodes	 the	 catalytic	 subunit	 components	 of	 the	
SWItch/sucrose	nonfermentable	 like	chromatin-remodeling	complex	 (SWI/SNF	complex).	The	
SWI/SNF	 complex	 is	 evolutionarily	 highly	 conserved	 from	 yeast	 to	 humans	 and	 works	 as	 a	
chromatin	remodeler;	altering	chromatin	structure	through	ATP	hydrolysis.	SWI/SNF	proteins	
regulate	 gene	 expression	 by	 re-positioning	 nucleosomes	 and	 altering	 DNA	 transcription.	 A	
close	 connection	 between	 the	 SWI/SNF	 complex	 and	 neurological	 development	 has	 been	
implicated	through	the	identification	of	numerous	variants	in	genes	encoding	the	subunits	in	a	
range	 of	 neurodevelopmental	 disorders	 such	 as	 Coffin-Siris	 syndrome,	 sporadic	 ID,	 ASD,	
schizophrenia	and	Kleefstra	syndrome276.		
	
In	 conclusion,	 the	 epilepsy	phenotype	 in	NBCRS	 can	be	 consistent	with	MAE	 syndrome,	 and	
NBCRS	spectrum	features	can	be	caused	by	variants	outside	the	ATPase	region	of	SMARCA2.	




have	 no	 history	 of	 epilepsy.	 Her	 mother	 (subject	 20526)	 was	 identified	 with	 an	 incidental	
epileptic	 sharp	 wave	 in	 familial	 EEG	 studies	 performed	 here.	 Subject	 00526	 has	 a	 novel	







with	 overlapping	 phenotypes	 of	 developmental	 delay,	 hearing	 loss,	 macrocephaly,	 distinct	
facial	 dysmorphisms,	 palatal	 abnormalities,	 ventriculomegaly	 and	 hypogonadism.	 A	 further	
four	 patients	 were	 identified	 in	 the	 updated	 DDD	 study,	 but	 they	 had	 no	 history	 of	
seizures165,238.	
	
CHD4	 encodes	 the	 Chromodomain	 helicase	 DNA-binding	 protein	 4	 (CHD4),	 which	 is	 an	 ATP	
dependent	 chromatin	 remodeller	 like	 SMARCA2.	 Chromatin	 remodelling	 is	 an	 epigenetic	
mechanism	 that	 controls	 DNA	 accessibility	 to	 transcription,	 replication	 and	 DNA	 repair	
regulation.	 CHD4	 helps	 drives	 this	 process	 by	 mobilising	 nucleosomes	 and	 modifying	 DNA	
packaging277.	 In	 addition,	 CHD4	 belongs	 to	 the	 CHD	 subfamily	 II,	 and	 among	 its	 paralogs	 is	
CHD2,	which	 is	associated	with	MAE12,14,15.	 	The	variant	 identified	 in	subject	00526	 is	 located	
within	 the	 ATPase/helicase	 domain	 (http://www.uniprot.org),	 and	 may	 disrupt	 the	 ATPase	
activity	 of	 CHD4.	 In	mouse	models,	 Chd4	 is	 highly	 expressed	 in	 the	 central	 nervous	 system	
(http://www.informatics.jax.org)	 and	 the	 lack	 of	 Chd4	 results	 in	 impaired	 parallel	
fiber/Purkinje	cell	synaptic	connectivity	in	the	developing	central	nervous	system278.	
	
The	variant	 identified	 in	CHD4	 summarises	as	a	 suitable	candidate	gene:	RVIS	2.82%,	ExAC	Z	
7.05,	gnomad	MAF	novel,	predicted	pathogenic	by	SIFT	and	PP2hvar,	CADD	24.6.	The	spectrum	
of	 phenotypic	 expressivity	 of	 seizure-associated	 genes	 have	 been	 suggested	 in	 the	 updated	
DDD	 study;	 where	 285	 of	 4293	 individuals	 had	 truncating	 or	 missense	 de	 novo	 variants	 in	
known	seizure	associated	genes	but	56%	of	 these	 individuals	had	no	coded	 terms	 related	 to	




Gene	 exploration	 with	 the	 neuropsychiatric	 gene	 set	 identified	 another	 candidate	 gene,	
ASH1L.	 Subject	 S2392/00530	 is	 a	 7-year-old	 male	 with	 seizure	 onset	 at	 6	 months.	 He	 has	
severe	MAE	with	multiple	refractory	seizure	types.	He	has	moderate	to	severe	ID,	autism	and	
ADHD.	There	 is	no	 family	history	of	epilepsy.	He	has	a	de	novo	p.R1342X	ASH1L	 variant.	The	
curated	variant	within	the	neuropsychiatric	gene	set	was	a	de	novo	p.A724S	variant	identified	
in	1/100	patients	with	ID.	The	patient	reported	by	de	Ligt	et	al.	 is	a	37	year	old	male	with	ID,	






ASH1L	 variants	 have	been	 reported	 in	ASD	patients,	 detailed	 phenotype	 in	 one	 reported	no	
history	of	seizures279,280.	
	
ASH1L	 (Absent,	 small,	 or	 homeotic	 disc	 1	 Like	 Histone	 Lysine	Methyltransferase)	 encodes	 a	
member	 of	 the	 trithorax	 group	 of	 histone	 modifiers,	 histone	 methyltransferase	 which	 is	
involved	 in	 gene	 activation.	 The	 expression	 of	 Ash1L	 is	 enriched	 in	 the	 brain	 and	 a	 role	 in	
epigenetic	 modification	 in	 brain	 functioning	 was	 implicated	 when	 Ash1L	 knockout	 mice	
completely	abolished	the	activity	dependent	repression	of	neurexin	1α,	a	presynaptic	adhesion	
molecule	required	for	synaptic	formation236.	This	highly	conserved	variant	is	located	between	




Summing	 up	 the	 evidence,	 subject	 S2393/00530’s	 phenotype	 is	 supportive	 given	 his	
neurodevelopmental	features	of	ID	and	ASD	which	are	present	in	other	patients	with	de	novo	
ASH1L	 variants.	 It	 is	 difficult	 to	 extrapolate	 a	 direct	 causative	 association	 for	ASH1L	 in	MAE	






exome	 sequencing,	 (2)	 poor	 detection	 of	 somatic	 variants,	 (3)	 use	 of	 novelty	 as	 a	 filtering	




in	 identification	 of	 structural	 variants	 such	 as	 translocations	 and	 inversions,	 indels,	 copy	
number	 variants	 and	 triplet	 repeats.	 This	 technique	 does	 not	 explore	 potentially	 disease-
causing	variants	in	intronic	regions,	promotor,	enhancer	regions	and	micro	RNAs.	In	addition,	


















ExAC	 and	 ESP,	 and	 subsequently	 a	 gnomAD	 MAF	 was	 annotated	 following	 its	 launch.	 It	 is	
worth	 considering	 potential	 confounders	 within	 these	 population	 databases.	 First,	 these	
databases	 may	 not	 account	 sufficiently	 for	 ethnic	 populations	 such	 as	 Middle	 Eastern	 and	
African	populations	and	may	 lead	 to	under	 representation	of	MAF	 in	 these	cases160.	 Second,	
the	 individuals	 ascertained	 for	 these	 databases	 had	 biomedically	 important	 adult	 onset	
diseases,	 and	 to	 that	 end,	 it	 is	widely	 understood	 that	 that	 these	 control	 databases	 contain	
disease	 associated	 variants281,	 although	 severe	paediatric	 diseases	were	excluded.	 Third,	 the	
re-annotation	of	a	gnomAD	MAF	on	variants	that	were	previously	annotated	novel	reveals	the	
scope	 of	 diversity	 of	 protein	 coding	 genetic	 variation	 that	 remains	 to	 be	 investigated.	
Nevertheless,	 all	 published	 pathogenic	 variants	 identified	 in	 the	 Euroepinomics	 cohort	were	
novel	in	all	four	population	databases	(see	Table	7.4).		
	
I	 used	 a	 CADD	 score	 of	 >20	 as	 a	 filtering	 parameter	 during	 burden	 analysis	 of	 aetiologically	
relevant	 gene	 sets.	 CADD	 is	 a	 high	 performing	 pathogenic	 predictor	 that	 captured	 93%	 of	
Pure_epilepsy	 variants	 using	 a	 cut	 off	 score	 of	 20	 (see	 section	 7.3.2).	 CADD	 has	 also	 been	
verified	 by	 other	 investigators	 in	 filtering	 for	 epilepsy	 related	 variants150.	 Still,	 no	 in	 silico	
prediction	 tool	 is	 able	 to	 capture	 all	 potentially	 pathogenic	 variants	 and	as	CADD	 scores	 are	
only	available	for	missense	variants,	indels	and	frameshift	variants	may	be	underestimated.	
	
I	was	 not	 able	 to	 Sanger	 validate	 and	 perform	 inheritance	 studies	 on	 all	 genetic	 variants	 of	





and/or	with	 only	 a	 handful	 of	 previously	 reported	 cases.	 Further	 functional	 assessment	 in	 a	






given	 the	 rarity	 of	 these	 gene	 variants,	 web	 based	 gene	 matching	 platforms	 (e.g.	
https://genematcher.org/)	can	be	a	useful	tool	to	facilitate	collection	of	larger	cohorts.	
	
Last,	 the	 limitations	 described	 above,	 plus	 the	 rapidly	 evolving	 pace	 in	 the	 field	 of	 epilepsy	
genetics,	brings	home	the	point	of	the	importance	of	re-assessment	of	variants.		Hagman	et	al.	
reported	a	re-classification	rate	of	22%	of	candidate	variants	following	literature	review	after	








be	 associated	 with	 congenital	 syndromes	 with	 seizures	 (SMARCA2,	MECP2).	 The	 extent	 of	
genetic	 heterogeneity	 in	 MAE	 is	 now	 clear,	 with	 each	 gene	 accounting	 for	 only	 a	 small	
proportion	of	cases.	The	major	pathways	involved,	which	have	also	been	previously	recognised	
in	 other	 epilepsies,	 are	 ion	 channels283	 (SCN1A,	 GABRG2,	 KCNA2,	 KCNB1,	 KCNH5),	 synaptic	










Ion	 channelopathies	 are	 an	 established	 mode	 of	 pathogenesis	 in	 epilepsy,	 while	 chromatin	
remodelling	is	more	recently	recognised.	Ion	channels	are	transmembrane	proteins	that	after	
activation	allow	the	passive	flow	of	ions	in	and	out	of	cells	or	cellular	organelles	following	their	
electrochemical	 gradients.	 This	 flux	 of	 ions	 generates	 a	 membrane	 potential	 and	 this	 can	
function	as	neuronal	 signalling	and	allow	neurotransmitter	 release.	Examples	are	SCN1A	 and	
GABRG2.	SCN1A	encodes	 the	Nav1.1	channel,	one	of	nine	subtypes	of	voltage	gated	 sodium	
channels	 that	 is	preferentially	expressed	 in	GABAergic	neurons.	GABRG2	encodes	 the	GABAA	
receptor,	 which	 is	 the	 major	 inhibitory	 neurotransmitter	 receptor	 in	 the	 central	 nervous	
system.	 Hence	 dysfunction	 of	 either	 NaV1.1	 channels	 or	 GABAA	 receptors	 leads	 to	 reduced	
excitability	 of	 GABAergic	 neurons	 and	 increased	 brain	 hyperexcitability.	 As	 a	 group,	 ion	
channels	 comprise	 over	 400	members,	 each	 with	 a	 unique	 but	 overlapping	 functional	 role.	
However,	they	conferred	similar	variant	complexity	when	unaffected	individuals	and	patients	
with	epilepsy	were	compared178.	Therefore,	in	silico	modelling	of	channel	variation	in	cell	and	






allowing	 transcription	 factors	 or	 other	 DNA	 binding	 proteins	 to	 access	 the	 DNA	 and	 control	
gene	 expression277.	 Defects	 in	 this	 process	 can	 lead	 to	 impaired	 synaptic	 differentiation	 and	
neuronal	 connectivity	 in	 animal	 models278.	 DNA	 accessibility	 is	 facilitated	 by	 chromatin	




The	 genetic	 heterogeneity	 of	MAE	 leads	 to	 a	 phenotypic	 heterogeneity	 and	 reciprocally	 the	
reverse	is	true.	Table	8.1	summarises	the	likely	pathogenic	or	candidate	variants	 identified	in	
this	cohort	and	specific	phenotypic	features	which	may	offer	discriminatory	clues	to	a	genetic	
correlation.	 In	 general,	 a	 variable	 epilepsy	 prognosis	 was	 seen	 (5/10	 achieved	 seizure	
remission	>2	years),	although	the	phenotype	leaned	towards	an	EE	as	is	reflected	in	significant	
neurodevelopmental	 comorbidity:	 ID	 (11/11),	 ASD	 (6/11)	 and	 ADHD	 (3/11),	 supporting	 a	
shared	 genetic	 and	 biological	 link	 between	 these	 various	 neurodevelopmental	 disorders166.	
These	 neurodevelopmental	 comorbidities	 may	 also	 be	 a	 primary	 feature	 of	 genetic	 disease	
rather	than	secondary	to	disturbance	of	brain	function	due	to	excessive	epileptiform	activity.	








Gene	 Subject	 Variant	identified	 MAE	course		
Phenotypic	clues	
EEG	
ASH1L*	 00530	 c.G2170T:p.A724S	 Unfav	MAE	
ID,	ASD,	ADHD	
GSW	and	focal	spikes	




CHD4*	 00526	 c.A2687G:p.H896R	 Unfav	MAE	
ID	
GSW	

















































years,	Unfav	MAE	unfavourable	MAE	epilepsy	 course	with	 on-going	 seizures,	 ID	 intellectual	 disability,	












The	 GGE	 syndromes	 encompass	 a	 group	 of	 epilepsies	 with	 a	 presumed	 genetic	 basis	 and	






EE	 is	 a	 very	 different	 entity	 and	 is	 defined	 by	 the	 ILAE	 as	 a	 process	 by	 which	 the	 epileptic	
activity	 itself	 may	 contribute	 to	 severe	 cognitive	 and	 behavioural	 impairments	 above	 and	
beyond	what	might	 be	 expected	 from	 the	 underlying	 pathology	 alone	 and	 that	 these	might	
worsen	over	time35.	However,	in	the	literature	the	term	EE	is	also	used	as	a	category	for	severe	
epilepsy	 syndromes	 characterised	 by	 multiple	 seizure	 types,	 abundant	 epileptiform	 activity,	





typically	 present	 in	 normal	 developing	 children	 and	 apart	 from	 the	 presence	 of	 myoclonic	
atonic	 seizures	 have	main	 seizure	 types	 of	 GTCS,	 myoclonic	 seizures	 and	 absences	 seizures	
similar	to	GGE.	Furthermore,	EEG	patterns	in	MAE	are	similar	to	GGE.	In	some	cases,	seizures	
are	well	controlled	with	minimal	comorbidity	eventually	leading	to	seizure	remission.	However	
in	 other	 cases,	 seizures	 are	 multiple	 and	 refractory,	 associated	 with	 severe	
neurodevelopmental	comorbidity,	EEG	shows	a	slow	background,	shifting	the	overall	picture	to	
an	 EE.	 Table	 8.2	 compares	 the	 main	 electroclinical	 features	 of	 GGE,	 using	 sub	 syndromes	


























































the	 interactions	 of	 several	 susceptibility	 genes	 of	 minor	 effect	 along	 with	 environmental	
factors287.	 The	 high	 proportion	 of	 relatives	 with	 epilepsy	 in	 GGE	 and	 MAE	 supports	 this	
hypothesis.	This	complex	genetic	architecture	remains	difficult	to	unravel.	Linkage	analysis	has	
identified	 several	 susceptibility	 loci	 for	 GGE	 sub	 syndromes102,288,289,	 for	 example	 EF	 hand	
domain	containing	protein	(EFHC1)	at	6p12-p11	locus290	and	bromodomain	containing	protein	
(BRD2)	 at	 the	6p21	 loci	 for	 JME289,	but	 they	are	poorly	 replicated	due	 to	 the	high	degree	of	
genetic	complexity	and	heterogeneity.	Large	scale	association	analysis	did	not	identify	specific	
rare	 variants	 to	 confer	 significant	 risk	when	using	 a	 genome	wide	 approach291,	 or	 through	 a	
subset	 of	 ion	 channel	 genes178.	 Genome	 wide	 association	 analysis	 of	 3020	 GGE	 cases	
implicated	 susceptibility	 loci	 at	 2p16.1	 and	 17q21.32103,	 and	 at	 2q24.3	 with	 a	 larger,	 more	
heterogenous	overlapping	cohort	of	8696	cases292.	Recently,	a	case	control	sequencing	study	
demonstrated	that	patients	with	GGE	have	ultra	rare	genetic	variants	(MAF<0.001)	 in	known	
epilepsy	 genes	 relative	 to	 the	 rest	 of	 protein	 coding	 genes	 (P=5.8	 ×10-8)283,	 suggesting	 a	
connection	 between	 GGE	 and	 rare	 epilepsies.	 A	 monogenic	 aetiology	 per	 se	 has	 been	
identified	 in	 a	 small	 number	 of	 rare	 multiplex	 families.	 Of	 note,	 Wallace	 et	 al.	 identified	
GABRG2	mutations	in	a	large	epilepsy	pedigree	with	CAE	and	febrile	seizures	that	had	a	single	





similar	 genetic	 influences	 can	account	 for	phenotypic	 variability	 consisting	of	MAE	and	GGE.	




associations	 identified	 in	 this	 study;	 KCNB1,	 MECP2	 and	 KCNH5,	 can	 result	 in	 an	 EE-like	




sequencing	 of	 SLC6A1	 was	 performed	 as	 it	was	 one	 of	 two	 genes	 in	 a	de	 novo	 3p25.3	 CNV	
deletion	in	a	single	case	with	MAE,	which	subsequently	led	to	its	discovery	of	association	in	a	
further	6/160	MAE	patients17.	This	is	in	contrast	to	GGE	where	recurrent	deletions	of	15q13.3,	
15q11.2	 and	 16p13.11	 have	 been	 identified	 as	 specific	 risk	 factors91,92.	 In	 EE,	 these	 CNV	
hotspots	are	 rarely	seen	and	 it	 is	 the	overlapping	genes	within	CNVs	 that	offer	a	pathogenic	
role.	 In	 MAE,	 both	 these	 situations	 have	 been	 reported:	 a	 de	 novo	 16p13.11	 GGE	 hotspot	






GGE).	 The	 overall	MAE	 phenotype	 of	 the	 individual	 depends	 on	 the	 unique	 combination	 of	
genes	 and	 environmental	 factors	 involved,	 and	 can	 extend	 from	 an	 EE-like,	 to	 a	 GGE-like	





This	 work	 demonstrates	 the	 phenotypic	 and	 genetic	 spectrum	 of	 MAE,	 both	 of	 which	 will	
continue	 to	 grow	 through	 continued	 progress	 in	 genomic	 research.	 The	 overall	 yield	 of	
identifying	a	genetic	aetiology	 in	 this	MAE	cohort	was	17.4%	(19/109).	This	 is	comparable	 to	
recent	 epilepsy	 panel	 gene	 studies	 in	 patients	 with	 heterogenous	 phenotypes	 of	 severe	
developmental	delay,	familial	epilepsies	and	EE	of	18%	by	Trump	et	al.293	and	23%	by	Møller	et	
al.294.	 A	 gene	 panel	 is	 a	 frequently	 used	 NGS	 technique	 where	 only	 genes	 of	 interest	 are	









candidate	 genes.	 In	 addition,	 exomes	 can	 be	 continually	 re-analysed	 for	 newly	 identified	
discoveries	 until	 a	 genetic	 aetiology	 is	 identified.	 Pipelines	 for	 the	 pathogenic	 validation	 of	
variants	have	been	developed	with	 specific	 scoring	 criteria250,282,295.	Notable,	 is	 the	American	
College	of	Medical	Genetics	and	Genomics	guidelines	 for	 interpretation	of	 sequence	variant,	




Even	 without	 direct	 therapeutic	 impact,	 a	 genetic	 diagnosis	 can	 significantly	 impact	 on	
families.	For	example,	a	de	novo	genetic	diagnosis	can	help	relieve	guilt	from	false	attribution	
form	the	parents’	consciousness	that	an	early	life	event	could	have	produced	symptoms,	and	
offer	 informed	guidance	 for	parents	 intending	 to	extend	their	 family.	 In	addition,	ending	 the	




remain.	 The	 impact	 of	 variants	 in	 non-coding	 regions,	 regulatory	 regions	 and	 microRNAs	




lobe	epilepsy	were	 found	 to	have	 increased	micro	RNA-181a	 levels	 in	 the	hippocampus296.	A	
further	 example	was	by	Panjwani	et	al.,	who	demonstrated	 that	 the	homozygous	T	 allele	 at	
microRNA-328	binding	site	conferred	increased	risk	to	EEG	features	of	centro	temporal	spikes	
in	 patients	 with	 rolandic	 epilepsy	 (P=2.6	 x	 10-4)298.	 The	 specific	 cell	 types	 and	 targets	 for	
specific	 microRNAs	 remains	 to	 be	 identified	 and	 offers	 an	 untapped	 research	 resource	 in	
contributing	to	the	pathogenesis	of	epilepsy.	
	
Further	 genetic	 studies	 exploring	 other	 models	 will	 shed	 more	 light.	 CNVs	 in	 my	 cohort	
remains	to	be	thoroughly	investigated	and	were	not	explored	as	first	line	due	to	the	limitations	




Phenome/Genome	 Project	 and	 Epi4K	 consortium	 demonstrated	 the	 level	 of	 false	 positives	
with	 this	 method	 and	 were	 able	 to	 validate	 by	 array	 based	 methods	 only	 66%	 (53/80)	 of	
inherited	CNVs	and	24%	(5/21)	of	de	novo	CNVs	called	from	exome	sequencing	data	in	patients	
with	 EE299.	 The	 ascertainment	 of	 rare	multiplex	MAE	 families	may	offer	 further	 insights	 into	
allelic	 contribution	 of	 specific	 phenotypic	 and	 EEG	 features,	 for	 example	 transmission	 of	
specific	 EEG	 features	 or	 power	 spectra	 frequency	 bands,	 and	 aid	 in	 offering	 causal	 variant	
discovery	in	alleles	with	incomplete	penetrance.		
	
Somatic	 mosaic	 variants	 in	 epilepsy	 are	 not	 well	 studied.	 Somatic	 mosaicism	 occurs	 in	
embryogenesis,	 resulting	 in	 variants	 confined	 to	 a	 proportion	 of	 all	 cell	 types,	 specific	 body	





availability	of	 testing	brain	 tissue	 following	surgery	 in	 these	patients,	which	would	otherwise	
have	 been	 difficult	 to	 assess.	 However,	 Halvorsen	 et	 al.	 constructed	 a	 mosaic	 transmission	
screen	 using	 trio	 exome	 sequencing	 data	 on	 nine	 cases	 with	 sudden	 unexplained	 death	 in	
childhood	and	338	cases	with	EE.	In	brief,	the	screen	extracted	novel	nonsynonymous	variant	
calls	from	the	proband	and	parents,	and	then	performed	a	binomial	exact	test	on	the	mutant	
allele	 read	 ratio	 for	 the	 carrier	 parent	 and	 proband	 child	 to	 determine	 the	 probability	 of	
obtaining	 the	 observed	 read	 ratio	 given	 an	 expected	 value	 of	 0.5	 for	 heterozygous	 variants.	
They	 identified	 six	 parental-mosaic	 transmissions	 across	 the	 two	 cohorts	 (estimated	 0.02	
transmission	 per	 trio)83.	 This	 mechanism	 appears	 lower	 than	 de	 novo	 variants	 but	 remains	
applicable	in	epilepsy.	
	
Collaborative	 approaches	 will	 be	 necessary	 to	 overcome	 the	 difficulties	 due	 to	 genetic	
heterogeneity	 and	 rarity	 of	 MAE,	 in	 order	 to	 make	 fundamental	 leaps	 in	 understanding.	 A	
proposed	 model	 is	 a	 ‘lumping	 and	 splitting’	 experimental	 design	 where	 larger	 cohorts	 are	
assembled	through	multicentre	collaborations	 in	order	to	generate	sufficient	power	for	gene	
identification	 followed	 by	 fractionation	 into	 specific	 gene/allele	 related	 phenotypic	
characteristics165,292.	The	Epilepsy	Genetics	Initiative	(www.cureepilepsy.org/egi)	seeks	to	grant	
access	 to	 exome	 databases	 to	 enable	 collaborations	 and	 collection	 of	 gene	 cohorts.	 The	
collection	of	patients	with	specific	rare	pathogenic	gene	variants	can	also	be	achieved	through	
patient-gene	 registries	 (www.geneticepilepsy.com)	 and	 gene	 matching	 web	 platforms	




delineation	 of	 the	 natural	 history	 of	 specific	 gene	 related	 epilepsies,	 allow	 more	 precise	
phenotype	 quantification,	 longitudinal	 studies	 on	 specific	 comorbidities,	 and	 investigate	
phenotype	 genotype	 correlation	 pertaining	 to	 position	 dependent	 effects	 or	 variant	 type	
effects.	 Additionally,	 it	 can	 lead	 to	 more	 comprehensive	 investigations	 in	 understanding	 of	





recognition	 of	 specific	 epilepsy	 associated	 genes	 (SCN1A,	 SCN2A,	 SCN8A,	 KCNQ2).	 This	
targeted	therapy	can	be	taken	on	by	different	approaches:	(1)	use	of	pharmacological	agents	
that	 target	 the	 abnormal	 protein	or	 disrupted	pathway,	 (2)	 use	of	 induced	pluripotent	 stem	
cells	 for	 in	 vitro	 disease	 modelling,	 tagged	 with	 reprogramming	 technologies	 in	 genetic	























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of	 our	 hair	 and	 eyes.	 Differences	 in	 our	 genes	 can	 also	 explain	 why	 some	 people	 develop	 certain	
diseases,	 like	 epilepsy,	 and	 others	 do	 not.	We	 are	 studying	 individuals	with	 epilepsy,	 as	well	 as	 their	

















This	 research	study	may	 involve	an	EEG	(brainwave)	 recording;	some	tests	of	hearing	and	vision	done	















You	 will	 be	 asked	 to	 participate	 in	 completing	 questionnaires	 that	 take	 about	 50-60	 minutes.	 The	








the	 head.	 Wires	 are	 lightly	 attached	 to	 your	 scalp	 using	 paste	 and	 these	 are	 connected	 to	 the	 EEG	
machine.	After	the	recording,	the	paste	is	removed.	Recordings	will	last	for	about	1-3	hours.	Sometimes	
the	 technician	 shines	a	 flickering	 light	 in	 front	of	 your	 face	 for	a	minute	or	 so	 (photic	 stimulation);	 at	
other	times	s/he	may	ask	you	to	breathe	deeply	for	a	minute	(hyperventilation).	During	the	recording,	




































Studies	 using	 high-throughput	 sequencing	 are	 often	 performed	 in	 national	 or	 international	 research	








Mental	Health	Biomedical	 Research	Centre	 (BRC)	Bioresource.	 The	NIHR	 is	 responsible	 for	 supporting	
research	and	development	across	 the	NHS.	The	Mental	Health	BRC	Bioresource	has	been	designed	 to	
create	 a	 resource	 or	 ‘Biobank’	 for	 psychiatric/neurological	 disorders,	 which	 will	 include	 biological	
information	 (e.g.	 blood,	 saliva	 for	 analyzing	 genes),	 combined	 with	 other	 information	 (e.g.	 clinical	
assessments	 from	your	child’s	neurological	examination	and	existing	neuroimaging	data).	The	purpose	




initiative	 involving	 a	 number	 of	 other	 Biomedical	 Research	 Centers	 in	 the	 country.	 This	 is	 in	 order	 to	
bring	 together	 groups	of	 healthy	 volunteers,	 patients	 and	 relatives	who	have	 agreed	 to	be	 contacted	
and	 can	 be	 invited	 to	 participate	 in	 relevant	 clinical	 research.	 Therefore,	 some	 BRC	 Bioresource	




Your	 sample	 will	 be	 anonymised,	 processed	 and	 stored	 at	 secure	 laboratories	 at	 the	 Institute	 of	






standard	 evaluation	 using	 written,	 spoken	 and	 physical	 materials,	 administered	 by	 a	 trained	
psychologist.	 During	 parts	 of	 the	 assessment	 you	may	 have	 an	 EEG	 recording.	 The	 assessment	 takes	
about	 4	 hours.	 Additional	 time	will	 be	 allocated	 for	 rest	 and	 refreshment.	 This	 assessment	 looks	 for	
patterns	of	brain	function	that	may	help	in	finding	genes	for	epilepsy	and	is	not	intended	for	educational	
or	 career	 guidance.	 Your	 child	 may	 ask	 for	 pause	 or	 termination	 of	 testing	 at	 any	 time	 during	 the	
procedure.	
	
You	 may	 be	 asked	 to	 repeat	 a	 series	 of	 words	 and	 phrases	 into	 a	 recording	 machine	 over	 about	 3	



























































any	 information	we	might	already	have	collected.	However,	 if	you	want	us	to	destroy	the	 information	
we	have	collected,	we	will.	You	will	need	to	tell	is	whether	you	wish	to	withdraw	from	the	rare	epilepsy	
study,	Bioresource	study	or	both.	Biological	samples	e.g.	saliva,	blood,	blood	products,	DNA	and	RNA	will	









will	 do	 their	 best	 to	 answer	 your	 questions	 (020	 7848	 5435).	 If	 you	 remain	 unhappy	 and	 wish	 to	
complain	formally,	you	can	do	this	through	the	NHS	Complaints	Procedure.	Details	can	be	obtained	from	
the	hospital.	In	the	event	that	something	does	go	wrong	and	you	are	harmed	during	the	research	study	
there	 are	 no	 special	 compensation	 arrangements.	 If	 you	 are	 harmed	 and	 this	 is	 due	 to	 someone’s	
negligence	 then	 you	 may	 have	 grounds	 for	 a	 legal	 action	 for	 compensation	 against	 King’s	 College	




Yes.	We	will	collect	 information	about	you,	which	could	 identify	you	personally	 (for	example,	because	
the	 information	 includes	 your	 name	 or	 date	 of	 birth).	 We	 will	 also	 collect	 information	 about	 you	





one	outside	 the	 team	will	have	access	 to	your	 information.	We	will	use	 the	 information	we	collect	 to	
answer	the	questions	relevant	 to	 this	 research	project.	 In	 the	 future	 it	 is	possible	we	might	have	new	




then	 destroyed	 securely.	 The	 hospital	 has	 a	 duty	 to	 ensure	 research	 conducted	 here	 is	 of	 a	 high	
standard	and	auditors	 from	the	hospital	may	need	to	review	any	 information	we	hold	about	you.	The	















This	 research	 is	being	organized	by	Professor	Deb	Pal	and	 is	 sponsored	by	King’s	College	London.	The	





The	 Great	 Ormond	 Street	 Hospital/Institute	 of	 Child	 Health	 Research	 Ethics	 Committee	 (reference	
number:	09/H0713/76)	has	reviewed	this	rare	epilepsy	study	and	given	a	favourable	ethical	opinion	for	





























































of	 our	 hair	 and	 eyes.	 Differences	 in	 our	 genes	 can	 also	 explain	 why	 some	 people	 develop	 certain	
diseases,	 like	 epilepsy,	 and	 others	 do	 not.	We	 are	 studying	 individuals	with	 epilepsy,	 as	well	 as	 their	

















epilepsy	will	 not	 be	 changed	 in	 any	way.	 This	 research	 study	 involves	 an	 EEG	 (brainwave)	 recording;	











You	 and	 your	 child	 will	 be	 asked	 to	 participate	 in	 completing	 questionnaires	 that	 take	 about	 50-60	
minutes.	The	questions	deal	with	your	child's	medical	history,	 including	any	symptoms	of	seizures.	We	




relevant	 medical	 condition.	 We	 may	 also	 ask	 you	 to	 contact	 your	 relatives,	 if	 they	 have	 relevant	





the	 head.	 Wires	 are	 lightly	 attached	 to	 your	 scalp	 using	 paste	 and	 these	 are	 connected	 to	 the	 EEG	










RNA	 (the	message	 copied	 from	 DNA),	 protein	 and	 cells.	 If	 you	 and	 your	 child	 choose	 to	 have	 blood	
drawn,	the	amount	of	blood	we	will	draw	is	approximately	15-20	ml	(1.5-2	tablespoons),	and	the	blood	

























Studies	 using	 high-throughput	 sequencing	 are	 often	 performed	 in	 national	 or	 international	 research	











(NIHR)	 Mental	 Health	 Biomedical	 Research	 Centre	 (BRC)	 Bioresource.	 The	 NIHR	 is	 responsible	 for	
supporting	 research	 and	 development	 across	 the	NHS.	 The	Mental	 Health	 BRC	 Bioresource	 has	 been	
designed	 to	 create	 a	 resource	 or	 ‘Biobank’	 for	 psychiatric/neurological	 disorders,	 which	 will	 include	
biological	 information	 (e.g.	 blood,	 saliva	 for	 analyzing	 genes),	 combined	 with	 other	 information	 (e.g.	





initiative	 involving	 a	 number	 of	 other	Biomedical	 Research	Centers	 in	 the	 country.	 This	 is	 in	 order	 to	
bring	 together	 groups	of	 healthy	 volunteers,	 patients	 and	 relatives	who	have	 agreed	 to	be	 contacted	
and	 can	 be	 invited	 to	 participate	 in	 relevant	 clinical	 research.	 Therefore,	 some	 BRC	 Bioresource	











a	 standard	 evaluation	 using	 written,	 spoken	 and	 physical	 materials,	 administered	 by	 a	 trained	
psychologist.	 During	 parts	 of	 the	 assessment	 your	 child	may	 have	 an	 EEG	 recording.	 The	 assessment	
takes	about	4	hours.	Additional	time	will	be	allocated	for	rest	and	refreshment.	This	assessment	 looks	

































































any	 information	we	might	already	have	collected.	However,	 if	you	want	us	to	destroy	the	 information	
we	have	collected,	we	will.	You	will	need	to	tell	is	whether	you	wish	to	withdraw	from	the	rare	epilepsy	
study,	Bioresource	study	or	both.	Biological	samples	e.g.	saliva,	blood,	blood	products,	DNA	and	RNA	will	









will	 do	 their	 best	 to	 answer	 your	 questions	 (020	 7848	 5435).	 If	 you	 remain	 unhappy	 and	 wish	 to	
complain	formally,	you	can	do	this	through	the	NHS	Complaints	Procedure.	Details	can	be	obtained	from	
the	hospital.	In	the	event	that	something	does	go	wrong	and	you	are	harmed	during	the	research	study	
there	 are	 no	 special	 compensation	 arrangements.	 If	 you	 are	 harmed	 and	 this	 is	 due	 to	 someone’s	
negligence	 then	 you	 may	 have	 grounds	 for	 a	 legal	 action	 for	 compensation	 against	 King’s	 College	




Yes.	We	will	collect	 information	about	you,	which	could	 identify	you	personally	 (for	example,	because	
the	 information	 includes	 your	 name	 or	 date	 of	 birth).	 We	 will	 also	 collect	 information	 about	 you	





one	outside	 the	 team	will	have	access	 to	your	 information.	We	will	use	 the	 information	we	collect	 to	
answer	the	questions	relevant	 to	 this	 research	project.	 In	 the	 future	 it	 is	possible	we	might	have	new	




then	 destroyed	 securely.	 The	 hospital	 has	 a	 duty	 to	 ensure	 research	 conducted	 here	 is	 of	 a	 high	
standard	and	auditors	 from	the	hospital	may	need	to	review	any	 information	we	hold	about	you.	The	















This	 research	 is	being	organized	by	Professor	Deb	Pal	and	 is	 sponsored	by	King’s	College	London.	The	





The	 Great	 Ormond	 Street	 Hospital/Institute	 of	 Child	 Health	 Research	 Ethics	 Committee	 (reference	
number:	09/H0713/76)	has	reviewed	this	rare	epilepsy	study	and	given	a	favourable	ethical	opinion	for	












































CONSENT FORM 5/12/13 version 4 
 
Title of Project: Genetics of Human Epilepsies – Rare Epilepsies 
 
Name of Researcher: Professor Deb Pal                Please initial box  
  
 
1. I confirm that I have read and understand the information sheet dated 05/12/13 
(version 4) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected. 
Biological samples will be destroyed as detailed. 
 
3. I understand that relevant sections of any of my medical notes from hospital 
and GP medical records and data collected during the study, may be looked at 
by responsible individuals from regulatory authorities or from the NHS trust, or 
the BRC Bioresource team, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records 
 
4. I agree to have my/child’s samples and data included in the National NIHR 
Bioresource 
 
5. I agree that my biological material e.g. blood, saliva, DNA can be removed and 
used for the above study and that I have been made aware of surplus material 
disposal methods according to the Human Tissue Act 2004. 
 
6. I agree that any biological material surplus to this study and relevant clinical 
information can be used in future related research, which has been approved 
by a recognised Research Ethics Committee 
 
7. I agree to be contacted in the future by the BRC Bioresource team requesting 
my/child’s participation in similar studies or other medical research studies 
 
8. I agree that my blood/tissue sample may be used for high throughput 
sequencing projects and that my data may be transferred, managed and stored 
externally. I understand that I will not receive any information about my/child’s 
individual results. 
 
9. I agree to my GP being informed of my participation in the study  





_____________________ ________________ _______________ 
Name of Subject Signature  Date 
 
 
_____________________ ________________ _______________ 
Name of Parent/Guardian Signature Date 
 
 
_____________________ ________________ _______________ 








Appendix B. Questionnaires 
Genetics in Human Epilepsy Study Myoclonic Astatic Epilepsy - Postal Form C_V3 
 
1. Today’s Date: 
 
2. Name of person completing form: 
 
3. Your relationship to Child: 
 
4. Your full address:  
 
 
5. Your contact Home number: 
               Mobile number: 
                              Email: 
 
6. Name of Child: 
 
7. Is your Child: ☐ Male  ☐ Female  
 
8. Child’s birth date:  
      





10. Were there any complications in pregnancy? 
☐ No    ☐ Yes, please specify: 
 
11. Was your child born: 
☐ Expected dates 
☐ Early, please specify at how many weeks your child was born: 
☐ Late, please specify at how many weeks your child was born: 
 




☐ Normal vaginal delivery 
☐  Forceps or Ventouse (vacuum) extraction 
☐ Planned caesarian section 
☐ Emergency caesarian section 
☐ Other, please specify: 
 
13. What was the birth weight of your child? 
 
 
14. What was the condition of your child at the time of birth? 
☐ Normal, good 
☐ Other, please specify: 
 
15. How old was your child when s/he could walk without help? 
☐ Less than 18 months 
☐ More than 18 months, please specify: 
 
16. Did s/he ever have trouble with any of the following? (Check those that apply): 
☐ Breast or bottle feeding? (latching; took long time) 
☐ Chewing solids 
☐ Sucking through a straw 
☐ Blowing bubbles or candles 
☐ Sticking out the tongue 
 
17. In preschool or kindergarten, did you notice that your child: 
 
17.1. Spoke their first words with meaning late, ie had not spoken their first word 
by 18 months 
☐ No   ☐ Yes 
 
17.2. Spoke their first sentence late ie only after two and a half years age 





17.3. S/he was missing off the consonants at the beginning and/or ends of words, 
even after two and a half years of age 
 
☐ No   ☐ Yes 
 
17.4. His/her words were unintelligible to strangers even after three years of age 
☐ No   ☐ Yes 
 
17.5. Stuttered after the age of four years 
☐ No   ☐ Yes 
 
17.6. Got words or parts of words jumbled 
☐ No   ☐ Yes 
 
17.7. Could not understand spoken language in a sentence by the age of three years 
☐ No   ☐ Yes 
 
18. Did s/he ever have speech and language therapy? 
☐ No   ☐ Yes 
 
 
19. Do you think your child has a learning problem? 
                                              ☐ No  ☐ Yes, please describe:  
 
 
20. How old was your child when s/he had his first seizures? 
  
____ years ____ months 
 

















23: Did any of the seizures last for at least 30 minutes or did s/he have several seizures 
without regaining consciousness over at least 30 minutes? 
☐ No  ☐ Yes  ☐ Not sure 
 
 
24. What is the longest time your child has ever been seizure free? 
 
 
25. What medication for epilepsy is your child currently on? 
 
 
26. What other medication for epilepsy has your child previously tried? 
 
 
27. When was your child’s last seizure? 
 
 
28. Does/did your child have seizures with fever?  ☐ No  ☐ Yes   
 
 
29. Is there anyone else in the family (including cousins, aunties, uncles and grandparent) 
with epilepsy?  






30. Is there anyone else in the family (including cousins, aunties, uncles and grandparent) 
have seizures with fever? 
☐ No  ☐ Yes, please specify how they are related: 
 
  
31. Has you child had a brain scan?  
☐ No, go to question 32 
☐ Yes   
 
32. Was your child’s brain scan normal? 
☐ Yes 
☐ No, please specify: 
 
 
33. Does your child have any medical problems apart from her/his epilepsy? 
☐ No 
☐ Yes, please specify: 
 
 
33. Would you describe your child as having behavioural problems? 
☐ No 
















































Appendix C. Conner’s CBRS subscales 
Subscale	 Description	of	subscale	components	
A	 Oppositional:	 Are	 likely	 to	 break	 rules,	 have	 problems	 with	 authority,	 are	 easily	
annoyed.	











I	 CGI	 Restless-Impulsive:	 This	 subscale	 indicates	 restlessness,	 impulsivity	 and	
inattentiveness.	
J	 CGI	 Emotional	 Lability:	 Individuals	with	 high	 scores	 on	 this	 subscale	 are	 prone	 to	
more	emotional	responses/behaviours	than	is	typical.	
K	 CGI	Total:	The	CGI	Score	reflects	general	problematic	behaviour.	
L	 DSM	 IV	 Inattentive:	 High	 scores	 indicate	 an	 above	 average	 correspondence	 with	
the	DSM	IV	diagnostic	criteria	for	Inattentive	type	ADHD.	
M	 DSM	 IV	 Hyperactive-Impulsive:	 High	 scores	 indicate	 an	 above	 average	
correspondence	with	the	DSM	IV	diagnostic	criteria	for	Hyperactive-Impulsive	type	
ADHD.	


















































































Appendix F. DNA extraction protocols 
Blood	DNA	extraction	protocol	




• Pipet	 500μl	 of	QIAGEN	 Protease	 into	 a	 50ml	 tube.	 Add	 the	 blood	 collected	 and	mix	
briefly.	






placed	 in	 a	 50ml	 centrifuge	 tube.	 Close	 the	 cap	 and	 centrifuge	 at	 3000rpm	 for	 3	
minutes.	








• Pipet	 600μl	 of	 Buffer	 AE	 directly	 onto	 the	membrane	 of	 the	 QIAamp	Maxi	 column,	
close	 the	 cap	 and	 incubate	 at	 room	 temperature	 for	 5	 minutes,	 then	 centrifuge	 at	
5000rpm	for	2	minutes	
• Reload	 the	 600μl	 eluate	 onto	 the	membrane	 of	 the	QIAamp	Maxi	 column	 and	 then	
add	500μl	Buffer	AE.	


























• Completely	 remove	 the	 ethanol	 and	 leave	 to	 dry	 inverted	 for	 10	 minutes.	 Ethanol	
drops	on	the	inner	surface	of	the	tube	may	be	removed	with	tissue	paper.	
























































Appendix G. DNA sample IDs 
UK	DNA	sample	IDs	
Proband	ID	 Exome	sequencing	ID	 Sex	 DNA	of	family	members	
3000301	 S1040	 Male	 F,	M,	B,	C	
3001301	 	 Male	 	
3002301	 S1271	 Male	 F,	M,	S,	B,	B	
3003301	 S1272	 Female	 F,	M	
3004301	 S1273	 Male	 F,	M	
00500*	 S2286	 Male	 M	
00504*±	 S2340	 Female	 F,	M	
00505*±	 S2341	 Male	 F,	M,	B,	S	
00506*	 S2388	 Male	 F,	M	
00512*	 S2389	 Male	 F,	M	
00513*	 -	 Male	 F,	M,	S	
30513	 S2574	 Female	 	
00514*	 S2287	 Male	 	
00518*	 S1616	 Male	 F,	M,	B,	S	
00523*	 S2288	 Male	 F,	M	
00524*	 	 Male	 F,	M,	B	
00525*	 S2391	 Female	 F,	M	
00526*	 S1883	 Female	 M,	B	
00528*	 S2488	 Female	 F,	M,	S	
00529*	 S2289	 Female	 F,	M	
00530*	 S2392	 Male	 F,	M	
00533*	 S2393	 Female	 F,	M	
00534*	 S2290	 Male	 F,	M	
00536	 	 Male	 F,	M	
00538*	 	 Male	 M	
00539*	 S2291	 Male	 F,	M,	B	
00545*	 S2292	 Male	 F,	M,	S	
00546*	 S2342	 Female	 F,	M	
00550*	 S2343	 Male	 F,	M	
00551*	 S2293	 Female	 F,	M,	S	
00554*	 S2294	 Female	 F,	M,	B	
00556*	 	 Male	 M	
00559*	 S2331	 Female	 F,	M	
00560*	 S2295	 Male	 F,	M	
00561*	 S2332	 Female	 F,	M	
00562*	 	 Male	 F,	M,	C	
00566	 S2296	 Male	 F,	M	




00568*	 S2297	 Male	 F,	M	
00570*	 S2298	 Female	 F,	M	
00571	 S2390	 Male	 F,	M,	B	
00572*	 S2330	 Male	 M	
00574	 	 Male	 F,	M,	S	
00576	 S2299	 Male	 F,	M	
00577	 	 Male	 F,	M	
00580	 S2534	 Male	 F,	M	
00584	 S2535	 Male	 M	
00586	 	 Male	 F,	M	
00587	 	 Female	 F,	M	
00590	 	 Male	 F,	M	
00591	 	 Female	 F,	M	
00594	 S2536	 Female	 F,	M	
00595	 S2537	 Male	 F,	M	
00597	 	 Female	 F,	M	
00598	 S2538	 Male	 F,	M	
00599	 S2539	 Male	 F,	M	
00600	 S2540	 Female	 M	
00602	 S2541	 Male	 F,	M,	B,	B,	S	
00603	 S2542	 Male	 F,	M	
00605	 	 Female	 F,	M	
00607	 	 	 F,	M	
00608	 S2543	 Male	 F,	M	
00609	 S2544	 Male	 M	
00610	 S2545	 Male	 F,	M	
00613	 	 Male	 F,	M	
00615	 	 Male	 F,	M	
00616	 	 Male	 F,	M	
00618	 	 Male	 F,	M	
00621	 	 Male	 F,	M	
00622	 	 Female	 F,	M	
00623	 	 Male	 F,	M	










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix J. Primers 
Primer	 Forward	 Reverse	 PCR	





























KLHL1_518_1FR	 cttgcttggcttcacaaacatc	 TCTGCCTTACATTCACGACCTA	 RT	




























SMARCA2_3003_1FR	 tgccttgagaaatgggaccc	 acagaaaaaggggcagaggt	 S	
STX1B_00504_1FR	 TCTGTTTTGGGAGTGAGCCT	
	
ACTGTCTGCCTGTCTCACTC	
	
S	
UBE3A_3000_1FR	 GCCCAACTGTGTGCTTTCAT	
	
TGTAGTTCTATGGTGGCCTCA	
	
S	
S	Standard	PCR,	Opt	Optimised	PCR,	RT	real	time	PCR	
	
	
	
